CA2436770A1 - Methods of treating inflammatory and immune diseases using inhibitors of ikb kinase (ikk) - Google Patents
Methods of treating inflammatory and immune diseases using inhibitors of ikb kinase (ikk) Download PDFInfo
- Publication number
- CA2436770A1 CA2436770A1 CA002436770A CA2436770A CA2436770A1 CA 2436770 A1 CA2436770 A1 CA 2436770A1 CA 002436770 A CA002436770 A CA 002436770A CA 2436770 A CA2436770 A CA 2436770A CA 2436770 A1 CA2436770 A1 CA 2436770A1
- Authority
- CA
- Canada
- Prior art keywords
- ikk
- inhibitor
- activity
- disease
- inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 113
- 230000002757 inflammatory effect Effects 0.000 title claims abstract description 51
- 108091000080 Phosphotransferase Proteins 0.000 title claims abstract description 20
- 102000020233 phosphotransferase Human genes 0.000 title claims abstract description 20
- 208000027866 inflammatory disease Diseases 0.000 title claims description 21
- 239000003112 inhibitor Substances 0.000 title abstract description 29
- 208000026278 immune system disease Diseases 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 245
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 136
- 239000003458 I kappa b kinase inhibitor Substances 0.000 claims abstract description 118
- 201000010099 disease Diseases 0.000 claims abstract description 92
- PSPFQEBFYXJZEV-UHFFFAOYSA-N N'-(1,8-dimethyl-4-imidazo[1,2-a]quinoxalinyl)ethane-1,2-diamine Chemical compound C1=C(C)C=C2N3C(C)=CN=C3C(NCCN)=NC2=C1 PSPFQEBFYXJZEV-UHFFFAOYSA-N 0.000 claims abstract description 45
- 208000035475 disorder Diseases 0.000 claims abstract description 44
- 150000003839 salts Chemical class 0.000 claims abstract description 42
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 21
- 230000000694 effects Effects 0.000 claims description 82
- -1 4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a) quinoxaline compound Chemical class 0.000 claims description 69
- 230000005764 inhibitory process Effects 0.000 claims description 47
- 230000002401 inhibitory effect Effects 0.000 claims description 38
- 230000026731 phosphorylation Effects 0.000 claims description 33
- 238000006366 phosphorylation reaction Methods 0.000 claims description 33
- 230000004913 activation Effects 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 25
- 230000003197 catalytic effect Effects 0.000 claims description 24
- 230000001419 dependent effect Effects 0.000 claims description 18
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 16
- 230000014509 gene expression Effects 0.000 claims description 15
- 241000124008 Mammalia Species 0.000 claims description 14
- 239000013543 active substance Substances 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 14
- 206010052779 Transplant rejections Diseases 0.000 claims description 13
- 206010003246 arthritis Diseases 0.000 claims description 11
- 239000003085 diluting agent Substances 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 208000019693 Lung disease Diseases 0.000 claims description 10
- 208000006673 asthma Diseases 0.000 claims description 9
- 210000000056 organ Anatomy 0.000 claims description 8
- 208000024827 Alzheimer disease Diseases 0.000 claims description 7
- 201000001320 Atherosclerosis Diseases 0.000 claims description 7
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 229940088597 hormone Drugs 0.000 claims description 6
- 239000005556 hormone Substances 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 201000006474 Brain Ischemia Diseases 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims description 5
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 5
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 5
- 230000009529 traumatic brain injury Effects 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 4
- 230000000414 obstructive effect Effects 0.000 claims description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 3
- 230000027405 negative regulation of phosphorylation Effects 0.000 claims description 2
- 206010039083 rhinitis Diseases 0.000 claims 3
- 206010038687 Respiratory distress Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 54
- 238000001727 in vivo Methods 0.000 abstract description 17
- 230000002265 prevention Effects 0.000 abstract description 9
- 239000000203 mixture Substances 0.000 description 65
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 61
- 238000002360 preparation method Methods 0.000 description 58
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 56
- 125000000217 alkyl group Chemical group 0.000 description 56
- 108090000623 proteins and genes Proteins 0.000 description 42
- 239000007787 solid Substances 0.000 description 39
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
- 238000012360 testing method Methods 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 34
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 32
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 32
- 238000005481 NMR spectroscopy Methods 0.000 description 32
- 239000000243 solution Substances 0.000 description 32
- 235000019439 ethyl acetate Nutrition 0.000 description 30
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 28
- 102000004169 proteins and genes Human genes 0.000 description 28
- 102000003390 tumor necrosis factor Human genes 0.000 description 28
- 235000018102 proteins Nutrition 0.000 description 27
- 125000001072 heteroaryl group Chemical group 0.000 description 26
- 241000699670 Mus sp. Species 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 25
- 206010061218 Inflammation Diseases 0.000 description 24
- 230000004054 inflammatory process Effects 0.000 description 24
- 238000003818 flash chromatography Methods 0.000 description 19
- 229910052757 nitrogen Inorganic materials 0.000 description 19
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 19
- 239000002904 solvent Substances 0.000 description 19
- 239000000725 suspension Substances 0.000 description 19
- 239000003981 vehicle Substances 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 125000003118 aryl group Chemical group 0.000 description 18
- 239000003795 chemical substances by application Substances 0.000 description 18
- 238000010172 mouse model Methods 0.000 description 18
- 125000000547 substituted alkyl group Chemical group 0.000 description 18
- 239000012267 brine Substances 0.000 description 17
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 17
- 238000003556 assay Methods 0.000 description 16
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 16
- 235000019341 magnesium sulphate Nutrition 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 239000002253 acid Substances 0.000 description 15
- 239000013058 crude material Substances 0.000 description 15
- 125000000753 cycloalkyl group Chemical group 0.000 description 15
- 230000001225 therapeutic effect Effects 0.000 description 15
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 14
- 108700012920 TNF Proteins 0.000 description 14
- 208000027418 Wounds and injury Diseases 0.000 description 14
- 125000004432 carbon atom Chemical group C* 0.000 description 14
- 230000006378 damage Effects 0.000 description 14
- 208000014674 injury Diseases 0.000 description 14
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 14
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 13
- 239000012044 organic layer Substances 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- 229910052799 carbon Inorganic materials 0.000 description 12
- 229910052739 hydrogen Inorganic materials 0.000 description 12
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 12
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 11
- 229930105110 Cyclosporin A Natural products 0.000 description 11
- 108010036949 Cyclosporine Proteins 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 208000009386 Experimental Arthritis Diseases 0.000 description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 150000001412 amines Chemical class 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 239000002158 endotoxin Substances 0.000 description 11
- 210000002216 heart Anatomy 0.000 description 11
- 239000001257 hydrogen Substances 0.000 description 11
- 229920006008 lipopolysaccharide Polymers 0.000 description 11
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- 241000282412 Homo Species 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 238000010171 animal model Methods 0.000 description 10
- 230000028993 immune response Effects 0.000 description 10
- 230000007246 mechanism Effects 0.000 description 10
- 125000001424 substituent group Chemical group 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical class OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 101150041968 CDC13 gene Proteins 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 9
- 125000003545 alkoxy group Chemical group 0.000 description 9
- 230000015556 catabolic process Effects 0.000 description 9
- 210000001072 colon Anatomy 0.000 description 9
- 238000006731 degradation reaction Methods 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 125000005842 heteroatom Chemical group 0.000 description 9
- 125000000623 heterocyclic group Chemical group 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- 125000004414 alkyl thio group Chemical group 0.000 description 8
- 125000002619 bicyclic group Chemical group 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000001186 cumulative effect Effects 0.000 description 8
- GGSUCNLOZRCGPQ-UHFFFAOYSA-N diethylaniline Chemical compound CCN(CC)C1=CC=CC=C1 GGSUCNLOZRCGPQ-UHFFFAOYSA-N 0.000 description 8
- 229910052736 halogen Inorganic materials 0.000 description 8
- 150000002367 halogens Chemical class 0.000 description 8
- 210000004969 inflammatory cell Anatomy 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- 150000003141 primary amines Chemical class 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 206010035664 Pneumonia Diseases 0.000 description 7
- 230000008595 infiltration Effects 0.000 description 7
- 238000001764 infiltration Methods 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 125000004093 cyano group Chemical group *C#N 0.000 description 6
- 208000037765 diseases and disorders Diseases 0.000 description 6
- 125000005843 halogen group Chemical group 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 125000002950 monocyclic group Chemical group 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- IIRWITSTDWORDS-UHFFFAOYSA-N 1,8-dimethyl-5h-imidazo[1,2-a]quinoxalin-4-one Chemical compound CC1=CC=C2NC(=O)C3=NC=C(C)N3C2=C1 IIRWITSTDWORDS-UHFFFAOYSA-N 0.000 description 5
- 108010058846 Ovalbumin Proteins 0.000 description 5
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000012320 chlorinating reagent Substances 0.000 description 5
- 229940126214 compound 3 Drugs 0.000 description 5
- 229940125898 compound 5 Drugs 0.000 description 5
- 210000000805 cytoplasm Anatomy 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 125000002883 imidazolyl group Chemical group 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229940092253 ovalbumin Drugs 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 125000004434 sulfur atom Chemical group 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 230000034512 ubiquitination Effects 0.000 description 5
- 238000010798 ubiquitination Methods 0.000 description 5
- DZBGUIUMPUTEMS-UHFFFAOYSA-N 3-iodonaphthalene-2-carboxylic acid Chemical class C1=CC=C2C=C(I)C(C(=O)O)=CC2=C1 DZBGUIUMPUTEMS-UHFFFAOYSA-N 0.000 description 4
- JJFAGUZOWDICTQ-UHFFFAOYSA-N 4-chloro-1-methylbenzo[g]imidazo[1,2-a]quinoxaline Chemical compound C1=CC=C2C=C(N3C(C)=CN=C3C(Cl)=N3)C3=CC2=C1 JJFAGUZOWDICTQ-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 101150091206 Nfkbia gene Proteins 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 229940124639 Selective inhibitor Drugs 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 208000028004 allergic respiratory disease Diseases 0.000 description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 description 4
- 239000002260 anti-inflammatory agent Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 230000000536 complexating effect Effects 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 4
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 230000017854 proteolysis Effects 0.000 description 4
- 125000003226 pyrazolyl group Chemical group 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 125000000335 thiazolyl group Chemical group 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 125000006168 tricyclic group Chemical group 0.000 description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 4
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 3
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 238000011725 BALB/c mouse Methods 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 3
- 150000001241 acetals Chemical class 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- YUFRAQHYKKPYLH-UHFFFAOYSA-N benzo[f]quinoxaline Chemical compound C1=CN=C2C3=CC=CC=C3C=CC2=N1 YUFRAQHYKKPYLH-UHFFFAOYSA-N 0.000 description 3
- PQIUGRLKNKSKTC-UHFFFAOYSA-N benzo[h]quinazoline Chemical class N1=CN=C2C3=CC=CC=C3C=CC2=C1 PQIUGRLKNKSKTC-UHFFFAOYSA-N 0.000 description 3
- WZJYKHNJTSNBHV-UHFFFAOYSA-N benzoquinoline Natural products C1=CN=C2C3=CC=CC=C3C=CC2=C1 WZJYKHNJTSNBHV-UHFFFAOYSA-N 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 206010009887 colitis Diseases 0.000 description 3
- 230000037020 contractile activity Effects 0.000 description 3
- 238000006880 cross-coupling reaction Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 238000013265 extended release Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 150000004795 grignard reagents Chemical class 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- 239000008241 heterogeneous mixture Substances 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 239000012948 isocyanate Substances 0.000 description 3
- 150000002513 isocyanates Chemical class 0.000 description 3
- 125000000468 ketone group Chemical group 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 150000003873 salicylate salts Chemical class 0.000 description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 229940037128 systemic glucocorticoids Drugs 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- KWMGFYVFHSAISD-UHFFFAOYSA-N 1-methyl-4-chlorobenzo(g)imidazo(4,5-c)quinoline Chemical compound C1=CC=CC2=CC3=C4N(C)C=NC4=C(Cl)N=C3C=C21 KWMGFYVFHSAISD-UHFFFAOYSA-N 0.000 description 2
- OMPIJMOZKLHFCC-UHFFFAOYSA-N 11,14,17-triazatetracyclo[8.7.0.03,8.011,15]heptadeca-1,3,5,7,9,12,14,16-octaene Chemical compound c1cn2c(cnc3cc4ccccc4cc23)n1 OMPIJMOZKLHFCC-UHFFFAOYSA-N 0.000 description 2
- MRPXDPJAIOQHFO-UHFFFAOYSA-N 12-methyl-14,15,17-triazatetracyclo[8.7.0.03,8.011,15]heptadeca-1,3,5,7,9,11,13-heptaen-16-one Chemical compound Cc1cnn2c1c1cc3ccccc3cc1[nH]c2=O MRPXDPJAIOQHFO-UHFFFAOYSA-N 0.000 description 2
- HTBIZVQWEZWUCQ-UHFFFAOYSA-N 1h-benzimidazolo[4,5-h]quinoline Chemical class C1=CC2=CC=CN=C2C2=C1C(N=CN1)=C1C=C2 HTBIZVQWEZWUCQ-UHFFFAOYSA-N 0.000 description 2
- IWQXKMLJNVDOMB-UHFFFAOYSA-N 1h-benzimidazolo[5,4-f]quinoxaline Chemical class C1=CC2=NC=CN=C2C2=C1C(N=CN1)=C1C=C2 IWQXKMLJNVDOMB-UHFFFAOYSA-N 0.000 description 2
- GDWJSZKXUXMVTM-UHFFFAOYSA-N 1h-indazolo[4,5-h]quinazoline Chemical class N1=CN=C2C3=CC=C4NN=CC4=C3C=CC2=C1 GDWJSZKXUXMVTM-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- LYIIBVSRGJSHAV-UHFFFAOYSA-N 2-aminoacetaldehyde Chemical compound NCC=O LYIIBVSRGJSHAV-UHFFFAOYSA-N 0.000 description 2
- WZMOWQCNPFDWPA-UHFFFAOYSA-N 2-fluoro-4-methyl-1-nitrobenzene Chemical compound CC1=CC=C([N+]([O-])=O)C(F)=C1 WZMOWQCNPFDWPA-UHFFFAOYSA-N 0.000 description 2
- XFXOLBNQYFRSLQ-UHFFFAOYSA-N 3-amino-2-naphthoic acid Chemical class C1=CC=C2C=C(C(O)=O)C(N)=CC2=C1 XFXOLBNQYFRSLQ-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- HATLLUIOEIXWGD-UHFFFAOYSA-N 5-bromo-1-methylimidazole Chemical compound CN1C=NC=C1Br HATLLUIOEIXWGD-UHFFFAOYSA-N 0.000 description 2
- USVZHTBPMMSRHY-UHFFFAOYSA-N 8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]-9-[2-(2-chlorophenyl)ethyl]purin-6-amine Chemical compound C=1C=2OCOC=2C=C(Br)C=1SC1=NC=2C(N)=NC=NC=2N1CCC1=CC=CC=C1Cl USVZHTBPMMSRHY-UHFFFAOYSA-N 0.000 description 2
- 102000008102 Ankyrins Human genes 0.000 description 2
- 108010049777 Ankyrins Proteins 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 238000006418 Brown reaction Methods 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 206010063094 Cerebral malaria Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 239000007818 Grignard reagent Substances 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229930194542 Keto Natural products 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 150000004703 alkoxides Chemical class 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000007080 aromatic substitution reaction Methods 0.000 description 2
- AQLMHYSWFMLWBS-UHFFFAOYSA-N arsenite(1-) Chemical compound O[As](O)[O-] AQLMHYSWFMLWBS-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
- 150000001642 boronic acid derivatives Chemical class 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 229930194791 calphostin Natural products 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- KWTSZCJMWHGPOS-UHFFFAOYSA-M chloro(trimethyl)stannane Chemical compound C[Sn](C)(C)Cl KWTSZCJMWHGPOS-UHFFFAOYSA-M 0.000 description 2
- 101150116749 chuk gene Proteins 0.000 description 2
- 150000001860 citric acid derivatives Chemical class 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 150000001879 copper Chemical class 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 125000003963 dichloro group Chemical group Cl* 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229960002706 gusperimus Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 229940125721 immunosuppressive agent Drugs 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940076144 interleukin-10 Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 150000003951 lactams Chemical class 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- FCTVQOVDYDWVEP-UHFFFAOYSA-N methyl 3-iodonaphthalene-2-carboxylate Chemical compound C1=CC=C2C=C(I)C(C(=O)OC)=CC2=C1 FCTVQOVDYDWVEP-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- KFIGICHILYTCJF-UHFFFAOYSA-N n'-methylethane-1,2-diamine Chemical compound CNCCN KFIGICHILYTCJF-UHFFFAOYSA-N 0.000 description 2
- IDINUJSAMVOPCM-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-INIZCTEOSA-N 0.000 description 2
- XTBLDMQMUSHDEN-UHFFFAOYSA-N naphthalene-2,3-diamine Chemical class C1=CC=C2C=C(N)C(N)=CC2=C1 XTBLDMQMUSHDEN-UHFFFAOYSA-N 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000005937 nuclear translocation Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 229940046781 other immunosuppressants in atc Drugs 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 159000000001 potassium salts Chemical class 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- JKANAVGODYYCQF-UHFFFAOYSA-N prop-2-yn-1-amine Chemical class NCC#C JKANAVGODYYCQF-UHFFFAOYSA-N 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 2
- 229950005741 rolipram Drugs 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Chemical compound O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 2
- 229960000894 sulindac Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- BPLUKJNHPBNVQL-UHFFFAOYSA-N triphenylarsine Chemical compound C1=CC=CC=C1[As](C=1C=CC=CC=1)C1=CC=CC=C1 BPLUKJNHPBNVQL-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 239000011592 zinc chloride Substances 0.000 description 2
- 235000005074 zinc chloride Nutrition 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical class CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- FRJJJAKBRKABFA-TYFAACHXSA-N (4r,6s)-6-[(e)-2-[6-chloro-4-(4-fluorophenyl)-2-propan-2-ylquinolin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C(\[C@H]1OC(=O)C[C@H](O)C1)=C/C=1C(C(C)C)=NC2=CC=C(Cl)C=C2C=1C1=CC=C(F)C=C1 FRJJJAKBRKABFA-TYFAACHXSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- 125000006059 1,1-dimethyl-2-butenyl group Chemical group 0.000 description 1
- 125000006033 1,1-dimethyl-2-propenyl group Chemical group 0.000 description 1
- KLBLIQLOPBRDNC-UHFFFAOYSA-N 1,4-dihydrobenzo[g]quinoxaline-2,3-dione Chemical compound C1=CC=C2C=C(NC(C(=O)N3)=O)C3=CC2=C1 KLBLIQLOPBRDNC-UHFFFAOYSA-N 0.000 description 1
- PGIODXBHGOGYHU-UHFFFAOYSA-N 1,8-dimethyl-3h-imidazo[4,5-f]quinoxalin-2-one Chemical compound C12=NC(C)=CN=C2C=CC2=C1N(C)C(=O)N2 PGIODXBHGOGYHU-UHFFFAOYSA-N 0.000 description 1
- SOZFOLUZJUPGMQ-UHFFFAOYSA-N 1,8-dimethylimidazo[1,2-a]quinoxalin-2-amine Chemical compound C1=C(C)C=C2N3C(C)=C(N)N=C3C=NC2=C1 SOZFOLUZJUPGMQ-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- 125000006025 1-methyl-1-butenyl group Chemical group 0.000 description 1
- 125000006019 1-methyl-1-propenyl group Chemical group 0.000 description 1
- 125000006028 1-methyl-2-butenyl group Chemical group 0.000 description 1
- 125000006021 1-methyl-2-propenyl group Chemical group 0.000 description 1
- SOWFHRFETKCZMC-UHFFFAOYSA-N 1-methyl-4,5-dihydrobenzo(g)imidazo(4,5-c)quinolin-4-one Chemical compound C1=CC=C2C=C(NC(C=3N=CN(C=33)C)=O)C3=CC2=C1 SOWFHRFETKCZMC-UHFFFAOYSA-N 0.000 description 1
- ODFIBXFJCDPCHA-UHFFFAOYSA-N 1-methyl-4-methylaminobenzo(g)imidazo(4,5-c)quinoline Chemical compound C1=CC=C2C=C(C3=C(C(NC)=N4)N=CN3C)C4=CC2=C1 ODFIBXFJCDPCHA-UHFFFAOYSA-N 0.000 description 1
- 125000006018 1-methyl-ethenyl group Chemical group 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- NECFYTOWQYCZGB-UHFFFAOYSA-N 2,3-dichlorobenzo[g]quinoxaline Chemical compound C1=CC=C2C=C(N=C(C(Cl)=N3)Cl)C3=CC2=C1 NECFYTOWQYCZGB-UHFFFAOYSA-N 0.000 description 1
- 125000006068 2,3-dimethyl-1-butenyl group Chemical group 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- 125000006026 2-methyl-1-butenyl group Chemical group 0.000 description 1
- 125000006029 2-methyl-2-butenyl group Chemical group 0.000 description 1
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- 125000006087 2-oxopyrrolodinyl group Chemical group 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- CJNRGSHEMCMUOE-UHFFFAOYSA-N 2-piperidin-1-ylethanamine Chemical compound NCCN1CCCCC1 CJNRGSHEMCMUOE-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- 125000006071 3,3-dimethyl-1-butenyl group Chemical group 0.000 description 1
- ABFYPGFZVLQWSD-UHFFFAOYSA-N 3-(3-methylimidazol-4-yl)naphthalen-2-amine Chemical compound CN1C=NC=C1C1=CC2=CC=CC=C2C=C1N ABFYPGFZVLQWSD-UHFFFAOYSA-N 0.000 description 1
- SEWQJVRBABDFPJ-UHFFFAOYSA-N 3-(3-methylimidazol-4-yl)naphthalene-2-carboxylic acid Chemical compound CN1C=NC=C1C1=CC2=CC=CC=C2C=C1C(O)=O SEWQJVRBABDFPJ-UHFFFAOYSA-N 0.000 description 1
- HGOMRLICFHELGF-UHFFFAOYSA-N 3-(4-methyl-1h-pyrazol-5-yl)naphthalene-2-carboxylic acid Chemical compound C1=NNC(C=2C(=CC3=CC=CC=C3C=2)C(O)=O)=C1C HGOMRLICFHELGF-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- ZYRBKVBKUPYCFK-UHFFFAOYSA-N 3-chloro-n-prop-2-ynylbenzo[g]quinoxalin-2-amine Chemical compound C1=CC=C2C=C(N=C(C(Cl)=N3)NCC#C)C3=CC2=C1 ZYRBKVBKUPYCFK-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical class OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- 125000006027 3-methyl-1-butenyl group Chemical group 0.000 description 1
- IUQLFCKNGRPZIL-UHFFFAOYSA-N 4-chloro-1,8-dimethylimidazo[1,2-a]quinoxaline Chemical compound C1=C(C)C=C2N3C(C)=CN=C3C(Cl)=NC2=C1 IUQLFCKNGRPZIL-UHFFFAOYSA-N 0.000 description 1
- RPHGKWDIBRGJGG-UHFFFAOYSA-N 4-chloro-1,8-dimethylimidazo[4,5-f]quinoxaline Chemical compound C12=NC(C)=CN=C2C=C(Cl)C2=C1N(C)C=N2 RPHGKWDIBRGJGG-UHFFFAOYSA-N 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- DWUPYMSVAPQXMS-UHFFFAOYSA-N 5-bromo-1,3-thiazole Chemical compound BrC1=CN=CS1 DWUPYMSVAPQXMS-UHFFFAOYSA-N 0.000 description 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 101150007969 ADORA1 gene Proteins 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 206010001367 Adrenal insufficiency Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000008822 Ankylosis Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- QUMCIHKVKQYNPA-RUZDIDTESA-N C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC Chemical compound C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC QUMCIHKVKQYNPA-RUZDIDTESA-N 0.000 description 1
- WPZOOMBZZSELMO-UHFFFAOYSA-N C1=CC2=NC=CN=C2C2=C1C(N=C(N1)Cl)=C1C=C2 Chemical compound C1=CC2=NC=CN=C2C2=C1C(N=C(N1)Cl)=C1C=C2 WPZOOMBZZSELMO-UHFFFAOYSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 208000014997 Crohn colitis Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229940122204 Cyclooxygenase inhibitor Drugs 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 241000551547 Dione <red algae> Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000015689 E-Selectin Human genes 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 230000004950 I-kappaB phosphorylation Effects 0.000 description 1
- 229940122296 IKK2 inhibitor Drugs 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 241000087801 Ioba Species 0.000 description 1
- QZRGKCOWNLSUDK-UHFFFAOYSA-N Iodochlorine Chemical compound ICl QZRGKCOWNLSUDK-UHFFFAOYSA-N 0.000 description 1
- 206010023198 Joint ankylosis Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- 108091008648 NR7C Proteins 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- VEQPNABPJHWNSG-UHFFFAOYSA-N Nickel(2+) Chemical compound [Ni+2] VEQPNABPJHWNSG-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 206010033649 Pancreatitis chronic Diseases 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 229910002666 PdCl2 Inorganic materials 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000020424 Polyglandular disease Diseases 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 108010001859 Proto-Oncogene Proteins c-rel Proteins 0.000 description 1
- 102000000850 Proto-Oncogene Proteins c-rel Human genes 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 108010073443 Ribi adjuvant Proteins 0.000 description 1
- PQUGCKBLVKJMNT-UHFFFAOYSA-N SC560 Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(C(F)(F)F)=N1 PQUGCKBLVKJMNT-UHFFFAOYSA-N 0.000 description 1
- 101150055528 SPAM1 gene Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- JVVXZOOGOGPDRZ-SLFFLAALSA-N [(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-yl]methanamine Chemical compound NC[C@]1(C)CCC[C@]2(C)C3=CC=C(C(C)C)C=C3CC[C@H]21 JVVXZOOGOGPDRZ-SLFFLAALSA-N 0.000 description 1
- SAFSECRCYPBHDL-UHFFFAOYSA-N [1,3]benzothiazolo[4,5-h]quinoline Chemical class C1=CC2=CC=CN=C2C2=C1C(N=CS1)=C1C=C2 SAFSECRCYPBHDL-UHFFFAOYSA-N 0.000 description 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
- 229960004748 abacavir Drugs 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- GPWHDDKQSYOYBF-UHFFFAOYSA-N ac1l2u0q Chemical compound Br[Br-]Br GPWHDDKQSYOYBF-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N acetaldehyde dimethyl acetal Natural products COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 229940121359 adenosine receptor antagonist Drugs 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 208000017515 adrenocortical insufficiency Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005234 alkyl aluminium group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000006368 anti-apoptosis response Effects 0.000 description 1
- 230000000947 anti-immunosuppressive effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940053202 antiepileptics carboxamide derivative Drugs 0.000 description 1
- 229940111121 antirheumatic drug quinolines Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- FNXLCIKXHOPCKH-UHFFFAOYSA-N bromamine Chemical class BrN FNXLCIKXHOPCKH-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000006243 carbonyl protecting group Chemical group 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- KFIFSKNSIUVOCG-UHFFFAOYSA-N chembl230185 Chemical compound N=1C2=CC3=CC=CC=C3C=C2N2C(C)=CN=C2C=1NCCN1CCCCC1 KFIFSKNSIUVOCG-UHFFFAOYSA-N 0.000 description 1
- UOQMKZIYNRHZEF-UHFFFAOYSA-N chembl231530 Chemical compound C1=CC=C2C=C(N3C(C(NC)=N4)=NC=C3C)C4=CC2=C1 UOQMKZIYNRHZEF-UHFFFAOYSA-N 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- CZKMPDNXOGQMFW-UHFFFAOYSA-N chloro(triethyl)germane Chemical compound CC[Ge](Cl)(CC)CC CZKMPDNXOGQMFW-UHFFFAOYSA-N 0.000 description 1
- 125000004617 chromonyl group Chemical group O1C(=CC(C2=CC=CC=C12)=O)* 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- ARUKYTASOALXFG-UHFFFAOYSA-N cycloheptylcycloheptane Chemical compound C1CCCCCC1C1CCCCCC1 ARUKYTASOALXFG-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- MQYQOVYIJOLTNX-UHFFFAOYSA-N dichloromethane;n,n-dimethylformamide Chemical group ClCCl.CN(C)C=O MQYQOVYIJOLTNX-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 210000000624 ear auricle Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 231100000317 environmental toxin Toxicity 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- ZYBWTEQKHIADDQ-UHFFFAOYSA-N ethanol;methanol Chemical compound OC.CCO ZYBWTEQKHIADDQ-UHFFFAOYSA-N 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- VLDUBDZWWNLZCU-UHFFFAOYSA-N ethyl 5-methyl-1h-imidazole-4-carboxylate Chemical compound CCOC(=O)C=1NC=NC=1C VLDUBDZWWNLZCU-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- RIKMMFOAQPJVMX-UHFFFAOYSA-N fomepizole Chemical compound CC=1C=NNC=1 RIKMMFOAQPJVMX-UHFFFAOYSA-N 0.000 description 1
- 229960004285 fomepizole Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- UPBDXRPQPOWRKR-UHFFFAOYSA-N furan-2,5-dione;methoxyethene Chemical compound COC=C.O=C1OC(=O)C=C1 UPBDXRPQPOWRKR-UHFFFAOYSA-N 0.000 description 1
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 150000002315 glycerophosphates Chemical class 0.000 description 1
- QFWPJPIVLCBXFJ-UHFFFAOYSA-N glymidine Chemical compound N1=CC(OCCOC)=CN=C1NS(=O)(=O)C1=CC=CC=C1 QFWPJPIVLCBXFJ-UHFFFAOYSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical class CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical class CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000004124 hock Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000011645 inflammation animal model Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 108091006086 inhibitor proteins Proteins 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 239000006207 intravenous dosage form Substances 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003971 isoxazolinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- GWJVQQSRDYMGDC-UHFFFAOYSA-N methyl 3-(3-methylimidazol-4-yl)naphthalene-2-carboxylate Chemical compound COC(=O)C1=CC2=CC=CC=C2C=C1C1=CN=CN1C GWJVQQSRDYMGDC-UHFFFAOYSA-N 0.000 description 1
- PAUIXQJXAOSPHP-UHFFFAOYSA-N methyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalene-2-carboxylate Chemical compound COC(=O)C1=CC2=CC=CC=C2C=C1B1OC(C)(C)C(C)(C)O1 PAUIXQJXAOSPHP-UHFFFAOYSA-N 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 150000002814 niacins Chemical class 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 150000003901 oxalic acid esters Chemical class 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- LVSJDHGRKAEGLX-UHFFFAOYSA-N oxolane;2,2,2-trifluoroacetic acid Chemical compound C1CCOC1.OC(=O)C(F)(F)F LVSJDHGRKAEGLX-UHFFFAOYSA-N 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-M phenolate Chemical compound [O-]C1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-M 0.000 description 1
- 229940031826 phenolate Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 150000004714 phosphonium salts Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 125000001557 phthalyl group Chemical group C(=O)(O)C1=C(C(=O)*)C=CC=C1 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005547 pivalate group Chemical group 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 229940072288 prograf Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- ONCMJWSDNCJMLL-UHFFFAOYSA-N pyrazolo[1,5-c]quinazoline Chemical compound C12=CC=CC=C2N=CN2C1=CC=N2 ONCMJWSDNCJMLL-UHFFFAOYSA-N 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- SAEMKKTVBSCOFX-UHFFFAOYSA-N quinoxalin-1-ium;chloride Chemical compound Cl.N1=CC=NC2=CC=CC=C21 SAEMKKTVBSCOFX-UHFFFAOYSA-N 0.000 description 1
- SEPKUNXLGWMPHL-UHFFFAOYSA-N quinoxaline-2,3-dione Chemical class C1=CC=CC2=NC(=O)C(=O)N=C21 SEPKUNXLGWMPHL-UHFFFAOYSA-N 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229940099538 rapamune Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 201000004335 respiratory allergy Diseases 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 150000003355 serines Chemical class 0.000 description 1
- 206010040400 serum sickness Diseases 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000012622 synthetic inhibitor Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- LXIKEPCNDFVJKC-QXMHVHEDSA-N tenidap Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 LXIKEPCNDFVJKC-QXMHVHEDSA-N 0.000 description 1
- 229960003676 tenidap Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000006092 tetrahydro-1,1-dioxothienyl group Chemical group 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- HQOJMTATBXYHNR-UHFFFAOYSA-M thallium(I) acetate Chemical compound [Tl+].CC([O-])=O HQOJMTATBXYHNR-UHFFFAOYSA-M 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000006090 thiamorpholinyl sulfone group Chemical group 0.000 description 1
- 125000006089 thiamorpholinyl sulfoxide group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000003555 thioacetals Chemical class 0.000 description 1
- 150000003567 thiocyanates Chemical class 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- LMYRWZFENFIFIT-UHFFFAOYSA-N toluene-4-sulfonamide Chemical compound CC1=CC=C(S(N)(=O)=O)C=C1 LMYRWZFENFIFIT-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M toluenesulfonate group Chemical group C=1(C(=CC=CC1)S(=O)(=O)[O-])C LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- JQKHNBQZGUKYPX-UHFFFAOYSA-N tris(2,4,6-trimethoxyphenyl)phosphane Chemical compound COC1=CC(OC)=CC(OC)=C1P(C=1C(=CC(OC)=CC=1OC)OC)C1=C(OC)C=C(OC)C=C1OC JQKHNBQZGUKYPX-UHFFFAOYSA-N 0.000 description 1
- DLQYXUGCCKQSRJ-UHFFFAOYSA-N tris(furan-2-yl)phosphane Chemical compound C1=COC(P(C=2OC=CC=2)C=2OC=CC=2)=C1 DLQYXUGCCKQSRJ-UHFFFAOYSA-N 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical class CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 238000001086 yeast two-hybrid system Methods 0.000 description 1
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical class N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The present invention describes methods of preventing and treating inflammatory and immune-related diseases or disorders using inhibitors of I.kappa.B kinase (IKK). Also described are IKK inhibitors effective for the prevention and treatment of inflammatory and immune-related diseases or disorders, as demonstrated in vivo . Further embodiments of the present invention relate to a specific IKK inhibitors, 4(2'-aminoethyl)amino- 1,8- dimethylimidazo(1,2-a) quinoxaline and compounds of formula (I), salts thereof, and pharmaceutical compositions.
Description
METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES
USING INHIBITORS OF hcB KINASE (IKK) FIELD OF THE INVENTION
The present invention relates to methods of using inhibitors of Ix.B
kinase (IKK) in the treatment of inflammatory and immune diseases, to inhibitors of IKK, and to pharmaceutical compositions comprising such inhibitors, together with a pharmaceutically or physiologically-acceptable vehicle or excipient.
BACKGROUND OF THE INVENTION
Tumor necrosis factor (TNF-a) is a potent cytokine having pro-inflammatory properties that is released by many cell types when stimulated.
Studies have shown a relationship between elevated levels of TNF-a and a variety of diseases including septic shock, hematopoiesis, tumors, and inflammatory disorders of the central nervous system including HIV, encephalitis, cerebral malaria, and meningitis. Neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Creutzfeldt-Jacob disease also are reportedly associated with enhanced TNF-a levels. See, e.g., Arvin et al., "The Role of Inflammation and Cytokines in Brain Injury,"
Neuroscience and Biobehavioral Reviews, Vol. 20, No. 3 (1996), at pp. 445-452. Accordingly, various classes of compounds have been researched and developed to inhibit TNF-a production at both transcriptional and translational levels, e.g., corticosteroids, rolipram (a phosphodiesterase IV
inhibitor suppressing TNF-a mRNA synthesis), calphostin, and imidazole-type cytokine suppressing anti-inflammatory drugs (CSAIDs). See, e.g., Dinarello, "Role of Pro- and Anti-Inflammatory Cytokines During Inflammation: Experimental and Clinical Findings, Review, Vol. 0393-974X
(1997), at pp. 91-103.
USING INHIBITORS OF hcB KINASE (IKK) FIELD OF THE INVENTION
The present invention relates to methods of using inhibitors of Ix.B
kinase (IKK) in the treatment of inflammatory and immune diseases, to inhibitors of IKK, and to pharmaceutical compositions comprising such inhibitors, together with a pharmaceutically or physiologically-acceptable vehicle or excipient.
BACKGROUND OF THE INVENTION
Tumor necrosis factor (TNF-a) is a potent cytokine having pro-inflammatory properties that is released by many cell types when stimulated.
Studies have shown a relationship between elevated levels of TNF-a and a variety of diseases including septic shock, hematopoiesis, tumors, and inflammatory disorders of the central nervous system including HIV, encephalitis, cerebral malaria, and meningitis. Neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Creutzfeldt-Jacob disease also are reportedly associated with enhanced TNF-a levels. See, e.g., Arvin et al., "The Role of Inflammation and Cytokines in Brain Injury,"
Neuroscience and Biobehavioral Reviews, Vol. 20, No. 3 (1996), at pp. 445-452. Accordingly, various classes of compounds have been researched and developed to inhibit TNF-a production at both transcriptional and translational levels, e.g., corticosteroids, rolipram (a phosphodiesterase IV
inhibitor suppressing TNF-a mRNA synthesis), calphostin, and imidazole-type cytokine suppressing anti-inflammatory drugs (CSAIDs). See, e.g., Dinarello, "Role of Pro- and Anti-Inflammatory Cytokines During Inflammation: Experimental and Clinical Findings, Review, Vol. 0393-974X
(1997), at pp. 91-103.
Recently, attention has focused on the role of nuclear factor-KB (NF-~cB) in the activation pathway that leads to production of TNF-a and other inflammatory cytokines and gene types. Besides TNF-a, NF-KB modulates many genes involved in immune function and inflammation, including interleukin (IL)-2, IL-6, IL-8, IL-2Ra, GM-CSF, intercellular adhesion molecule (ICAM-1 ), and vascular cellular adhesion molecule-1 (VCAM-1 ).
Thus, inhibition of NF-~cB and/or its activation pathway provides a means for treating a wide range of diseases including autoimmune diseases, Alzheimer's disease, atherosclerosis, oncogenesis, and so forth. See, e.g., Baldwin, "The NF-oB and hcB Proteins: New Discoveries and Insights,"
Annual Rev. Immunol. Vol. 14 (1996), at pp. 649-81; see also Christman et al., "Impact of Basic Research on Tomorrow's Medicine, The Role of Nuclear Factor-oB in Pulmonary Diseases," Chest, Vol. 117 (2000), at pp.
1482-87.
NF-~cB is a transcriptional activator, which plays a central role in regulating the transcription of a number of genes including those, which encode proteins, involved in inflammatory and immune responses.
Representative examples of genes controlled by NF-KB include the cytokines tumor necrosis factor (TNF-a), IL-1 Vii, IL-6, and IL-8; the adhesion molecules E-selectin and vascular cell adhesion molecule (VCAM)-1; and the enzyme nitric oxide (NO)-synthase (for reviews, see Siebenlist et al.
Annu. Rev. Cell Biol. 10: 405-455, 1994; Bauerle and Baltimore, Cell 87:13-20, 1997). Also, NF-~cB has been shown to be inducible by several stimuli, in addition to mediators of immune function, such as UV irradiation, growth factors, and viral infection.
NF-~cB transcription factor normally resides in the cytoplasm in unstimulated cells as an inactive complex with a member of the inhibitor KB
(IxB) inhibitory protein family. The hcB class of proteins includes IKB-a, IKB-~i, and hcB-E all of which contain ankyrin repeats for complexing with NF-KB
(for review, see Whiteside et al., EMBO J. 16:1413-1426,1997). In the case of hcB-a, the most carefully studied member of this class, stimulation of cells with agents which activate NF-~cB-dependent gene transcription results in the phosphorylation of hcB-a at serine-32 and serine-36 (Brown et al.
Science, 267:1485-1488, 1995).
Potential inhibitors of NF-~cB and/or the NF-~cB pathway have been identified as including Interleukin-10, glucocorticoids, salicylates, nitric oxide, and other immunosuppressants. 1»B is a cytoplasmic protein that controls NF-oB activity by retaining NF-~cB in the cytoplasm. IoB is phosphorylated by the l7cB kinase (IKK), which has two isoforms, IKK-1 (or hcB kinase a, IKKa) and IKK-2 (or I~cB kinase ~, IKK~i) . Upon phosphorylation of IKB by IKK, NF-~cB is rapidly released into the cell and translocates to the nucleus where it binds to the promoters of many genes and up-regulates the transcription of pro-inflammatory genes. Inhibitors of IKK can block the phosphorylation of I~cB and further downstream effects, specifically those associated with NF-~cB transcription factors. Glucocorticoids reportedly inhibit NF-~cB activity by two mechanisms, i.e., upregulating I~cB protein levels and inhibiting NF-oB subunits. Nitric oxide also reportedly inhibits NF-oB through upregulation of IoB. However, these mechanisms of interaction are complex; for example, production of nitric oxide in lymphocytes reportedly enhances NF-~cB activity.
Phosphorylation of hcB-a is critical for its subsequent ubiquitination and proteolysis, upon which NF-~cB is released from complexing with IKB.
NF-~cB can then translocate into the nucleus and ultimately, activate gene transcription (Finco et al., Proc. Natl. Acad. Sci. USA 91:11884-11888, 1994; Baldi et al. J. Biol. Chem. 271:376-379, 1996; Roff et al. J. Biol.
Chem. 271:7844-7850, 1996). Substituting both serine-32 and serine-36 of I~cB with alanine prevents signal-induced NF-KB activation and also results in an IoB (e.g. I~cB-a), which is not phosphorylated, ubiquitinated, or proteolytically digested (Roff et al. J. Biol. Chem. 271:7844-7850, 1996).
Analogous serines have been identified in both IxB-~3 and I~cB-s, and phosphorylation at these residues appears to regulate the proteolytic degradation of these proteins by a mechanism similar to that of IKB-a (Weil et al. J. Biol. Chem. 272:9942-9949, 1997; Whiteside et al. EMBO J.
16:1413-1426, 1997).
More particularly, upon phosphorylation, ubiquitination, and degradation of IoB, NF-~cB is released from the hcB/NF-KB complex and allowed to translocate from the cytoplasm to the nucleus and activate a number of genes, particularly those involved in inflammatory and immune responses. Since NF-~cB is of significant importance in inflammation and immune responses, inhibition of the signal-inducible phosphorylation of IKB
can be an important target for novel anti-inflammatory and immune-related agents in the treatment of inflammatory and immune system-related diseases and disorders, as described herein.
IoB kinase (IKK) is a high molecular weight (500-900 kD) multisubunit enzyme which phosphorylates IoB-a at positions serine-32 and serine-36 and has been isolated from HeLa cells (Chen et al. Cell 84:853-862, 1996;
Lee et al. Cell 88:213-222, 1997; DiDonato et al. Nature 388:548-554, 1997). Two catalytic subunits termed IKK-1 and IKK-2 of IKK have been identified, cloned, and demonstrated to be widely expressed in human tissues (DiDonato et al. Nature 388:548-554, 1997; Zandi et al. Cell 91:243-252, 1997; Mercurio et al. Science 278:860-866, 1997; Woronicz et al.
Science 278:866-869, 1997; Li et al. J. Biol. Chem. 273:30736-30741, 1998;
Regnier et al. Cell 90:373-383, 1997).
The IKK-1 and IKK-2 catalytic subunits of IKK are highly homologous, having 50% sequence identity and more than 70% sequence similarity. IKK-1 and IKK-2 are 85- and 87-kDa proteins, respectively. Both kinases contain a catalytic domain followed by a leucine zipper domain and a helix-loop-helix (HLH) domain (Mercurio et al. Science, 278:860-866, 1997).
When one subunit is recombinantly expressed without the other subunit, either one is still able to catalyze the phosphorylation of hcB (Li et al. J.
Biol.
Thus, inhibition of NF-~cB and/or its activation pathway provides a means for treating a wide range of diseases including autoimmune diseases, Alzheimer's disease, atherosclerosis, oncogenesis, and so forth. See, e.g., Baldwin, "The NF-oB and hcB Proteins: New Discoveries and Insights,"
Annual Rev. Immunol. Vol. 14 (1996), at pp. 649-81; see also Christman et al., "Impact of Basic Research on Tomorrow's Medicine, The Role of Nuclear Factor-oB in Pulmonary Diseases," Chest, Vol. 117 (2000), at pp.
1482-87.
NF-~cB is a transcriptional activator, which plays a central role in regulating the transcription of a number of genes including those, which encode proteins, involved in inflammatory and immune responses.
Representative examples of genes controlled by NF-KB include the cytokines tumor necrosis factor (TNF-a), IL-1 Vii, IL-6, and IL-8; the adhesion molecules E-selectin and vascular cell adhesion molecule (VCAM)-1; and the enzyme nitric oxide (NO)-synthase (for reviews, see Siebenlist et al.
Annu. Rev. Cell Biol. 10: 405-455, 1994; Bauerle and Baltimore, Cell 87:13-20, 1997). Also, NF-~cB has been shown to be inducible by several stimuli, in addition to mediators of immune function, such as UV irradiation, growth factors, and viral infection.
NF-~cB transcription factor normally resides in the cytoplasm in unstimulated cells as an inactive complex with a member of the inhibitor KB
(IxB) inhibitory protein family. The hcB class of proteins includes IKB-a, IKB-~i, and hcB-E all of which contain ankyrin repeats for complexing with NF-KB
(for review, see Whiteside et al., EMBO J. 16:1413-1426,1997). In the case of hcB-a, the most carefully studied member of this class, stimulation of cells with agents which activate NF-~cB-dependent gene transcription results in the phosphorylation of hcB-a at serine-32 and serine-36 (Brown et al.
Science, 267:1485-1488, 1995).
Potential inhibitors of NF-~cB and/or the NF-~cB pathway have been identified as including Interleukin-10, glucocorticoids, salicylates, nitric oxide, and other immunosuppressants. 1»B is a cytoplasmic protein that controls NF-oB activity by retaining NF-~cB in the cytoplasm. IoB is phosphorylated by the l7cB kinase (IKK), which has two isoforms, IKK-1 (or hcB kinase a, IKKa) and IKK-2 (or I~cB kinase ~, IKK~i) . Upon phosphorylation of IKB by IKK, NF-~cB is rapidly released into the cell and translocates to the nucleus where it binds to the promoters of many genes and up-regulates the transcription of pro-inflammatory genes. Inhibitors of IKK can block the phosphorylation of I~cB and further downstream effects, specifically those associated with NF-~cB transcription factors. Glucocorticoids reportedly inhibit NF-~cB activity by two mechanisms, i.e., upregulating I~cB protein levels and inhibiting NF-oB subunits. Nitric oxide also reportedly inhibits NF-oB through upregulation of IoB. However, these mechanisms of interaction are complex; for example, production of nitric oxide in lymphocytes reportedly enhances NF-~cB activity.
Phosphorylation of hcB-a is critical for its subsequent ubiquitination and proteolysis, upon which NF-~cB is released from complexing with IKB.
NF-~cB can then translocate into the nucleus and ultimately, activate gene transcription (Finco et al., Proc. Natl. Acad. Sci. USA 91:11884-11888, 1994; Baldi et al. J. Biol. Chem. 271:376-379, 1996; Roff et al. J. Biol.
Chem. 271:7844-7850, 1996). Substituting both serine-32 and serine-36 of I~cB with alanine prevents signal-induced NF-KB activation and also results in an IoB (e.g. I~cB-a), which is not phosphorylated, ubiquitinated, or proteolytically digested (Roff et al. J. Biol. Chem. 271:7844-7850, 1996).
Analogous serines have been identified in both IxB-~3 and I~cB-s, and phosphorylation at these residues appears to regulate the proteolytic degradation of these proteins by a mechanism similar to that of IKB-a (Weil et al. J. Biol. Chem. 272:9942-9949, 1997; Whiteside et al. EMBO J.
16:1413-1426, 1997).
More particularly, upon phosphorylation, ubiquitination, and degradation of IoB, NF-~cB is released from the hcB/NF-KB complex and allowed to translocate from the cytoplasm to the nucleus and activate a number of genes, particularly those involved in inflammatory and immune responses. Since NF-~cB is of significant importance in inflammation and immune responses, inhibition of the signal-inducible phosphorylation of IKB
can be an important target for novel anti-inflammatory and immune-related agents in the treatment of inflammatory and immune system-related diseases and disorders, as described herein.
IoB kinase (IKK) is a high molecular weight (500-900 kD) multisubunit enzyme which phosphorylates IoB-a at positions serine-32 and serine-36 and has been isolated from HeLa cells (Chen et al. Cell 84:853-862, 1996;
Lee et al. Cell 88:213-222, 1997; DiDonato et al. Nature 388:548-554, 1997). Two catalytic subunits termed IKK-1 and IKK-2 of IKK have been identified, cloned, and demonstrated to be widely expressed in human tissues (DiDonato et al. Nature 388:548-554, 1997; Zandi et al. Cell 91:243-252, 1997; Mercurio et al. Science 278:860-866, 1997; Woronicz et al.
Science 278:866-869, 1997; Li et al. J. Biol. Chem. 273:30736-30741, 1998;
Regnier et al. Cell 90:373-383, 1997).
The IKK-1 and IKK-2 catalytic subunits of IKK are highly homologous, having 50% sequence identity and more than 70% sequence similarity. IKK-1 and IKK-2 are 85- and 87-kDa proteins, respectively. Both kinases contain a catalytic domain followed by a leucine zipper domain and a helix-loop-helix (HLH) domain (Mercurio et al. Science, 278:860-866, 1997).
When one subunit is recombinantly expressed without the other subunit, either one is still able to catalyze the phosphorylation of hcB (Li et al. J.
Biol.
Chem., 273:30736-30741, 1998). Thus, IKK, either IKK-1 or IKK-2, can play an important role in signaling hcB for ubiquination and further degradation.
In addition, in vitro studies have demonstrated that the full length IKK~ can autophosphorylate and phosphorylate its substrate, IKBa, as well;
however, neither the N-terminal kinase domain-containing form, nor the C-terminal HLH domain-containing form of IKK was capable of autophosphorylation (U.S. Patent No. 6,077,701 to Chu et al.). U.S. Patent 6,077,701 discloses that compounds which increase IKK~i activity and/ or binding to I~cB can be potential therapeutic targets for inflammatory disease.
Evidence that IKK is involved in the signal inducible degradation of IKB-a was provided by both anti-sense inhibition of IKK-1 and the use of dominant-negative, catalytically-inactive mutants of IKK-1 and IKK-2 (DiDonato et al. Nature 388:548-554, 1997; Mercurio et al. Science 278:860-866, 1997; Woronicz et al. Science 278:866-869, 1997). Both approaches abrogated cytokine- and lipopolysaccharide (LPS)-induced activation of NF
xB. These in vitro assays implicate a role for IKK in activating NF-xB.
There are other kinases which can phosphorylate I~cB and which have been implicated in the activation of NF-~cB. For example, two kinases (pp90rsk and IKK-s) have been demonstrated to phosphorylate hcB-a at serine-32 and! or serine-36. The overexpression of these kinases, and the use of dominant negative mutants to these kinases, have indicated a role for them in the phosphorylation of IoB in cells (Ghoda et al., J. Biol. Chem.
272:21281-21288, 1997; Peters et al., Mol. Cell. 5:513-522, 2000). The existence of multiple hcB kinases is indicative of redundant signaling pathways. Therefore, it is possible that an inhibitor of IKK-1 and/ or IKK-2 can not necessarily show anti-inflammatory or immunosuppressive effects due to redundant signaling pathways in at least some cells.
Several in vitro types of studies have been performed to further investigate IKK and its properties. The in vitro types of cell biology studies (for example, overexpression of either IKK-1 or IKK-2, or of dominant negative versions of these kinases (DiDonato et al. Nature 388:548-554, 1997; Mercurio et al. Science 278:860-866, 1997; Woronicz et al. Science 278:866-869, 1997; Regnier et al. Cell 90:373-383; Zandi et al: Cell 91:243-252)) that appear to implicate IKK-1 and IKK-2 in NF-~cB activation are sometimes artifactual. A particular example of such an artifactual study involves a kinase known as NF-~cB-inducing kinase, NIK.
Overexpression of NIK in cells activated IKK and NF-KB, while expression of kinase-inactive forms of the enzyme blocked the stimulated activation of IKK and NF-~cB (Malinin et al., Nature 385:540-544, 1997; Song et al., Proc. Nat. Acad. Sci. USA 94:9792-9796, 1997). Based on the foregoing, as well as on yeast two-hybrid studies showing a strong interaction between NIK and IKK (Regnier et al., Cell 90:373-383, 1997), NIK is suggested to be essential for the activation of IKK and, subsequently, N F-~cB.
Additional studies have demonstrated that the NIK-IKK protein-protein interaction is important for NF-oB-dependent responses (W099/43704; Publication Date: Sept. 2, 1999; Goeddel et al., U.S. Patent Nos.: 5,851,812; 5,916,760; and 5,939,302). Goeddel et al. show that transient IKK~i overexpression induces luciferase reporter gene activity in both HeLa and 293 cells and overexpression of kinase-inactive IKK(i, which still associates with NIK, blocks activation. However, it was further determined that cells derived from mice deficient in NIK had no abrogated NF-~cB activation (Karin and Ben-Nariah, Ann. Rev. Immunol., 18:621-663, 2000). Therefore, although some studies suggest the importance of NIK as a potential target for inhibiting NF-~cB activation, the experimental results were not demonstrable in vivo, as reported by Karin and Ben-Nariah (supra).
Thus, it is very important that in vitro-based and strictly cell biology-based experiments using overexpressed proteins always be cautiously interpreted.
Although there are several known synthetic inhibitors of IKK, none of these have played a successful role in vivo in disease inhibition. For example, aspirin (acetylsalicyclic acid) and salicylate have been demonstrated to be inhibitors of IKK-1 and IKK-2, but only at high, non-physiological concentrations which are much higher than those required to block prostaglandin synthesis through the inhibition of cyclooxygenase (Yin et al., Nature 396:77-80, 1998). Therefore, these agents are inappropriate for use in treatments or for testing the role of IKK in disease.
Similar to aspirin, 5-aminosalicyclic acid has been shown to inhibit IKK (Yan and Polk, J. Biol. Chem. 274:36631-36636, 1999), but this compound has several other activities, including the inhibition of prostaglandin and leukotriene synthesis (Peskar et al., Deg. Disc. Sci., 32:51 S-56S, 1987; Horn et al., Scand. J. Gastroenterol. 26:867-879, 1991 ) which thereby precludes its use in testing the role of IKK in disease.
Sulindac is a cyclooxygenase inhibitor that has been demonstrated to also inhibit IKK-2 (Yamamoto et al., J. Biol. Chem. 274:27307-27314, 1999).
However, in studies similar to those using aspirin, the concentrations of sulindac necessary for inhibiting IKK were much greater than those needed to inhibit cyclooxygenase. Therefore, this agent is also inappropriate for testing the role of IKK in disease.
Other inhibitors of IKK, more specifically of IKK-2, are cyclopentenone prostaglandins, such as 15dPGJ2 (Rossi et al., Nature 403:103-108, 2000). However, 15dPGJ2, can also activate peroxisome proliferator-activated receptor-gamma (PPAR-y), a nuclear receptor that interferes with NF-~cB transcriptional activity. Therefore, any anti-inflammatory effect could be explained by PPAR-y activity rather than IKK
inhibition. Thus, this inhibitor is not specific for inhibiting the downstream effects of NF-oB-induced inflammation via IKK.
Arsenite, another IKK inhibitor, is a reactive environmental toxin that has been shown to inhibit both IKK-1 and IKK-2 (Kapahi et al., J. Biol.
Chem., 275:36062-36066, 2000). Due to its toxic effects, the therapeutic benefits or in vivo treatment utility of arsenite would therefore preclude its use in patients.
_$_ U.S. Patent Nos. 4,229,452 and 4,200,750 to Warner et al., Colotta et al. (Eur. J. Med. Chem. 30:133-139, 1995) and Ceccarelli et al. (Eur. J. Med.
Chem. 33:943-955, 1998; W097/17079; May 29, 1997) disclose compounds that are structurally different from compound 6 as described herein.
The Aventis Pharma Deutschland GMBH (WO 01/68648) publication discloses particular substituted beta-carboline compounds. The WO
01/68648 publication does not disclose the IKK inhibitor compounds) of the present invention, which have been shown to function and have proven to be effective in a variety of in vivo animal models of diseases or pathologies associated with inflammation, e.g. animal models of arthritis, inflammatory bowel disease, and pulmonary inflammation, and graft survival.
The Astrazeneca AB (WO 01/58890) publication discloses particular heteroaromatic carboxamide derivatives that are structurally different from the compounds of the present invention. The compounds of the WO
01/58890 publication do not demonstrate in vivo efficacy of the IKK inhibitor compounds of the present invention in animal models of disease associated with inflammation and/or the immune system.
In animal models of disease (i.e. knock-out mice) designed to test inhibition of IKK, the deletion of IKK-1 or IKK-2 has been demonstrated to be embryonic lethal (Li et al. Science 284:321-325, 1999; Hu et al. Science 284:316-320, 1999). Therefore, the use of IKK knockout mice to demonstrate a role of IKK in disease is neither practical nor feasible. In contrast, the present invention demonstrates for the first time that inhibitors of the catalytic activity of IKK-1 and IKK-2 are effective in murine models of disease. Such models are believed to be predictive of similar effects in human patients. Therefore, the treatment methods, in vivo models, and effectiveness of IKK inhibitors as described herein, are extremely beneficial and advantageous for the advancement of discovering and employing therapeutics for inflammation and immune system diseases. These animal models are therefore important tools for studying human diseases, specifically inflammatory and immune-related diseases.
_g_ Lactam-based tetracyclic compounds useful as antagonists of NMDA
(N-methyl-D-aspartate) and AMPA (a-3-hydroxy-5-methylisoxazole-4-propionate) receptors are disclosed in WO 94/07893, Preparation of 5H, 10H-imidazo[1,2-a]indeno[1,2-a]pyrazine-4-one AMPA/KA Receptor Antagonist, filed by Aloup et al ; and in articles by Mignani, Aloup, et al., "Synthesis and Pharmacological Properties of 5H, 10H-imidazo[1,2-a]indeno[1,2-a]pyrazine-4-one, a New Competitive AMPA/KA Receptor Antagonist," Drug. Dev. Res., Vol. 48 (3) (1999), at pp. 121-29, and "An Efficient Preparative Route to Fused Imidazo[1,2-a]-Pyrazin-4-one Derivatives," Heterocycles, Vol. 50, No. 1 (1999), at pp. 259-267.
Compounds such as lactams that are claimed to be useful for blocking excitatory amino acid receptors found in the brain and spinal cord are shown in U.S. Pat. Nos. 5,153,196 and 5,196,421, both assigned to Eli Lilly and Company. Tricyclic compounds having amino-substituents claimed to be useful as brain receptor ligands are disclosed in U.S. Pat. No. 5,182,386, assigned to Neurogen Corp., and in U.S. Patents Nos. 4,160,097;
4,172,947; 4,191,766; 4,191,767; 4,198,508; 4,200,750; 4,225,724; and 4,236,015 in W097/19,079, and in S. Ceccarelli et al, "Imidazo[1,2-a]quinoxalin-4-amines: A Novel Class of Nonxanthine A1-Adenosine Receptor Antagonists," European Journal of Medicinal Chemistry Vol. 33, (1998), at pp. 943-955. To applicants' knowledge, 4-amino substituted tetracyclic compounds according to formula (I) have not been previously described.
As can be appreciated, those in the field of pharmaceutical research continue to seek to develop new compounds and compositions having increased effectiveness, bioavailability, and solubility, having fewer side effects, and/or providing the consumer with a choice of options. Particularly in the area of immune response, many individuals respond differently depending upon the type of treatment and chemical agent used.
Mechanisms of action continue to be studied to aid in understanding the immune response and in developing compounds effective for treating immune-related disorders.
In view of the dearth of safe, effective, and novel therapeutics for treating inflammatory or immune-related diseases, there is a need for new anti-inflammatories and agents that reduce, eliminate, and/ or ameliorate inflammation and immune-related disease. In addition, the discovery of additional proteins involved in the processes of inflammation and immune-related diseases and disorders is important for controlling inflammation and adverse immune responses, processes, and the diseases and disorders related thereto. Thus, the identification and characterization of the proteins involved in IKK-mediated cellular processes would benefit the art and be advantageous for providing therapies for those suffering from such disorders and diseases.
SUMMARY OF THE INVENTION
The present invention relates to methods of preventing and treating inflammatory and immune-related diseases or disorders using IKB kinase (IKK) inhibitors, compounds of formula (I) as described herein. Also provided is the IKK inhibitor4(2'-aminoethyl)amino- 1,8-dimethylimidazo(1,2-a) quinoxaline used to prevent and treat inflammatory and immune-related diseases or disorders.
It is an object of the present invention to provide methods of preventing and treating inflammatory and immune-related diseases or disorders using IKK inhibitors either alone, or optionally, in combination with at least one biologically active agent.
It is also an object of the present invention to provide IKK inhibitors for the prevention and treatment of inflammatory and immune-related diseases or disorders.
It is another object of the present invention to provide pharmaceutical compositions comprising IKK inhibitors in a pharmaceutically-acceptable carrier, excipient, or diluent for use in preventing and treating inflammatory and immune-related diseases or disorders.
It is a further object of the present invention to provide methods of preventing and treating diseases and disorders involving inflammation and the immune system. Preferably, the methods comprise the use of IKK
inhibitors for the prevention and treatment of inflammatory and immune-related diseases, non-limiting examples of which include, rheumatoid arthritis, transplant rejection, inflammatory bowel disease, osteoarthritis, asthma, chronic obstructive pulmonary disease, atherosclerosis, psoriasis, multiple sclerosis, stroke, systemic lupus erythematosus, Alzheimer's disease, brain ischemia, traumatic brain injury, Parkinson's disease, amyotrophic lateral sclerosis, subarachnoid hemorrhage or other diseases or disorders associated with excessive production of inflammatory mediators in the brain and central nervous system. , Yet another object of the present invention is to provide methods of inhibiting i) the catalytic activity of IKK; ii) the phosphorylation of IKB;
and/or iii) NF-oB gene expression using IKK inhibitors for the prevention and treatment of inflammatory and immune-related diseases or disorders. .
A more particular object of the present invention is to provide an IKK
inhibitor, 4(2'-aminoethyl)amino- 1,8-dimethylimidazo(1,2-a) quinoxaline, also known as compound 6 herein, or a pharmaceutically-acceptable salt thereof, useful as a preventative and/or therapeutic agent and in methods of treating inflammatory and immune diseases. In accordance with the present invention, compound 6 is shown by the below formula, Me~
Me N ~ N
i NHZ
N N~
H
Yet another embodiment of the present invention relates to 4-amino substituted benzoquinoline, benzoquinoxaline, and benzoquinazoline compounds having five-membered heterocycles (e.g., pyrazolyl, imidazolyl, and thiazolyl rings) fused thereto. The compounds are useful as anti-inflammatory agents and/or for treating conditions associated with TNF-a and NF-~cB activity.
It is a further object of the present invention to provide 4-amino substituted benzoquinoline, benzoquinoxaline, and benzoquinazoline compounds having five-membered heterocycles (e.g., pyrazolyl, imidazolyl, and thiazolyl rings) fused thereto, more specifically, the compounds of formula (I), as described herein. The compounds are useful as anti-inflammatory agents and/or for preventing and treating conditions associated with TNF-a and NF-rcB.
One embodiment of the present invention is further directed to a compound of the formula (I), useful in treating inflammatory diseases or disorders:
X__ ~ A ' / / Y~:YZ N
N NHRZ
C 4~n (R3~m 2~
(I), or a pharmaceutically-acceptable salt thereof, wherein X is NR~, CRS, or S;
Y~ and Y2 are nitrogen or carbon, provided that a) when X is CRS, at least one of Y~ and Y2 is nitrogen; and b) when one of Y~ and Y2 is carbon, the other of Y~ and Y2 is nitrogen and/or X is NR~ or S, so that ring A defines a five-membered heteroaryl ring having at least two heteroatoms;
R~ is hydrogen, halogen, alkyl, substituted alkyl, cyano, OR5, NR5R6, C(=O)R5, C02R5, or aryl;
R2 is alkyl, substituted alkyl, alkenyl, alkynyl, alkoxy, alkylthio, aryl, heteroaryl, heterocyclo, cycloalkyl, or substituted cycloalkyl;
R3 and R4 are independently selected from halogen, alkyl, substituted alkyl, nitro, cyano, ORS, NR7R8, C(=O)R~, CO~R~, C(=O)NR~R8, NR~C(=O)R8, NR7C(=O)OR8, S(O)qR~, NR~SO~R8, and S02NR~R8;
R5, R6, R7, and R$ are independently selected from hydrogen, alkyl, substituted alkyl, and phenyl, or when attached to the same nitrogen atom (as in NR5R6 or NR~R$) can join together to form a heterocycle or heteroaryl;
and m, n and q are independently 0, 1, or 2.
Advantageously, R2, as specified above, is an alkyl optionally substituted with OR' or NR'R", as defined in the specification.
The invention also relates to pharmaceutical compositions containing at least one compound of formula (I) and a pharmaceutically-acceptable carrier or diluent. Also included within the invention are methods of~
preventing and treating inflammatory and immune-related diseases and disorders comprising administering to a mammal in need of such prevention and/or treatment an efiFective amount of at least one compound of formula Another object of the present invention is to provide kits for treating inflammatory and immune-related diseases and disorders, comprising one or more IKK inhibitors, compound 6, and/or compounds of formula (!) as described herein.
BRIEF DESCRIPTION OF THE FIGURES
FIGURE 1 shows the effect of 4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a) quinoxaline (compound 6) on disease incidence in the murine model of collagen-induced arthritis. The compound was administered once daily in a preventative dosing mode. *p<0.05, Fisher's Exact test.
FIGURE 2 shows the effect of 4(2'-aminoethyl)amino- 1,8-dimethylimidazo(1,2-a) quinoxaline (compound 6) on the average gross clinical score for all mice within each treatment in the murine model of collagen-induced arthritis based on clinical scores corresponding to the study day. The test compound was administered once daily in the preventative dosing mode. *p<0.05, Mann-Whitney U-test.
FIGURE 3 shows the effect of 4(2'-aminoethyl)amino- 1,8-dimethylimidazo(1,2-a) quinoxaline (compound 6) on disease incidence in the murine model of collagen-induced arthritis based on the clinical score corresponding to the days after disease onset. The test compound was administered once daily in the established disease dosing mode. *p<0.05, Mann-Whitney U-test.
DESCRIPTION OF THE INVENTION
The present invention describes methods of preventing and treating inflammatory and immune-related diseases or disorders using inhibitors of hcB kinase (IKK). Such methods are efficacious in vivo in inhibiting IKK
activity in mammalian, including human and biological systems, e.g. animal models of disease.
In one of its aspects, the present invention relates to methods of inhibiting the catalytic activity of IKK using inhibitors. The inhibitors of the present invention preferably inhibit the catalytic activity of the IKKs (see, Example 2). For example, inhibitors can include small molecule enzyme inhibitors which bind directly to the enzyme, preferably IKK, and more preferably IKK-2. Without wishing to be bound by theory, it is believed that the binding of the inhibitor to the active site of IKK also inhibits binding of substrate, such as, for example, hcB or ATP.
One embodiment of the present invention provides a novel IKK
inhibitor, 4(2'-aminoethyl) amino-1,8-dimethylimidazo(1,2-a) quinoxaline (compound 6), wherein the compounds of the present invention can be used in methods for the prevention and treatment of inflammatory and immune-related diseases or disorders.
Another embodiment of the present invention provides 4-amino substituted benzoquinoline, benzoquinoxaline, and benzoquinazoline compounds having five-membered heterocycles (e.g., pyrazolyl, imidazolyl, and thiazolyl rings) fused thereto. The compounds are useful as anti-inflammatory agents and/or for treating conditions associated with TNF-a and NF-~cB.
Also provided are pharmaceutical compositions comprising IKK
inhibitor compounds or salts thereof, and kits comprising IKK inhibitor compounds or salts thereof.
Definitions The following definitions are provided to more fully describe the present invention in its various aspects. The definitions are intended to be useful for guidance and elucidation, and are not intended to limit the disclosed invention and its embodiments.
The term "IoB" as used herein, is defined as Inhibitor KB. The IKB
family comprises IoBa, IoB~i, and IoB~, all of which contain ankyrin repeats for complexing to NF-~sB.
The term "IKK" as used herein, refers to hcB-kinase (IKK). IKK
comprises two catalytic subunits, IKK-1 and IKK-2, also known as IKKa and IKK~i, respectively.
"Activation of IKK" as used herein means changing an inactive IKK
protein into an active IKK protein that functions as an IKB kinase. Activated IKK phosphorylates serine-32 and serine-36 of I~cB, which thus marks the IKB for ubiquitination and degradation.
"IKK inhibitors" according to the invention refer to those compounds or molecules which prevent, block, abolish, antagonize, suppress, or reduce the activation of IKK as defined above. In addition, IKK inhibitors inhibit the activity of IKK, preferably the in vivo activity of IKK, such that one or more of the following occurs: 1) inhibition of IKK catalytic activity; 2) inhibition of IKB
phosphorylation, preferably catalyzed phosphorylation of I~cB; and/or 3) inhibition of NF-~cB-dependent gene expression activation.
A "selective inhibitor", as referred to herein, inhibits one protein at a higher level or degree than another protein. An inhibitor is considered to be selective for one protein over another protein when there is preferably at least about a 5-fold or greater difference in inhibition of one protein compared with another protein. More preferably, there is at least about an 8-fold or greater difference in inhibition of one protein compared with another protein.
"Nuclear factor-oB" or "NF-KB" as used herein, is defined as a ubiquitously expressed family of eukaryotic transcription factors. This family comprises a homo- or hetero-dimer of DNA-binding proteins related to c-Rel, a proto-oncogene that controls the expression of many ~cB-dependent immune, inflammatory, and anti-apoptotic response genes.
The phrase "NF-~cB-dependent gene expression" as used herein, is defined as those immune-related and inflammatory genes that are under the regulatory control of the KB-enhancer. In most cells, NF-~cB exists in a dormant state in the cytoplasm bound to inhibitory proteins, collectively called hcB, that conceal the nuclear localization signal, thereby preventing nuclear translocation. Activation of NF-oB can be induced by cytokines, such as TNFa, and IL-1, where both TNF-a and IL-1 signaling results in sequential phosphorylation and activation of a cascade of proteins.
Specifically, activation of IKK or modification of the catalytic action of IKK
results in phosphorylation, ubiquitination, and degradation of IKB.
The term "treat", "treating", or "treatment" refers to the prevention, reduction, or amelioration, partial or complete alleviation, or cure of a disease, disorder, or condition. NF-~cB plays an important role in inflammation and immune response; therefore, the inhibition of hcB
phosphorylation can also be an important target for novel anti-inflammatory and immune-related agents.
The phrase "NF-~cB-associated condition" refers to diseases that are characterized by release of NF-ICB from the cytoplasm (e.g., upon phosphorylation of I~cB).
The phrase "TNF-a-associated condition" is a condition characfierized by enhanced levels of TNF-a. In the instant specification, the term NF-KB-associated condition includes a TNF-a-associated condition but is not limited thereto as 'NF-~cB is involved in the activity and upregulation of other pro-inflammatory proteins and genes.
The term "inflammatory or immune diseases or disorders" is used herein to encompass both IKK-associated conditions, NF-~cB-associated conditions, TNF-a-associated conditions, e.g., any condition, disease, or disorder that is associated with release of NF-KB and/or enhanced levels of TNF-a, including each of the conditions specifically referenced below.
"Bioavailability" as referred to herein is the rate and extent to which an active ingredient or moiety is absorbed from a pharmaceutical composition and becomes available at the site of action. For drug products that are not intended to be absorbed into the bloodstream, bioavailability may be assessed by measurements intended to reflect the rate and extent to which the active ingredient or active moiety becomes available at the site of action.
The term "prodrug" denotes a therapeutic agent that is prepared in an inactive form, which upon administration to a subject, undergoes chemical conversion by metabolic or chemical processes by the action of endogenous enzymes or other chemicals and/or conditions, to yield the active compounds of the present invention, and/or salt and/or solvate thereof. For example, compounds containing a carboxy group can form physiologically hydrolyzable esters which serve as prodrugs by being hydrolyzed in the body to yield formula I-II compounds per se.
The term "alkyl" refers to straight or branched chain hydrocarbon groups having 1 to 12 carbon atoms, preferably 1 to 8 carbon atoms. Lower alkyl groups, that is, alkyl groups of 1 to 4 carbon atoms, are most preferred.
When numbers appear in subscript after the symbol "C", the subscript defines with more specificity the number of carbon atoms that a particular group can contain. For example, "C~_6alkyl" refers to straight and branched chain alkyl groups with one to six carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, and so forth.
The term "substituted alkyl" refers to an alkyl group as defined above having one, two, or three substituents selected from the group consisting of halo, amino, cyano, hydroxy, alkoxy, alkylthio, -C(=O)H, -C02H, -(C=O)alkyl, -CO~alkyl, cycloalkyl, substituted cycloalkyl, aryl, heteroaryl, or heterocycle.
Thus, the term "substituted alkyl" includes a polyfluoroalkyl, i.e., where two or more hydrogen atoms of an alkyl chain are replaced by a fluorine atom, such as with trifluoromethyl. The term "substituted alkyl" also includes an alkyl group as defined above having the substituent NR'R", wherein each of R' and R" are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, hydroxy, alkoxy, -C(=O)H, -COSH -(C=0)alkyl, -C02-alkyl, cycloalkyl, substituted cycloalkyl, aryl, heteroaryl, and heterocycle.
Alternatively, R' and R" can together form a heterocyclo or heteroaryl ring.
A substituted lower alkyl or substituted C~_4alkyl refers to an alkyl group of 4 carbon atoms having one to three substituents selected from those recited above for alkyl groups generally.
The term "alkoxy" refers to an alkyl group as defined above bonded through an oxygen atom (-O-), and the term "alkylthio" refers to an alkyl group as defined above bonded through a sulfur atom (-S-). For example, such groups include methoxy, methylthio, ethoxy, ethylthio, n-propoxy, n-propylthio, isopropoxy, isopropylthio, n-butoxy, n-butylthio, tert-butoxy, tert-butylthio, n-pentoxy, n-pentylthio, and so forth.
The term "alkenyl" refers to straight or branched chain hydrocarbon groups having 2 to 12 carbon atoms and at least one double bond. Alkenyl groups having 2 to 6 carbon atoms and one double bond are most preferred.
Exemplary alkenyl groups include ethenyl, 1-methyl-ethenyl, 1- or 2-propenyl, 1-methyl-1-propenyl, 1-methyl-2-propenyl, 1,1-dimethyl-2-propenyl, 2-methyl-2-propenyl, 1- , 2- or 3-butenyl, 1-methyl-1-butenyl, 2-methyl-1-butenyl, 3-methyl-1-butenyl, 3,3-dimethyl-1-butenyl, 2,3-dimethyl-1-butenyl, 1-methyl-2-butenyl, 1,1-dimethyl-2-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 1,3-butadienyl, 1,3-dimethyl-1,3-butadienyl, 1-, 2-, 3- or 4-pentenyl, and so forth.
IS The term "alkynyl" refers to straight or branched chain hydrocarbon groups having 2 to 12 carbon atoms and at least one triple bond. Alkynyl groups of 2 to 6 carbon atoms and having one triple bond are most preferred. Exemplary alkynyl groups include ethynyl, 1- or 2-propynyl, 1-methyl-2-propynyl, 1,1-dimethyl-2-propynyl, 1-, 2- or 3-butynyl, 3-methyl-1-butynyl, 3,3-dimethyl-1-butynyl, 1-methyl-2-butynyl, 1,1-dimethyl-2-butynyl, 1-, 2- 3, or 4-pentynyl, and so forth.
The term "amino" when used alone refers to NH2. When used to define a substituent, as in 4-amino substituted tetracycles, the term "amino"
refers to the group NR'R", wherein R' and R" are as defined above for alkyl.
The term "carbonyl" refers to -C(=O)-, and "carboxy" refers to -C02-.
Thus, carbonylC~_4alkyl refers to the group -C(=O) linked to a C~_4 alkyl.
The term "halo" or "halogen" refers to chloro, bromo, fluoro and iodo.
The term "cycloalkyl" refers to fully saturated and partially unsaturated hydrocarbon rings of 3 to 9, preferably 3 to 7, carbon atoms as well as such rings having a fused aryl ring such as indan or a bridge of three to four carbon atoms as in bicycloheptane.
The term "substituted cycloalkyP' refers to such rings having one, two, or three substituents, preferably one, selected from the group consisting of alkyl, substituted alkyl, alkoxy, alkylthio, halo, hydroxy, cyano, amino, -NH(alkyl), -NH(cycloalkyl), -N(alkyl)2, -C02H, -C021ower alkyl, aryl, heterocyclo, heteroaryl, keto (=O), =N-OH, =N-O-lower alkyl, and a five or six membered ketal, i.e., 1,3-dioxolane or 1,3-dioxane.
The term "aryl" refers to phenyl, 1-naphthyl and 2-naphthyl, with phenyl being preferred. When the term "aryl" is used, it encompasses such rings having from zero, one, two or three substituents selected from the group consisting of alkyl, substituted alkyl, alkoxy, alkylthio, halo, hydroxy, nitro, cyano, amino, -NH(alkyl), -NH(cycloalkyl), -N(alkyl)2, -CO2H, -(C=O)alkyl, -C02-alkyl, cycloalkyl, substituted cycloalkyl, -(C=0)NH2, -(C=O)NH(alkyl), -(C=O)NH(cycloalkyl), -(C=O)N(alkyl)2, -NH-CH2-C02H, -NH-CHI-C02-alkyl, phenyl, benzyl, phenylethyl, phenyloxy, phenylthio, heterocyclo, and heteroaryl.
The term "heterocyclo" or "heterocycle" refers to substituted and unsubstituted non-aromatic 3 to 7 membered monocyclic groups, 7 to 11 membered bicyclic groups, and 10 to 15 membered tricyclic groups which have at least one heteroatom (O, S, or N) in at least one of the rings. When the heterocyclo is monocyclic, five- or six-membered rings are preferred;
when bicyclic, fused 5,6- or 6,6-membered ring systems are preferred; and when tricyclic, ring systems having one five and two six membered rings, or three six membered rings, are preferred. Each ring of the heterocyclo group containing a heteroatom can contain one or two oxygen or sulfur atoms and/or from one to four nitrogen atoms provided that the total number of heteroatoms in each ring is four or less, and further provided that the ring contains at least one carbon atom. The fused rings completing the bicyclic and tricyclic groups can contain only carbon atoms and can be saturated, partially saturated, or unsaturated. The nitrogen and sulfur atoms can optionally be oxidized and the nitrogen atoms can optionally be quaternized.
The heterocyclo group can be attached at any available nitrogen or carbon atom.
Whenever the term "heterocyclo" or "heterocyc(e" is used, any ring of the heterocyclo group can optionally contain one, two, or three substituents selected from the group consisting of halo, amino, cyano, alkyl, substituted alkyl, -NH(alkyl), -NH(cycloalkyl), -N(alkyl)2, alkoxy, alkylthio, hydroxy, nitro, phenyl, benzyl, phenylethyl, phenyloxy, phenylthio, -C02H, -C02-alkyl, cycloalkyl, substituted cycloalkyl, -(C=O)NH2, -(C=O)NH(alkyl), -(C=O)NH(cycloalkyl), -(C=O)N(alkyl)2, -NH-CH2-C02H, -NH-CH2-C02-alkyl, heterocyclo, heteroaryl, keto, =N-OH, =N-O-lower alkyl, and a five or six membered ketal, i.e., 1,3-dioxolane or 1,3-dioxane.
Exemplary monocyclic groups include tetrahydrothienyl, tetrahydrofuryl, azetidinyl, pyrrolidinyl, oxetanyl, imidazolinyl, oxazolidinyl, isoxazolinyl, thiazolidinyl, isothiazolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl, 4-piperidonyl, tetrahydropyranyl, morpholinyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, 1,3-dioxolane and tetrahydro-1,1-dioxothienyl and the like. Exemplary bicyclic heterocyclo groups include quinuclidinyl.
The term "heteroaryl" refers to substituted and unsubstituted aromatic 5 or 6 membered monocyclic groups, 9 or 10 membered bicyclic groups, and 11 to 14 membered tricyclic groups which have at least one heteroatom (O, S or N) in at least one of the rings. When the heteroaryl is monocyclic, five- or six membered rings are preferred; when bicyclic, fused 5,6- or 6,6-membered ring systems are preferred; and when tricyclic, ring systems having one five and two six membered rings, or three six-membered rings, are preferred. Each ring of the heteroaryl group containing a heteroatom can contain one or two oxygen or sulfur atoms and/or from one to four nitrogen atoms provided that the total number of heteroatoms in each ring is four or less and each ring has at least one carbon atom. The fused rings completing the bicyc(ic and tricyclic groups can contain only carbon atoms and can be saturated, partially saturated, or unsaturated. The nitrogen and sulfur atoms can optionally be oxidized and the nitrogen atoms can optionally be quaternized. Heteroaryl groups which are bicyclic or tricyclic include at least one fully aromatic ring but the other fused ring or rings can be aromatic or non-aromatic. The heteroaryl group can be attached at any available nitrogen or carbon atom of any ring.
Whenever the term "heteroaryl' is used herein, any ring of the heteroaryl group can optionally contain one, two or three substituents selected from the group consisting of halo, amino, cyano, alkyl, substituted alkyl, -NH(alkyl), -NH(cycloalkyl), -N(alkyl)2, alkoxy, alkylthio, hydroxy, nitro, phenyl, benzyl, phenylethyl, phenyloxy, phenylthio, -C02H, -C02-alkyl, cycloalkyl, substituted cycloalkyl, -(C=O)NH~, -(C=O)NH(alkyl), -(C=O)NH(cycloalkyl), -(C=O)N(alkyl)2, -NH-CH2-C02H, -NH-CH2-C02-alkyl, heterocyclo, and heteroaryl.
Exemplary monocyclic heteroaryl groups include pyrrolyl, pyrazolyl, pyrazolinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, furanyl, thienyl, oxadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, triazolyl, and the like.
Exemplary bicyclic heteroaryl groups include indolyl, isoindolyl, benzothiazolyl, benzodioxolyl, benzoxaxolyl, benzothienyl, quinolinyl, tetrahydroisoquinolinyl, isoquinolinyl, benzimidazolyl, benzopyranyl, indolizinyl, benzofuranyl, isobenzofuranyl, chromonyl, coumarinyl, benzopyranyl, cinnolinyl, quinoxalinyl, quinazolinyl, indazolyl, pyrrolopyridyl, furopyridinyl, dihydroisoindolyl, tetrahydroquinolinyl, napthyridinyl, pteridinyl, and the like.
Exemplary tricyclic heteroaryl groups include carbazolyl, benzidolyl, phenanthrollinyl, acridinyl, phenanthridinyl, xanthenyl and the like.
DETAILED DESCRIPTION OF THE INVENTION
Since activation of NF-~cB-dependent gene expression is associated with the activation of IKK-dependent phosphorylation of IKB and genes involved in inflammatory and immune-related diseases or disorders, one emobidment of the present invention generally relates to the prevention and treatment of inflammatory and immune-related diseases, disorders, or conditions using IKK inhibitors. More specifically, embodiments of the present invention relate to: 1 ) methods of inhibiting IKK to prevent and/or treat inflammatory and immune-related diseases, disorders, or conditions; 2) methods of inhibiting the activation of NF-~cB-dependent gene expression by inhibiting the IKK-dependent phosphorylation of IKB for preventing and treating inflammatory and/or immune-related diseases, disorders, or conditions; 3) inhibitors of IKK; 4) the use of inhibitors of IKK in the methods of the present invention; and 5) exemplary IKK inhibitor compounds which inhibit IKK.
As described herein, an embodiment of the present invention demonstrates the in vivo employment of an IKK inhibitor for use in methods for treating and preventing inflammatory and immune-related diseases or disorders (Examples 4-7). Prior to the present invention, there have been no demonstrations of the actual in vivo therapeutic effectiveness of IKK
inhibitors in treating and preventing inflammatory or immune-related diseases, such as, for example, asthma, inflammatory bowel disease, tissue/organ transplant rejection, e.g., graft versus host rejection, and pulmonary diseases, for example, involving inflammatory cell infiltration in the lung.
Accordingly, an aspect of the present invention provides therapeutic and prophylactic methods of treating and preventing inflammatory or immune-related diseases, disorders, or conditions by administering an effective amount of one or more IKK inhibitors, or salt thereof, alone, or optionally, in combination with another IKK inhibitor, to a subject, preferably a mammal, in need thereof. In addition, other therapeutic or biologically active agents can be used in combination with the IKK inhibitors, for example, drugs, hormones, or synthetic agents, such as those described below, for example. In the methods of the present invention, such therapeutic or biologically active agents can be administered prior to, simultaneously with, or following the administration of one or more of the IKK inhibitors of the present invention.
More specifically, IKK inhibitors can also be used in accordance with the described methods in conjunction with other drugs, such as cyclosporine A or CTLA4-Ig, to alleviate transplant rejection. Cyclosporine A is a potent immunosuppressive compound currently used therapeutically in humans to prevent graft rejection following solid organ transplantation. Most current therapeutic protocols for transplant include cyclosporine A in combination with other potent immunosuppressive drugs such as steroids and antiproliferative agents such as mycophenolic acid. When test compounds are examined for clinical efficacy in solid organ transplant, the protocols generally include treatment of the patients with test compounds in addition to standard therapeutics including cyclosporine A. Therefore, in order to progress with clinical development of new compounds, new compounds must work beneficially well with cyclosporine A.
CTLA4-Ig is an immunoglobulin fusion protein that binds to the ligands for CD28 and CTLA4 (Linsley et al. J. Exp. Med., 174:561-569, 1991 ). CTLA4-Ig is a promising agent that is effective in the treatment of transplant rejection (Larsen et al., Nature, 381:434-438, 1996). Since some form of CTLA4-Ig could become part of the standard treatment paradigm for transplantation, new compounds developed for the prevention of graft rejection would be important, particularly in conjunction with CTLA4-Ig.
Embodiments of the present invention further embrace methods of inhibiting the IKK enzyme, comprising administering to an individual suffering from an inflammatory or immune-related disease or disorder, an IKK inhibitor in an amount effective to inhibit the catalytic activity of IKK
and the IKK-dependent phosphorylation of I~cB. Without wishing to be bound by theory, the mechanism of inhibition of IKK involves inhibiting the catalytic activity of the IKKs, eifiher IKK-1 or IKK-2, preferably IKK-2, through binding to the active site of the enzyme and inhibiting the binding and/or phosphorylation of substrates such as hcB and ATP (see Example 2).
One embodiment of fihe present invention encompasses a method of inhibiting the phosphorylation of I~cB inhibitor protein which comprises the administration of IKK inhibitors in an amount effective to inhibit the phosphorylation of the hcB protein. In particular, inhibition of IKB-a phosphorylation is preferred, and the inhibition of phosphorylation of IxB-a at serine-32 and serine-36 is more preferred.
According to the present invention, compounds which inhibit IKK, i.e.
IKK inhibitors, can be used in the methods for preventing and treating inflammatory and immune system-related conditions, diseases, or disorders.
Non-limiting examples of such diseases, disorders, and conditions include arthritis, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, acute pancreatitis, chronic pancreatitis, psoriasis, glomerulonephritis, serum sickness, lupus (systematic lupus erythematosis), urticaria, scleraclerma, contact dermatitis, dermatomyositis, alopecia, atopic eczemas, ichthyosisrhinitis, inflammatory bowel disease (Crohn's and ulcerative colitis); Alzheimer's disease, brain ischemia, traumatic brain injury, Parkinson's Disease, Creutzfeldt-Jacob diseases, HIV encephalitis, cerebral malaria, and meningitis, atherosclerosis, ataxia telangiectasis, septic shock, multiple sclerosis, amyotrophic lateral sclerosis, atherosclerosis, subarachnoid hemorrhage, autoimmune diseases, systemic lupus erythematosus, multiple sclerosis, hematopoiesis, pulmonary diseases, respiratory allergies, asthma, acute respiratory distress syndrome, hayfever, allergic rhinitis, allergic respiratory disease, herpes simplex type 1 (HSV-1), herpes simplex type 2 (HSV-2), cytomegalovirus, Epstein-Barr, human immunodeficiency virus (HIV), Addison's disease (autoimmune disease of the adrenal glands), idiopathic adrenal insufficiency, autoimmune polyglandular disease (also known as autoimmune polyglandular syndrome), fungal infections, mycosis fungoides, chronic obstructive pulmonary disorder; tissue/ organ transplant rejection (e.g., kidney, liver, heart, lung, pancreas, bone marrow, cornea, small bowel, skin allografts, skin homografts, and heterografts, etc.); stroke, oncological diseases, cancer, tumors, breast cancer, prostate cancer, and Hodgkin's lymphoma.
IKK inhibitors of the present invention can be used to prevent, treat or ameliorate diseases and conditions, particularly inflammatory or immune-related diseases or conditions. Without wishing to be bound by theory, the IKK inhibitors are employed in preventing and treating diseases, disorders, or conditions characterized by NF-ICB activation via phosphorylation of IKB
by IKK. Specifically, the embodiments of the present invention further relate to IKK inhibitors that inhibit the catalytic activity of the IKK enzyme, thereby blocking phosphorylation of I~cB and downstream transcriptional activation of KB gene expression, such as NF-~cB.
In one embodiment of the present invention, an IKK inhibitor has an IC5o against IKK activity ranging from about 0.01 ~,M to about 50 p,M.
Preferably, the IKK inhibitor has an IC5o against IKK activity ranging from about 0.01 ~,M to about 10 ~,M, more preferably from about 0.01 ~,M to about 5 ~,M, and most preferably from about 0.01 ~.M to about 1 ~,M.
Yet another embodiment of the present invention encompasses IKK
inhibitors that have selectivity for IKK-2 over IKK-1 (see Example 2).
Preferably, a selective IKK inhibitor has at least about a 5-fold or greater selectivity for IKK-2 over IKK-1. More preferably, a selective IKK inhibitor has at least about an 8-fold or greater selectivity for IKK-2 over IKK-1. As a more particular guide, for example, inhibition of IKK-2 activity is about 5-to 500-fold, or about 8- to 100-fold, relative to IKK-1 activity, preferably about 10- to 100-fold, and more preferably, about 10 to 50-fold.
In a preferred aspect, according to the invention, selective inhibitors affect about 50% inhibition of IKK activity at an IC50 against IKK activity ranging from about 0.01 ~.M to about 50 ~.M. Preferably, selective inhibitors have an IC50 against IKK activity ranging from about 0.01 ~,M to about 10 p,M, and preferably, from about 0.01 p.M to about 5 pM. Most preferably, selective inhibitors have an IC50 ranging from about 0.01 ~,M to about 1 pM.
A preferred embodiment of the present invention comprises IKK
inhibitors selective for IKK-2. Preferably, the selective IKK-2 inhibitor has an IC50 against IKK-2 activity, ranging from about 0.01 ~,M to about 5 ~,M, and more preferably, an IC50 against IKK-2 activity, ranging from about 0.01 p,M
to about 1 p.M.
In another aspect, bioavailability of the inhibitor compounds was assessed. For example, the pharmacokinetics of compound 6 in mice is described in Example 3. For guidance, an effective oral bioavailability for the IKK inhibitor of the present invention ranges from about 10% to about 100%, preferably from about 50% to about 100%, and more preferably from about 80% to about 100%. From a pharmacokinetic perspective, bioavailability data for a given compound estimate the relative fraction of the orally administered dose that is absorbed into the systemic circulation when compared to the bioavailability data for a solution, suspension, or intravenous dosage form.
The present invention further relates to methods of testing the inhibitory potential of candidate IKK inhibitors. Specifically, Example 2 analyzes test compounds and their capacity to inhibit IKK activity by measuring the concentration of phosphorylated substrate, specifically IKB, and the concentration of test IKK inhibitor compound necessary to achieve 50% inhibition of IKK activity.
One embodiment of the present invention provides beneficial and advantageous in vivo animal studies using IKK inhibitors that demonstrate compound efficacy using methods of the present invention. For example, 4 (2'-aminoethyl)amino- 1,8-dimethylimidazo(1,2-a) quinoxaline, compound 6 herein, or a salt thereof, newly discovered by the present inventors, inhibits the catalytic activity of I~cB kinase by blocking the active site of IKK which is responsible for phosphorylating the IKB protein. Moreover, the examples described herein demonstrate that IKK inhibitors are particularly useful in methods of treating inflammatory and immune-related diseases or disorders in several different animal models of disease that are considered to be predictive of similar employment and effects in human patients.
The compounds and compositions of this invention are also useful in treating conditions that are characterized by release of NF-~cB and/or enhanced levels of TNF-a. Inhibition or suppression of NF-oB and/or TNF-a may occur locally, for example, within certain tissues of the subject, or more extensively throughout the subject being treated for such a disease.
Inhibition or suppression of NF-~cB and/or TNF-a may occur by one or more mechanisms, e.g., by inhibiting or suppressing any step of the pathway(s), preferably inhibition of IKK. The present invention thus provides methods for treating such conditions, comprising administering to a subject in need thereof an effective amount of at least one compound, of formula (I), compound 6, or salt thereof. Other therapeutic agents such as those described below may be employed in combination with the IKK inhibitors, compound 6, and/or compounds of formula (I). In the methods of the present invention, such other therapeutic agents) may be administered prior to, simultaneously with, or following the administration of the inventive compound.
Compound 6 is structurally represented by the following formula as shown below:
Me~
Me N s N
i NHz N N~
H
The formula of compound 6 or 4(2'-aminoethyl)amino- 1,8-dimethylimidazo(1,2-a) quinoxaline forms salts which are also within the scope of the present invention. Unless otherwise indicated, reference to an IKK compound according to this invention is understood to include reference to salts thereof, as further described below.
In another embodiment of the present invention compounds of formula (1) are useful in treating inflammatory diseases or disorders:
/ / Y~~Y;'N
( ~n (Rg~m (1), or a pharmaceutically-acceptable salt thereof, wherein X is NR~, CRS, or S;
Y~ and Y2 are nitrogen or carbon, provided that a) when X is CRS, at least one of Y~ and Y2 is nitrogen; and b) when one of Y~ and Y2 is carbon, the other of Y~ and Y2 is nitrogen and/or X is NR~ or S, so that ring A defines a five-membered heteroaryl ring having at least two heteroatoms;
R~ is hydrogen, halogen, alkyl, substituted alkyl, cyano, OR5, NR5R6, C(=O)R5, C02R5, or aryl;
R2 is alkyl, substituted alkyl, alkenyl, alkynyl, alkoxy, alkylthio, aryl, heteroaryl, heterocyclo, cycloalkyl, or substituted cycloalkyl;
R3 and R4 are independently selected from halogen, alkyl, substituted alkyl, nitro, cyano, ORS, NR~R8, C(=O)R~, C02R~, C(=O)NR7R8, NR~C(=O)R8, NR~C(=O)OR8, S(O)qR~, NR~SOZR8, and S02NR~R8;
R5, R6, R~, and R$ are independently selected from hydrogen, alkyl, substituted alkyl, and phenyl, or when attached to the same nitrogen atom (as in NR5R6 or NR7R$) can join together to form a heterocycle or heteroaryl;
and m, n and q are independently 0, 1, or 2.
Yet another embodiment of the present invention encompasses the compounds having the formula (If):
X__ ~A,N
Y ~ ' YZ
\ \ i\
N NHRZ (1.~, and pharmaceutically-acceptable salts thereof, wherein X is NR~, CRS, or S;
Y~ and Y2 are nitrogen or carbon. provided that a) when X is CRS, one of Y~ and Y2 is nitrogen, and b) when one of Y~ and Y2 is carbon, either the other of Y~ and Y2 is nitrogen or X is NR~ or S, so that ring A defines a five-membered heteroaryl ring having two heteroatoms;
R~ is hydrogen, halogen, lower alkyl, or substituted lower alkyl;
R2 is alkyl or substituted alkyl.
More preferred are the compounds of formula (If), above, and/or pharmaceutically acceptable salts thereof, wherein X is NR~ or CRS;
R~ is hydrogen, halogen, lower alkyl, or trifluoromethyl;
R2 is C~_~ alkyl optionally substituted with OR9 or NR~oR~~;
R9 is hydrogen or lower alkyl; and Rio and R~~ are (i) independently selected from hydrogen, C~_2alkyl, C~_ 2substituted alkyl, and -(C=O)C~_~alkyl, or alternatively (ii) together form a five to six membered heterocycle or heteroaryl.
Most preferred are the compounds of formula (If), above, and/or pharmaceutically acceptable salts thereof, wherein ring A is selected from:
R~ R~ R~
\N
and \ ,N
N
R~ is hydrogen, halogen, ethyl, methyl, or trifluoromethyl; and R2 is a C~_2 alkyl optionally substituted with one of:
OH, NH2, NH(C~_2alkyl), N(C~_2alkyl)2, NH(C~_~substituted alkyl), N(C~_ 2substituted alkyl)2, NH(C=O)C~_2alkyl, and piperidinyl.
Advantageously, R~ does not include hydroxy or an alkyl substituted with hyd roxy.
When reference is made herein to a bond having a solid and dashed line, such as in [ ] , it should be understood that the bonds) can be selected from a single or a double bond, as appropriate, given selections for X~B
y adjacent atoms. For example, when there is shown A , if X is sulfur or NH, the bonds linking X to adjacent atoms A and B are single bonds.
X/B
However, when in A , X is CRS or a nitrogen atom, one of the bonds linking X to A or B is a double bond and the other is a single bond.
Throughout this disclosure, groups and substituents thereof can be chosen by one skilled in the field to provide stable moieties and compounds.
The compounds of formula (I) and/or compound 6 form salts which are also within the scope of this invention. Unless otherwise indicated, reference to an inventive compound is understood to include reference to salts thereof. The term "salt(s)" denotes acidic and/or basic salts formed with inorganic and/or organic acids and bases. In addition, the term "salt(s) can include zwitterions (inner salts), e.g., when a compound of formula (I) contains both a basic moiety, such as an amine or a pyridine or imidazole ring, and an acidic moiety, such as a carboxylic acid. Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, such as, for example, acceptable metal and amine salts in which the cation does not contribute significantly to the toxicity or biological activity of the salt. However, other salts can be useful, e.g., in isolation or purification steps which can be employed during preparation, and thus, are contemplated within the scope of the invention. Salts of the compounds of the formula (I) can be formed, for example, by reacting a compound of the formula (i) with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.
Exemplary acid addition salts include acetates (such as those formed with acetic acid or trihaloacetic acid, for example, trifluoroacetic acid), adipates, alginates, ascorbates, aspartates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, cyclopentanepropionates, digluconates, dodecylsulfates, ethanesulfonates, fumarates, glucoheptanoates, glycerophosphates, hemisulfates, heptanoates, hexanoates, hydrochlorides (formed with hydrochloric acid), hydrobromides (formed with hydrogen bromide), hydroiodides, 2-hydroxyethanesulfonates, lactates, maleates (formed with malefic acid), methanesulfonates (formed with methanesulfonic acid), 2-naphthalenesulfonates, nicotinates, nitrates, oxalates, pectinates, persulfates, 3-phenylpropionates, phosphates, picrates, pivalates, propionates, salicylates, succinates, sulfates (such as those formed with sulfuric acid), sulfonates (such as those mentioned herein), tartrates, thiocyanates, toluenesulfonates such as tosylates, undecanoates, and the like.
Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts; alkaline earth metal salts such as calcium and magnesium salts; barium, zinc, and aluminum salts; salts with organic bases (for example, organic amines) such as trialkylamines such as TEA, procaine, dibenzylamine, N-benzyl-~i-phenethylamine, 1-ephenamine, N,N'-dibenzylethylene-diamine, dehydroabietylamine, N-ethylpiperidine, benzylamine, dicyclohexylamine or similar pharmaceutically acceptable amines and salts with amino acids such as arginine, lysine and the like. Basic nitrogen-containing groups can be quaternized with agents such as lower alkyl halides (e.g., methyl, ethyl, propyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g., dimethyl, diethyl, dibutyl, and diamyl sulfates), long chain halides (e.g., decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides), aralkyl halides (e.g., benzyl and phenethyl bromides), and others. Sodium or potassium salts are preferred.
Compounds of the formula (I) and/or compound 6 and salts thereof can exist in their tautomeric form, in which hydrogen atoms are transposed to other parts of the molecules and the chemical bonds between the atoms of the molecules are consepuently rearranged. It should be understood that the all tautomeric forms, insofar as they can exist, are included within the invention. Additionally, inventive compounds can have trans and cis (E and Z) isomers and can contain one or more chiral centers, therefore existing in enantiomeric and diastereomeric forms. The invention includes all such isomers, as well as mixtures of cis and trans isomers, mixtures of diastereomers and racemic mixtures of enantiomers (optical isomers).
When no specific mention is made of the configuration (cis, trans or R or S) of a compound (or of an asymmetric carbon), then any one of the isomers or a mixture of more than one isomer is intended.
Another embodiment of the present invention relates to pharmaceutical or physiological compositions having at least one IKK
inhibitor, or salt thereof, and preferably containing a pharmaceutically or physiologically acceptable vehicle, such as a carrier, diluent, or excipient.
Furthermore, these pharmaceutical or physiological compositions comprise one or more IKK inhibitors, or salt thereof, either alone or in combination with a biologically active agent, such as but not limited to drugs, steroids, or synthetic compounds, particularly for use in the methods according to the present invention. The pharmaceutical compositions can preferably comprise any one of the IKK inhibitors of the present invention, for example, 4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline (compound 6) or any one of the compounds of formula (I). Such a pharmaceutical or physiological composition can be administered to any individual in need of such therapy, including, for example, mammals such as monkeys, dogs, cats, cows, horses, rabbits, and most preferably, humans, for any of the above-described therapeutic or preventative uses and effects.
More particularly, the present invention also provides pharmaceutical compositions capable of treating conditions that are related to the activity of NF-~cB, TNF-a , and/or enzymes modulating NF-oB and/or TNF-a levels such as IKK. Such compositions may contain other therapeutic agents and may be formulated, as described herein.
In the method embodiments of the present invention, IKK inhibitors, or pharmaceutical or physiological compositions thereof, can be administered alone or in combination with at least one other biologically active agent, which can be introduced in any sterile, biologically compatible pharmaceutical or physiologically acceptable carrier, excipient, or diluent, including, but not limited to, saline, buffered saline, dextrose, and water.
The compositions can be administered to a patient alone, or optionally in combination with other biologically active agents, drugs, or hormones.
Additionally, in the methods according to this invention, the IKK
inhibitors, or pharmaceutical or physiological compositions thereof, can be administered by any means suitable for the condition to be treated, which can depend on the need for site-specific treatment or quantity of drug to be delivered, by any number of routes including, but not limited to, oral, nasal, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, and sublingual means. Preferably, IKK inhibitors are administered orally, nasally, topically, or by inhalation.
Administration of IKK inhibitor compositions of the invention can also include local or systemic administration, including injection, oral administration, particle gun, or catheterized administration, and topical administration. Various methods can be used to administer an IKK inhibitor composition directly to a specific site in the body. For example, in instances where topical delivery is preferred, generally for skin-related diseases, transdermal patches and/or permeation enhancers can be used, a variety of which are commonly known in the art. Systematic treatment is preferred for cancerous or pre-cancerous conditions, although other modes of delivery are contemplated.
Both the dose of an IKK inhibitor, or composition thereof, and the means of administration can be determined based on the specific qualities of the IKK inhibitor or therapeutic composition thereof; the condition, age, and weight of the patient; the progression of the disease; and other relevant factors. Preferably, an IKK inhibitor, or therapeutic composition thereof, according to the invention, increases or decreases gene expression of NF-~cB. Methods well known in the art can be used to determine the effectiveness of the mechanism chosen to alter expression of the NF-~cB
gene, such as hybridization of nucleotide probes to mRNA of the NF-KB
gene, quantitative RT-PCR, or detection of an NF-oB protein using specific antibodies (e.g. Santa Cruz Biotechnology; Santa Cruz, CA).
In addition to the active ingredients, the pharmaceutical compositions can contain suitable pharmaceutically acceptable carriers, diluents, or excipients comprising auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration are provided in the latest edition of Remington's Pharmaceutical Sciences (Mack Publishing Co.; Easton, Pa.).
Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.
The compounds of the present invention can be delivered orally, such as in the form of tablets, capsules, granules, powders, or liquid formulations S including syrups; topically, such as in the form of solutions, suspensions, gels, creams, or ointments; nasally such as by inhalation spray; parenterally, such as by subcutaneous, intravenous, intramuscular or intrasternal injection or infusion techniques (e.g., as sterile injectable aqueous or non-aqueous solutions or suspensions); rectally such as in the form of suppositories; sublingually; bucally; or liposomally.
Pharmaceutical preparations for oral use can be obtained by the combination of active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropyl-methylcellulose, or sodium carboxymethylcellulose; gums, including arabic and tragacanth, and proteins such as gelatin and collagen. If desired, disintegrating or solubilizing agents can be added, such as cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a physiologically acceptable salt thereof, such as sodium alginate.
Pharmaceutical preparations, which can be orally administered in the methods according to the present invention, include push-fit capsules made of gelatin, as well as soft, scaled capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds can be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.
Exemplary compositions for oral administration include suspensions which can contain, for example, microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners or flavoring agents such as those known in the art; and immediate release tablets which can contain, for example, microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and/or lactose and/or other excipients, binders, extenders, disintegrants, diluents and lubricants such as those known in the art. The inventive compounds can also be orally delivered by sublingual and/or buccal administration, e.g., with molded, compressed, or freeze-dried tablets. Exemplary compositions can include fast-dissolving diluents such as mannitol, lactose, sucrose, and/or cyclodextrins. Also included in such formulations are high molecular weight excipients such as celluloses (AVICEL~) or polyethylene glycols (PEG); an excipient to aid mucosal adhesion such as hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), sodium carboxymethyl cellulose (SCMC), andlor malefic anhydride copolymer (e.g., GANTREZ~); and agents to control release such as polyacrylic copolymer (e.g., CARBOPOL 934~). Lubricants, glidants, flavors, coloring agents and stabilizers can also be added for ease of fabrication and use.
Exemplary compositions for rectal administration include suppositories which can contain, for example, suitable non-irritating excipients, such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures but liquefy and/or dissolve in the rectal cavity to release the drug.
Dragee cores can be used in conjunction with physiologically suitable coatings, such as concentrated sugar solutions, which can also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/ or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments can be added to the tablets or dragee coatings for product identification, or to characterize the quantity of active compound, i.e., dosage.
Pharmaceutical formulations suitable for parenteral administration in the methods of the present invention can be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions can contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. In addition, suspensions of the active compounds can be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyloleate or triglycerides, or liposomes. Optionally, the suspension can also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. Additional exemplary compositions for parenteral administration include injectable solutions or suspensions which can contain, for example, suitable non-toxic, parenterally acceptable diluents or solvents, such as mannitol, 1,3-butanediol, water, Ringer's solution, an isotonic sodium chloride solution, or other suitable dispersing or wetting and suspending agents, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.
For topical or nasal administration, penetrants or permeation-enhancing agents that are appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art. Exemplary compositions for topical administration include a topical carrier such as PLASTIBASE~ (mineral oil gelled with polyethylene). Exemplary compositions for nasal aerosol or inhalation administration include solutions which can contain, for example, benzyl alcohol or other suitable preservatives, absorption promoters to enhance absorption and/or bioavailability, and/or other solubilizing or dispersing agents such as those known in the art.
The pharmaceutical compositions of the present invention can be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.
Dosage unit formulations containing non-toxic, pharmaceutically acceptable vehicles or diluents can be administered. The compounds can be administered in a form suitable for immediate release or extended release. Immediate release or extended release can be achieved with suitable pharmaceutical compositions or, particularly in the case of extended release, with devices such as subcutaneous implants or osmotic pumps.
The IKK inhibitor, or pharmaceutical composition thereof, can be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, and the like. Salts tend to be more soluble in aqueous solvents, or other protonic solvents, than are the corresponding free base forms. In other cases, the preferred preparation can be a lyophilized powder which can contain any or all of the following: 1-50 mM histidine, 0.1 %-2% sucrose, and 2-7% mannitol, at a pH range of 4.5 to 5.5, combined with a buffer prior to use. After the pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of IKK inhibitors, such labeling would include amount, frequency, and method of administration.
Pharmaceutical compositions comprising one or more IKK inhibitors suitable for use in the present invention include compositions in which the active ingredients are contained in an amount effective to achieve the intended purpose. The determination of an effective dose or amount is well within the capability of those skilled in the art. For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., using neoplastic cells, or in animal models, usually mice, rats, rabbits, dogs, or pigs. The animal model can also be used to determine the appropriate dosage, concentration range and route of administration. Such information can then be used and extrapolated to determine useful doses, concentration ranges, and routes for administration in humans. For guidance, in accordance with the methods of the present invention, an effective amount of IKK inhibitor optimally results in a level of inhibition of IKK activity ranging from about 20-100%, preferably, about 50-100%, more preferably about 80-100%, and most preferably about 90-100%, for the treatment of inflammatory and/ or immune-related diseases.
A therapeutically effective dose refers to that amount of active ingredient or compound, such as an IKK inhibitor, which ameliorates, reduces, or eliminates the symptoms, condition, disease, or disorder.
Therapeutic efficacy and toxicity can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population). The dose ratio of therapeutic to toxic effects is the therapeutic index, which can be expressed as the ratio, ED50/LD50. Pharmaceutical compositions which exhibifi large therapeutic indices are preferred. As understood by the skilled practitioner, data obtained from cell culture assays and animal studies are used in determining a range of dosages for human use. Preferred dosage of a pharmaceutical composition is within a range of circulating concentrations that include the EDSO with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.
It will be understood that the specific dose level and frequency of dosage for any particular subject can be varied and will depend upon a variety of factors; the exact dosage will be determined by the practitioner, who will consider the factors related to the individual requiring treatment.
Dosage and administration are adjusted to provide sufficient levels of the IKK inhibitor active moiety or to maintain the desired effect. Factors which are taken into account include the severity of the individual's disease state, general health of the patient, age, weight, and gender of the patient, diet, and mode, time and frequency of administration, rate of excretion, drug combination(s), reaction sensitivities, and tolerance/response to therapy. As a general guide, long-acting pharmaceutical compositions can be administered every 3 to 4 days, every week, or once every two weeks, depending on half-life and clearance rate of the particular formulation.
Normal dosage amounts can vary from about 0.1 to about 100,000 micrograms (~,g), up to a total dose of about 1 gram (g), depending upon the route of administration. Preferably, dosages range from about 1 to about 100 ~,g. Guidance as to particular dosages and methods of delivery is provided in the literature, via empirical determination, and is generally available to, and routinely able to be determined by practitioners in the art.
Single or multiple doses can be administered on, for example, a daily, every other day, or weekly schedule. In particular, the effective amount of a compound of the present invention can be determined by one of ordinary skill in the art, and includes exemplary dosage amounts for a mammal of from about 0.05 to 100 mg/kg of body weight of active compound per day, which can be administered in a single dose or in the form of individual divided doses, such as from 1 to 4 times per day. Preferred subjects for treatment include animals, most preferably mammalian species such as humans, and domestic animals such as dogs, cats, horses, and the like.
The compounds of the invention, and pharmaceutically acceptable salts thereof, also embrace prodrugs, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents. Prodrugs and solvates of the inventive compounds are also contemplated. As will be appreciated by the skilled practitioner, prodrugs are suitable for use in the methods according to the present invention. Such prodrugs are preferably administered orally since hydrolysis in many instances occurs principally under the influence of the digestive enzymes. Parenteral administration can be used where the ester per se is active, or in those instances where hydrolysis occurs in the blood. Examples of physiologically hydrolyzable esters of compounds of formula (I) include C~_6alkylbenzyl, 4-methoxybenzyl, indanyl, phthalyl, methoxymethyl, C~_6 alkanoyloxy-C~_6alkyl, e.g. acetoxymethyl, pivaloyloxymethyl or propionyloxymethyl, C~_6alkoxycarbonyloxy-C~_6alkyl, e.g. methoxycarbonyl-oxymethyl or ethoxycarbonyloxymethyl, glycy(oxymethyl, pheny(glycyloxymethyl, (5-methyl-2-oxo-1,3-dioxolen-4-yl)-methyl and other well known physiologically hydrolyzable esters used, for example, in the penicillin and cephalosporin arts. Such esters can be prepared by conventional techniques known in the art.
The inventive compounds and compositions can be employed alone or in combination with each other and/or other suitable therapeutic agents useful in treating NF-~cB and TNF-a associated conditions. Exemplary of such other therapeutic agents include corticosteroids, rolipram, calphostin, CSAIDs, 4-substituted imidazo [1,2-A]quinoxalines as disclosed in US Pat.
No. 4,200,750 and Ceccarelli et al., supra; Interleukin-10, glucocorticoids, salicylates, nitric oxide, and other immunosuppressants; nuclear translocation inhibitors, such as deoxyspergualin (DSG); non-steroidal antiinflammatory drugs (NSAIDs) such as ibuprofen, celecoxib and rofecoxib; steroids such as prednisone or dexamethasone; antiviral agents such as abacavir; antiproliferative agents such as methotrexate, leflunomide, FK506 (tacrolimus, Prograf); cytotoxic drugs such as azathiprine and cyclophosphamide; TNF-a inhibitors such as tenidap, anti-TNF antibodies or soluble TNF receptor, and rapamycin (sirolimus or Rapamune) or derivatives thereof; and other cancer drugs and treatments, including radiation treatments and daunorubicin. , The above other therapeutic agents, when employed in combination with the compounds of the present invention, can be used, for example, in those amounts indicated in the Physicians' Desk Reference (PDR) or as otherwise determined by one of ordinary skill in the art.
It should be understood that one skilled in the field is able to make various modifications to the compounds, compositions and schemes described above, applying the ordinary level of skill in the field, without departing from the spirit or scope of the invention. All such modifications are.
intended to be included within the invention as defined in the appended claims.
EXAMPLES
The Examples below are provided to illustrate the subject invention and are not intended to limit the invention.
METHOD OF PREPARATION OF IKK INHIBITOR 4(2' AMINOETHYL)AMINO- 1,8-DIMETHYL-IMIDAZO(1,2-A) QUINOXALINE
(COMPOUND 6) The IKK inhibitory compound 4(2'-aminoethyl)amino- 1,8-dimethylimidazo(1,2-a) quinoxaline, or compound 6 newly described herein, can be prepared by a method as described in the following scheme.
Starting materials are commercially available or can be readily prepared by one of ordinary skill in the art, andl or modifications can be made to the method of the scheme by one skilled in the art, using known methods and practices.
Chemical Scheme for Pre~paringCompound 6 Me COzH Me Me P Me COOEt Me Me / N / N
PhzO, + NHS N ~ ~ ~ \ reflux ~ N
NOz H O 4 H
Me Me PhNEtz _ Me / N s N HzN,~ NH~ Me / N ~, N
POCI3 I ' 60 C ~ ~ ~ NHZ
N CI N
2~ 5 6 Compound 6 or 4(2'-aminoethyl)amino- 1,8-dimethylimidazo(1,2-a) quinoxaline, can be prepared as shown in the above scheme: 3-fluoro-4-nitrotoluene (compound 1) is reacted with ethyl 5-methylimidazole-4-caboxylate (compound 2) according to known procedures to produce, after several steps, the imidazoquinoxalone-2-carboxylic acid (compound 3).
Upon decarboxylation of said acid (compound 3) in a high-boiling solvent, such as diphenyl ether (Ph20), 1,8-dimethylimidazoquinoxalone (compound 4) is produced. Compound 4 is then chlorinated using standard reagents, such as phosphorus oxychloride (POC13) and N,N-diethylaniline (PhNEt2) to give 4-chloro-1,8-dimethylimidazoquinoxaline (compound 5). Compound 5 is then condensed with 1,2-diaminoethane or ethylenediamine to produce the final compound 4(2'-aminoethyl)amino- 1,8-dimethylimidazo(1,2-a) quinoxaline (compound 6).
PREPARATION OF REAGENTS AND STARTING MATERIALS FOR
3-fluoro-4-nitrotoluene (Compound 1) Compound 1 is commercially available from Aldrich Chemical Company (Milwaukee, WI).
Ethyl 5-methylimidazole-4-carboxylate (Compound 2) Compound 2 is commercially available from Aldrich Chemical Company (Milwaukee, WI).
Preparation of imidazoauinoxalone-2-carbox~rlic acid (Compound 3) Compound 1 and compound 2 are reacted to give, after several steps, compound 3, following the procedure of Trieber et al. (German Offen.
4,329,970 (October 6, 1994)).
Preparation of 4,5-Dihydro-1 8-dimethylimidazo(1 2-a)auinoxalin-4-one (Compound 4) A suspension of 4,5-dihydro- 1,8-dimethyfimidazo(1,2-a)quinoxalin-4-one-2-carboxylic acid (compound 3) (32 g, 124 mmol) in diphenyl ether (400 mL) was refluxed at 260°C for 2 hours. After the suspension cooled down to room temperature, hexanes (C6H~4; 500 mL) were added to further precipitate the product. The solid was filtered, giving the title compound 4 as a white solid (29.6 g). ~H nuclear magnetic resonance, NMR (500 MHz, hexadeuterio-dimethylsulfoxide, d6-DMSO) 8 11.7 (s, 1 H), 7.91 (s, 1 H), 7.31 (s, 1 H), 7.29 (d, J=8.1 Hz, 1 H), 7.22 (d, J=8.3 Hz, 1 H), 2.81 (s, 3H), 2.41 (s, 3H); MS (ESI), m/z 214.13 [(M+H)+; calculated for compound 4, C~2H~~N3O:
213.09].
Preparation of 4-chloro- 1 8-dimethylimidazo(1 2-a)auinoxaline (Compound A mixture of 4,5-dihydro-1,8-dimethylimidazo(1,2-a)quinoxalin-4-one (compound 4) (29.6 g, 139 mmol) and N,N-diethylaniline (PhNEt2, 45 mL) was refluxed in phosphorus oxychloride (POC13; 250 mL) for 1 hour. The solvent was evaporated under vacuum; the residue was diluted with chloroform, CHC13 (1000 mL), followed by careful neutralization with cold saturated sodium carbonate, (Na2C03) solution. The aqueous layer was further extracted with CHC13. The combined organic layer was dried over magnesium sulfate (MgS04) filtered and concentrated. Flash chromatography using ethyl acetate and hexanes (EtOAc/ Hexanes, 60/ 40) provided the title compound 5 as a white solid (25 g). ~H NMR (500 MHz, CDC13) 8 8.07 (s, 1 H), 7.93 (d, J=8.3 Hz, 2 H), 7.54 (d, J=0.7 Hz, 1 H), 7.41 (dd, J= 8.4, 1.2 Hz, 1 H), 2.97 (s, 3H), 2.59 (s, 3H); MS (ESI), m/z 232.04 [(M+H)+; calculated for compound 5, C~zH~oCIN3: 231.06].
Preparation of 4(2'-Aminoethyl)amino-1,8-dimethylimidazo(1 2-a) guinoxaline (Compound A solution of 4-chloro-1,8-dimethylimidazo(1,2-a) quinoxaline (compound 5) (4.8 g, 21 mmol) in ethylenediamine (300 mL) was heated at 60°C under nitrogen gas (N2) for 16 hours. The solvent was evaporated under vacuum. The residue was diluted with EtOAc (200 mL), washed with saturated Na2C03 and brine, dried over MgS04, filtered and concentrated.
Flash chromatography using methanol (MeOH) provided a solid, which was then dissolved with CHC13 and filtered to remove any dissolved silica gel.
The filtrate was concentrated under vacuum, providing the title compound 6 as a white solid (4.67 g). ~ H NMR (500 MHz, CDC13) 8 7.88 (s, 1 H), 7.63 (d, J=8.3 Hz, 1 H), 7.26 (s, 1 H), 7.22 (d, J=8.3 Hz, 1 H), 6.31 (s, 1 H), 3.63 (apparent q, J=5.9 Hz, 2 H), 2.96 (t, J=6.0 Hz, 2 H), 2.88 (s, 3 H),1.38 (br, H); MS (ESI), m/z 256.15 [(M+H)+; calculated for compound 6, C~4H~~N~:
255.15].
Preparation of HCI Salt of 4(2'-Aminoethyl)amino-1,8-dimethylimidazo(1,2-a) cLuinoxaline (Compound 6~
Compound 6 or 4(2'-Aminoethyl)amino-1,8-dimethylimidazo(1,2-a) quinoxaline (4.67 g, 18.3 mmol) was dissolved with aqueous hydrochloric acid, HCI (1.0 N, 18.3 mL) and water, H20 (50 mL) at room temperature.
Subsequent removal of water using a lyophilizer provided the hydrochloride salt as a white solid (5.22 g). The hydrochloride salt of compound 6 is preferred in the described methods although other salts, e.g. acetate, sulfate, citrates, as well as the free base of compound 6, are also suitable for use.
In Examples 2-7, a salt form of 4(2'-Aminoethyl)amino-1,8-dimethylimidazo(1,2-a) quinoxaline was used.
ANALYSIS OF INHIBITORY POTENTIAL OF IKK INHIBITORS, USING
4(2'-AMINOETHYL)AMINO- 1,8-DIMETHYLIMIDAZO(1,2-A) QUINOXALINE
(COMPOUND 6) I KK-1 /I KK-2 Enzyme Assay Assays for measuring the inhibitory potential of test compounds, specifically compound 6, (4(2'-aminoethyl)amino- 1,8-dimethylimidazo(1,2-a) quinoxaline), against IKK activity employed 33P-labeled ATP and a recombinant IoB-a as substrates. In this assay, test compound was added to a solution of 0.5 mM hcB-a in 40 mM Tris-HCI, pH 8, containing 4 mM
MgCl2, 1 mM dithiothreitol, and 2 mM 33P-labeled ATP. IKK enzyme (either the multisubunit complex from HeLa cells, recombinantly expressed IKK-1, or recombinantly expressed IKK-2) was then added to initiate the reaction.
The multisubunit complex was isolated according to the procedure of Lee et al. [(1997) Cell 88:213-222] or Mercurio et al. [(1997) 278:860-866]. The recombinant IKK-1 and IKK-2 were expressed using the procedure of Burke et al. [(1999) J. Biol. Chem. 274:36146-36152]. After incubating for 10 minutes at 30°C, the reaction was quenched by the addition of EDTA to a final concentration of 30 mM. In order to separate the phosphorylated IKB-a (Santa Cruz Biotechnology; Santa Cruz, CA) product from unreacted ATP, sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) was performed. Phosphoimager analysis of the amount of 33P incorporation into IKB-a was executed using a Molecular Dynamics 445 Phosphoimager, and the inhibition of IKK activity by the test compound was calculated from control samples containing no inhibitor. The IC5o is defined as the concentration of test compound which produces 50% inhibition of IKK
activity.
The results presented in Table 1 show the inhibition of IKK activity using 33P-labeled ATP and hcB-a as substrates for recombinantly expressed IKK-1 and IKK-2, wherein a test compound concentration of 5 ~M and 0.5 p,M, respectively, was shown to achieve inhibition of (KK activity by 50%.
The IKK inhibitor, compound 6, inhibits IKK-2 at an IC5o which is 10 fold less than that necessary to inhibit IKK-1 by 50%. As presented in Table 1, compound 6 inhibits IKK-2 with greater effectiveness than IKK-1, thus demonstrating a selectivity of this compound for IKK-2 inhibition over IKK-1.
Test Compound IKK-1 ICSO IKK-2 IC5o Compound 6 5 u,M 0.5 u,M
Compound 6 was administered to BALBIc mice either per orally (p.o.) or intravenously (i.v.). Blood was drawn at various times (0.5 to 4 hours) after dosing and the plasma drug levels measured by liquid chromatography-mass spectral analysis. An oral bioavailability of 100% for compound 6 was calculated from the area under the curve (AUC) derived from a plot of plasma levels versus time after the p.o. dose, and then dividing by the AUC from the i.v. dose. An i.v. half-life of 7.9 hours was calculated from the apparent terminal elimination phase after the i.v. dose.
Generally, to be considered, oral bioavailability ranges from about 10% to about 100%, more preferably from about 50% to about 100%, and most preferably from 80% to about 100%.
MEASUREMENT OF MEDIAN SURVIVAL TIME OF TRANSPLANTED
HEARTS IN BALB/C MICE
Murine Neonatal Heart to Ear Transplants Cardiac transplants were performed as described by Fulmer et al.
(Fulmer, R.I. et al. The American Journal of Anatomy 113:273-281, 1963).
Neonatal hearts were obtained from newborn C57BL/6 mice not more than 48 hours after birth. The hearts were transplanted into recipient BALB/c mice, which were prepared under anesthesia by making a small incision at the base of the ear pinna and forming a pocket by gently lifting the skin away from the ear. The incision permitted the insertion of the donor heart subcutaneously into the pocket. Post-operatively, the cardiac tissue typically does not begin to beat until 3 to 5 days after transplantation until vascular connections are established. The pulsations of the heart were measured by contractile activity with an appropriate electrocardiogram (ECG) monitoring device. The contractile activity of the transplanted graft was monitored daily. The time of graft rejection was defined as the day after transplantation on which contractile activity ceased. Without therapeutic intervention, the host mounts an immune response to the transplanted heart (i.e., graft rejection). This immune response causes the transplanted heart to cease beating typically 10-14 days post transplantation.
Test compounds were administered in daily doses either alone or in combination with other therapies, such as Cyclosporine A (15 mg/ kg, orally, "p.o.") or CTLA4-Ig (200 gg in 200 ~,I PBS given intraperitaneally on only days 0, 2, and 4). Table 2 presents fihe effects of test compounds on median survival time of transplanted hearts, either alone or in combination with Cyclosporine A (CsA). Table 3 presents the effects of test compounds on median survival time of transplanted hearts, either alone or in combination with CTLA4-Ig.
Test Compound Median Graft Statistical Significance Survival Time Vehicle water) 12 da s C closporine A, 15 m /k 14 da s , .o.
Com ound 6, 50 m /k , 12 da s .o.
Cyclosporine A, 15 mg/kg, P < 0.01 vs. vehicle, p.o. 29 days P < 0.01 vs. CsA alone Plus Compound 6, 50 m /k , p.o.
Test Compound Median Graft Statistical Significance Survival Time Vehicle water 12 da s CTLA4-I 22 da s P < 0.01 vs. vehicle Com ound 6, 50 m /k , 12 da s I
.o.
Com ound 6, 100 m /k , 18 da s P < 0.01 vs. vehicle p.o.
CTLA4-Ig ' Plus 32 days P < 0.01 vs. vehicle, I
Compound 6, 50 mg/kg, P = 0.02 vs. CTLA4-Ig p.o.
alone CTLA4-Ig Plus >60 days P < 0.01 vs. vehicle, Compound 6, 100 mg/kg, P < 0.01 vs. CTLA4-Ig p.o.
alone The synergistic effects between compound 6 and either cyclosporine A or CTLA4-Ig indicate that an IKK inhibitor is highly efficacious in the in vivo treatment of solid organ transplant rejection particularly when co-administered with other immunosuppressive agents. Because these agents are not completely effective when administered alone, transplant patients typically receive a "cocktail" of immunosuppressive agents.
EFFECT OF IKK INHIBITOR 4(2'-AMINOETHYL)AMINO- 1,8 DIMETHYLIMIDAZO(1,2-A) QUINOXALINE (COMPOUND 6) ON DISEASE
INCIDENCE IN THE MURINE MODEL OF COLLAGEN-INDUCED
ARTHRITIS
Collagen-Induced Arthritis The murine model of collagen-induced arthritis is widely used to study disease mechanisms and potential therapies for rheumatoid arthritis in humans (Staines et al., Br. J. Rheumatol. 33:798-807, 1994; Feldmann et al., Annu. Rev. Immunol. 14:397-440, 1996).
DBA/1 LacJ male mice 6-8 wk (Jackson Laboratories; Bar Harbor, ME) were immunized subcutaneously on day 0 and on day 21 with 100 p,g bovine type II collagen in 0.1 mL RIBI Adjuvant System (RAS) with monophosphoryl lipid A (RIBI ImmunoChem Research; Hamilton, MT). In this model, disease onset occurs within one week after the second collagen injection.
When treated in a preventative mode, test compounds were administered daily beginning on day 0 through day 41. Figure 1 shows a graph of the percentage of mice within each treatment group (6-10 animals per group) which show any sign of disease regardless of severity.
Administration of 4(2'-aminoethyl)amino- 1,8-dimethylimidazo(1,2-a) quinoxaline (compound 6) at a concentration of 100 mg/ kg, resulted in a significant difference in incidence of disease compared with vehicle alone.
In the established (i.e. therapeutic) mode, the administration of test compounds was initiated only after paw inflammation of an animal had achieved a score of 2 (as defined below), at which time, the animal was randomly assigned to a treatment group. Treatment continued daily for all four paws as described below.
Following the Day 21 booster, mice were regularly monitored for the development and severity of paw inflammation. Each paw was visually scored by the following clinical scoring scheme as presented in Table 4:
Score Description 0 Normal 1 One or more 'oints inflamed on di its 2 Plantar surface of paw inflamed and aw thickness increased 3 Ankylosis (significantly reduced hock 'oint motion on flexion/ extension Clinical paw scores for all four paws were summed for each mouse and the mean ~ standard deviation (SD) was calculated for each treatment group. The incidence of disease is defined as the percent of animals within a treatment group which showed any sign of disease regardless of severity.
Histological scoring involved evaluating histologically and grading semi-quantitatively tibiotarsal joints of sacrificed mice, specifically examining the severity of inflammation, synovial hyperplasia, bone resorption, and cartilage erosion. Cumulative arthritis injury scores for each group were compared by the nonparametric Kruskal-Wallis analysis of variance.
Figure 2 shows the average gross clinical score for all mice within each treatment in the collagen-induced arthritis murine model as determined on each study day. The test compound was administered once daily in the preventative dosing mode. Table 5 presents the histological evaluation of the effect of 4(2'-aminoethyl)amino- 1,8-dimethylimidazo(1,2-a) quinoxaline (compound 6) on the cumulative arthritis injury scores ~ standard error mean (sem) upon sacrificing the animals at the end of the study in the murine model of collagen-induced arthritis. Administration of 4(2'-aminoethyl)amino- 1,8-dimethylimidazo(1,2-a) quinoxaline (compound 6) at concentrations of 30 and 100 mg/ kg resulted in histological cumulative arthritis injury scores of 0.4 and 0, which parallels the results depicted in Figure 2.
Preventative Mode Treatment Cumulative arthritis Statistical Significance in'ur score (sem Vehicle (water) 4.4 1.5 Compound 6, 10 mg/kg5.3 1.7 Compound 6, 30 mg/kg0.4 0.4 P = 0.02 Compound 6, 100 mg/kg0.0 P = 0.004 'ws. vehicle-treated group.
Figure 3 shows the effects of 4(2'-aminoethyl)amino- 1,8-dimethylimidazo(1,2-a) quinoxaline (compound 6) administered in the established disease mode (i.e., after disease onset) on the average gross clinical score for all mice within each treatment in the murine model of collagen-induced arthritis as determined on the days following disease onset.
Table 6 presents the histological evaluation of the effect of 4(2'-aminoethyl)amino- 1,8-dimethylimidazo(1,2-a) quinoxaline (compound 6) on the cumulative arthritis injury scores in the established disease mode of murine model of collagen-induced arthritis two weeks after disease onset.
Established Mode Treatment ~ Cumulative ArthritisStatistical In'ur Score (sem) significance*
Vehicle (water) 7.0 0.5 Compound 6, 10 mg/kg 4.2 1.0 P = 0.028 Compound 6, 30 mg/kg 2.1 0.9 P = 0.004 Compound 6, 100 mg/kg 0.9 0.5 P = 0.001 ~'vs. vehicle-treated group.
The murine model of collagen-induced arthritis shares many of the same biochemical and pathological mechanisms as does rheumatoid arthritis in humans, and was used for preventing and treating arthritis upon the administration of 4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a) quinoxaline (compound 6). Figures 1 and 2 and Table 5 show that daily administration of 30 mg/kg (p.o.) of compound 6 inhibited disease onset, and that 100 mg/kg (p.o.) of compound 6 prevented any disease onset when dosed in a preventative mode. When the IKK inhibitor was administered after disease onset (i.e., established mode of therapy), Figure 3 and Table 6 show that treatment with 30 mg/kg (p.o.) of compound 6 significantly inhibited disease progression when compared with vehicle treated animals, while a dose of 100 mg/kg (p.o.) of compound 6 actually led to significant disease resolution. These results support the advantages provided by the present invention in which inflammatory diseases or disorders, such as rheumatoid arthritis, are prevented or ameliorated by inhibiting IKK activity.
EFFECT OF IKK INHIBITOR 4(2'-AMINOETHYL)AMINO- 1,8 DIMETHYLIMIDAZO(1,2-A) QUINOXALINE ON DISEASE INCIDENCE IN
THE MURINE MODEL OF DEXTRAN SULFATE SODIUM-INDUCED
INFLAMMATORY BOWEL DISEASE
Dextran Sulfate Sodium-Induced Murine Model of Inflammatory Bowel Disease Dextran sulfate sodium (DSS)-induced colitis in mice shows several of the same pathological mechanisms of inflammatory bowel disease (IBD) as it presents in humans, and has been used to study various treatments (Okayasu et al., Gastroenterology 98:694-702, 1990; Axelsson et al., Aliment. Pharmacol. Ther. 12:925-934, 1998). The mouse models are used as predictors of IBD in humans and to develop effective treatments for human use.
IS In this model, Swiss-Webster mice (8 weeks old, 5 animals per treatment group) were given 6% DSS in their drinking water for 7 consecutive days to induce intestinal inflammation. Test compounds were administered daily throughout the study. On day 9, animals were sacrificed and the colons were removed for clinical and histological evaluation.
Clinical scoring was determined by the gross clinical evaluation of the injury on a scale from 0 (normal) to 3 (severe) as detailed in Table 7.
Score Description 0 Normal 1 Relatively normal colon length, slight thickenin of tissue.
2 Shortened colon length, thick along entire length of colon with loss of striations. Some areas of redness.
3 Considerably shortened length with very thick tissue containing areas of raised lesions.
For histological scoring, colon sections were graded as to the severity of crypt injury and the degree of inflammation. The crypt injury was scored as detailed in Table 8, wherein the crypt is part of the glandular make-up of the colon.
Score Description 0 Normal; intact c pt 1 Loss of basilar - one- third of the cr pt 2 Loss of basilar - two-thirds of the crypt 3 Loss of the entire crypt with surface epithelium intact 4 Loss of the entire crypt with epithelial erosion Tissue involvement was scored as detailed in Table 9. Any signs of crypt injury or inflammation, regardless of severity, constitute tissue involvement.
Score Description 0 No involvement 1 1-25% involvement 2 26-50% involvement 3 51-75% involvement 4 76-100% involvement The injury histological score is defined as the product of the crypt injury grade and the tissue involvement grade. The scoring of severity of inflammation is detailed in Table 10.
Score Description 0 Normal; non-remarkable 1 Minimal 2 -- -Mild Score Description 3 Moderate 4 Severe The infilammation histological score is the product of the severity of inflammation grade and the extent ofi tissue involvement grade. Crypt injury and inflammatory scoring were performed on each colon section and a mean score and standard error were determined for each section.
Cumulative crypt injury and inflammatory scores for each group were determined. Table 11 presents the clinical scores of colons in mice with DSS-induced colitis. The results of Table 12 present the cumulative injury and inflammation scores of colons in mice with DSS-induced colitis.
Treatment Mean clinical score UNTREATED 2.50 0.45 COMPOUND 6, 30 mg/kg, 1.10 0.49*
p.o.
COMPOUND 6, 100 mg/kg, 1.00 0.35*
p.o.
*Statistical significance vs. untreated group, P<0.05 Treatment Group Mean Injury Group Mean Histological Score Inflammation Histolo ical Score UNTREATED 8.52 0.81 12.33 0.40 COMPOUND 6, 30 4.83 0.55* 7.58 0.81*
m /k , .o.
COMPOUND 6, 100 5.66 0.87* 6.82 0.85*
m /k , .o.
*Statistical significance vs. untreated group, P<0.05 The results show that 4(2'-aminoethyl)amino- 1,8-dimethylimidazo(1,2-a) quinoxaline (compound 6) prevented and treated IBD in the well-established murine model of inflammatory bowel disease (IBD) in humans. Tables 11 and 12 show that daily administration of the IKK
inhibitor (compound 6) resulted in a statistically significant decrease in clinical and histological score when compared with untreated mice. Such results support the advantageous outcome afforded by the present invention in which inhibition of the IKK enzyme prevents and/ or ameliorates inflammatory diseases and disorders such as IBD.
EFFECT OF IKK INHIBITOR 4(2'-AMINOETHYL)AMINO- 1,8 DIMETHYLIMIDAZO(1,2-A) QUINOXALINE ON DISEASE INCIDENCE IN
THE MURINE MODEL OF OVALBUMIN-INDUCED INFLAMMATORY CELL
INFILTRATION IN THE LUNG OF SENSITIZED MICE
Inflammatory Cell Infiltration into the Lung of Ovalbumin-Challenged Mice Pulmonary inflammation with infiltration of eosinophils and other inflammatory cells is a hallmark of asthma and other allergic respiratory disorders. To determine whether an IKK inhibitor was efficacious in the in vivo treatment of respiratory disorders which afflict many patients, test compounds were administered in a murine model of pulmonary inflammation similar to that described by Kung et al. (Kung, T.T. et al., Int. Arch.
Allergy Immunol. 105:83-90, 1994).
In the pulmonary inflammation animal model, BALB/c mice were sensitized by an intraperitoneal injection of 0.1 mL alum-precipitated antigen containing 40 ~,g ovalbumin adsorbed to aluminum hydroxide gel on days 0 and 10. On day 14, animals received intranasal challenge with 100 ~g ovalbumin in 50 p1 saline (PBS). Mice were injected intraperitoneally with antigen to sensitize the animals prior to intranasal challenge to induce lung inflammation. Administration of the test compound was given on days 14 to 17. On day 18, bronchoalveolar lavage fluid (BAL) was collected for measurements of total inflammatory cell infiltration (eosinophils, monocytes, lymphocytes, and neutrophils). Table 13 presents the effect of 4(2'-aminoethyl)amino- 1,8-dimethylimidazo(1,2-a) quinoxaline (compound 6) on ovalbumin-induced inflammatory cell infiltration into the lungs of sensitized mice after daily administration of compound.
Test Compound Total InflammatoryStatistical Cells in BAL Significance vs.
Vehicle Control Vehicle (water) 5.8x10 1.2x10 Compound 6, 30 mg/kg, 2.8x10 1.3x10 P = 0.13 p.o.
Compound 6, 100 mg/kg, 2.2x10 0.3x10 P = 0.02 p.o. ~
'Statistical significance vs. untreated group, P<0.05 Ovalbumin-induced inflammatory cell infiltration in murine lung provides a model system for pulmonary inflammation, specifically asthma and other allergic respiratory disorders in humans. Compound 6, 4(2'-aminoethyl)amino- 1,8-dimethylimidazo(1,2-a) quinoxaline, was administered in a murine model of pulmonary inflammation for the treatment of inflammation and immune-related conditions. The results presented in Table 13 show that administration of compound 6 after ovalbumin challenge to sensitized mice resulted in a statistically significant decrease in total inflammatory cells in the lungs, as determined by measurements from bronchoalveolar lavage fluid when compared with untreated mice. These results support the advantages provided by the present invention in which inflammatory diseases or disorders, such as asthma and chronic obstructive pulmonary disease, are ameliorated by inhibiting IKK activity.
TNFa PRODUCTION ASSAY
THP-1 (human monocytic cell line) obtained from ATCC was cultured in RPMI-1640 supplemented with 10% FBS, sodium pyruvate, HEPES, 2-mercaptoethanol, Penicillin/Streptomycin. To a 96-well plate containing THP-1 cells (1.4x106/mL, 2.5x105 cells/well) in 180 p,L RPMI-1640 was added 20 ~,L of the test compound in 10% DMSO. Typically, test compound concentrations of 0.1-100 ~M were used in the assay. After one hour at 37°C, 20 ~,L of 1000 ng/mL lipopolysaccharide (LPS from Salmonella typhosa, Sigma) was added to each well. After an additional 6 hours at 37°C, the supernatants were collected following a 5 minute centrifugation of the plate to pellet the cells. The amount of TNFa in these supernatants was then measured using a TNFa-specific ELISA (Pharmingen). After subtracting out the amount of TNFa in a control that had not been treated with LPS, the percent inhibition was calculated versus a control that was treated with LPS but with no test compound added. ICSO values were calculated from the percentage inhibition at various doses. In the TNF-a production assay, compound 6 was determined to have an ICSO of 4 ~,M.
Compounds of Examples 12-19 demonstrated IC5o values of below 9 ~,M, with preferred and more preferred compounds having ICSO values of below 2 ~.M and 1 ~,M, respectively, in this assay.
TNFa-STIMULATED DEGRADATION OF hcBa IN THP-1 CELLS
TNFa stimulation of monocytic THP-1 cells leads to the proteolytic degradation of IxBa. Both an IKK-dependent phosphorylation and ubiquitin ligase-dependent ubiquitination of IxBa are essential steps in the TNFa-stimulated pathway targeting IKBa for proteolytic degradation by the proteosome.
THP-1 cells were suspended in RPMI-1640 supplemented with 10%
fetal bovine serum, preincubated for 60 mins with test agent, then stimulated for 15 mins with TNFa (100 ng/mL, R&D Systems). Total cell lysates were fractionated by sodium dodecylsulfate-polyacrylamide electrophoresis followed by Western blot analysis. IxBa was detected using a polyclonal antibody from Santa Cruz (catalog #sc-4094) and ECL reagents (Amersham). Films were scanned using a Kodak ID Image Analysis system t to quantitate the amount of IxBa. Compounds of formula (I) demonstrated up to 100% inhibition of the TNFa-induced degradation of IKBa in THP-1 cells at 10 p,M. In the IxB degradation assay, compound 6 had an ICSO of 5 ~,M upon measuring the TNFa-induced degradation of IKBa in THP-1.
LPS-INDUCED SERUM TNFa IN MICE
As a measure of activity against NF-KB-dependent TNFa production in vivo, test compounds were administered to BALB/c mice subsequently challenged with an intravenous dose of E. coli LPS (1 ~g in 100 p,L
phosphate-buffered saline). One hour after LPS challenge, blood was collected from the mice and the levels of TNFa in the serum measured by EIA (R&D Systems). Inhibition was calculated from control animals which received LPS challenge with no test compound. Compounds of formula (I) demonstrated inhibition of the LPS-induced serum TNFa levels in vivo in the range of about 30 to 65% at 10 mg/kg, p.o; in the range of about 70 to 90%
at 30 mg/kg, p.o.; and in the range of above 90% at 100 mg/kg p.o.
Compound 6 demonstrated inhibition of the LPS-induced serum TNF levels in vivo in the range of about 27-63% at 10 mg/kg, p.o.; in the range of about 53-89% at 30 mg/kg, p.o.; and in the range of about 83-92% at 50 mg/kg, p.o.
Accordingly, compounds of formula (I) have been tested and shown active as inhibitors of TNF-a and the NF-xB pathway.
METHODS OF PREPARATION RELATED TO FORMULA (I) COMPOUNDS
The inventive compounds of formula (I) can be prepared by methods such as those illustrated in the following Schemes I to V in this example.
Starting materials are commercially available or can be readily prepared by one of ordinary skill in the art, and/or modifications can be made to the methods of Schemes I to V by one skilled in the art, using known methods.
For all of the schemes and compounds, the groups R~, R2, R3 and R4 are as described herein for a compound of formula (I), unless otherwise indicated, and appropriate starting materials can be selected by one skilled in the field having the desired groups R~, RZ, R3 and R4. Groups designated R', as well as solvents, temperatures, pressures, and other reaction conditions, can be selected by one of ordinary skill in the art. For example, in these schemes chlorinating agents can include phosphorous oxychloride, catalytic agents can include metals such as Pd, and solvents can be selected from 1,2-dichlorobenzene, methylene chloride, DMF, THF, alcohols, ethers, dioxane, acetonitrile, water, mixtures of ethers and water, and the like.
Abbreviations For ease of reference the following abbreviations are used in the schemes and Examples herein:
Me = methyl Et = ethyl MeOH = methanol EtOH = ethanol i-PrOH = isopropanol Ph = phenyl Bz = benzyl DCM = dichloromethane DMF = dimethyl formamide DMSO = dimethyl sulfoxide NaOH = sodium hydroxide TEA or Et3N = triethylamine TFA = trifluoroacetic acid THF = tetrahydrofuran K2C03 = potassium carbonate Na2S203= sodium thiosulfate min = minutes) L = LITER
mL = milliliter ~,L = microliter G = GRAMS) mg = milligrams) mol = moles mmol = millimole(s) meq = milliequivalent RT = room temperature sat or sat'd = saturated aq. = aqueous TLC = thin layer chromatographyHPLC = high performance liquid chromatography LC/MS = high performance MS = mass spectrometry liquid chromatography/mass spectrometry NMR = nuclear magnetic resonancemp = melting point Definitions Of Terms Used In The Reaction Schemes in Example 11 The following are definitions of terms used herein and in the reaction schemes.
"Acetal, ketal, thioacetal or thioketal formation" are processes known in the art and illustrated in "Protective Groups in Organic Synthesis", Second Ed., T. W. Green and P. G. W. Wuts, John Wiley & Sons, New York, 1991, Chapter 4 and references therein, incorporated herein by reference.
"Acid halide formation" includes methods of converting a carboxylic acid to an acid halide. For example, this reaction can be performed with thionyl chloride, oxalyl chloride or bromide in the presence of DMF in DCM
and phosphorus trichloride or tribromide.
"Alkylation" includes all alkylation procedures such as alkylation of desired alcohol or ketone groups by treatment with organic or inorganic base in an appropriate organic solvent, followed by addition of an alkylating agent such as an alkyl, allyl or benzyl halide, mesylate or tosylate to the generated enolate, phenolate or thiophenolate.
"Aromatic substitution" includes all aromatic substitution methods known in the field including nucleophilic substitutions of aromatic halides by water in presence of sulfuric acid or trifluoroacetic acid, or by alkoxides, aryloxides, thioalkoxides or thioaryloxides in an inert organic solvent.
Copper salts can be used to promote the reaction of aryl halides with alkoxides, and Pd(0) salts can be used to promote the reaction with thioalkoxides.
"Aromatic halogenation" includes the addition of chlorine, bromine or iodine to an aromatic ring optionally with a catalyst, e.g. iron or a Lewis acid.
It also includes the reaction of N-chloro and N-bromoamides catalyzed by the addition of acids. For iodination, iodine can be used with copper salts, silver trifluoromethanesulfonate, thallium(I) acetate, or with an oxidizing agent such as nitric acid, iodic acid, sulfur trioxide or hydrogen peroxide.
Iodine monochloride can also bemused.
"Cross-coupling" includes all cross-coupling methods known by those skilled in the art. Such methods include the reaction of a vinyl or aromatic triflate, bromide or iodide with a tin (Stills-type), zinc, magnesium or boronate (Suzuki-type) derivative catalyzed by a palladium(0), palladium(II), nickel(0) or nickel(II) catalyst. Copper iodide, lithium chloride, zinc chloride or triphenylarsine, tris(2-furyl)phosphine or tris(2,4,6-trimethoxyphenyl)phosphine advantageously can also be added. When a boronic acid derivative is used, the reaction proceeds in the presence of an inorganic base such as potassium phosphate or carbonate or sodium carbonate. The cross-coupling reactions are performed in an inert organic solvent.
"Grignard type reaction" includes the addition of an organometallic compound to a carbonyl-containing compound. This includes addition of Grignard reagents, alkyl or aryllithiums, alkylzinc, alkylaluminum, organotitanium, organozirconium or organocerium compounds in an inert organic solvent such as ethyl ether, THF, DCM, benzene, toluene, or the like. Complexing of the ketone or the Grignard reagent with cerium halides, perchlorate salts or tetraalkylammonium halides can sometimes be advantageous to improve the addition reaction. The term "Grignard type reaction" is also intended to include the addition of a Grignard reagent to an acid chloride that has been first reacted with tributylphosphine to form the corresponding phosphonium salt. The reaction is performed in an inert .
organic solvent.
"Hydrolysis" includes the hydrolysis of esters and carbonyl protecting groups. For example, methyl or ethyl esters can be removed with aqueous ' solutions of sodium or potassium alkoxides in THF or EtOH. The hydrolysis of tent-butyl esters advantageously is carried out under acidic conditions such as 90% trifluoroacetic acid or 6N hydrochloric acid in solvents such as THF or DCM. Allyl esters can be removed with Pd(0) catalyst in an organic solvent. Silyl esters such as trimethylsilylethyl esters can be cleaved with tetrabutylammonium fluoride in THF. The hydrolysis of ketals and acetals can be carried out under acidic conditions such as 1 N hydrochloric acid, 80% acetic acid or p-toluenesulfonic acid in solvents such as THF or acetone.
"Imine formation" procedures are known in the field. For example, a ketone can be reacted with an amine in presence of an acid with or without a drying agent. Various inorganic and organic acids can be used, such as zinc chloride, titanium chloride, hydrochloric acid, sulfuric acid, trifluoroacetic acid, acetic acid, p-toluenesulfonic acid and the like, in solvents such as DCM, EtOH, benzene, toluene, THF, DMF and the like.
Scheme I
Benzo-imidazo-quinoxalines NHZ ~ ~ NH O
/ /
~R4) ~ R3)~NHZ ~R4) ~ ( 3)m NH O
~ N\ CI ~ ~ N\ NH-CHZCH(OR)2 ~ ~ N N
/ / ~ ~/// ~ ~ ~///
(R4) ~ (R3)m N CI (Rq)n (R3)m N CI (Rq)n (R3)m N CI
g 4a 5a N\ CI ~ ~ N\ NH-CHZCH(OR)Z ~ ~ N N
/ / ~ ~/// N~ ~///
NH-R N NH-R~
(R4)n (R3)m N NH-RZ (R4)n (R3)m 2 (R4)n (R3)m ' 4b 5b la Benzo-imidazo-quinoxalines of formula la (wherein Y~ of formula (I) is N, X is CRS and R~ is hydrogen) can be prepared as above. Substituted 2,3-diaminonaphthalenes 1 are reacted with, for example, diethyl oxalate or oxalyl chloride to give annulated quinoxalinediones 2. Diones 2 are reacted with a chlorinating agent to give dichlorides 3. Dichlorides 3 are reacted with amine reagents comprising aminoacetaldehyde acetal and an appropriate primary amine (R2-NH2), and cyclized, wherein the order of reactivity can be adjusted depending upon chlorine atom reactivity.
For example, dichlorides 3 can first be reacted with an aminoacetaldehyde acetal to give amino-chloro derivatives 4a. The amino-chloro derivatives 4a can be cyclized to give the chloro-benzo-imidazoquinoxaline 5~ which can, in turn, be reacted with various primary amines (R2-NH2) to give compounds of formula (la).
Alternatively, where the undesired chlorine atom has greater reactivity (e.g., due to substituents R3 and R4), the order of addition of the amine reagents can be reversed, as shown for structures 4b and 5b.
Dichloride 3 is reacted with primary amines (R2-NH2) to give amino-chloro derivatives 4b, which are then reacted with an aminoacetaldhyde acetal to give diamino compounds 5b, which are then cyclized to give the compound of formula la.
Exemplary aminoacetaldehyde acetals comprise amino-acetaldehyde, dimethyl acetal, or aminoacetaldehyde, diethyl acetal.
Cyclization is typically performed under acidic conditions.
Scheme II
1-Substituted benzo-imidazo-guinoxalines R~
R~
\ \ N~ CI \ \ N\ NH % \ \ N N
/ / ~ ~ ~/// ~ ~///
(R4) ~ / N CI (R4)n (R3)m N CI (R4)n (R3)m N CI
(R3)m 3 6a 7 R~
Rq \ \ Nw CI \ \ N\ NH ~ \ \ N N
/ / ~ ~/ / / N_ \ ~ / /
NH-R ~ _ (R4) ~ ( )m N NH-RZ (R4)n (R3)m Z (R4)n (R3)m N NH R2 4b gb Ib 1-Substituted benzo-imidazo(1,2-a)quinoxalines of formula Ib (wherein Y1 of formula (I) is N, X is CR1 and R1 is substituted lower alkyl) can be prepared as shown in Scheme II. Dichloro compounds 3 are prepared as shown in Scheme I and reacted with substituted propargylamines (R1-C---C-CH2-NH2) to give amino-chloro derivatives 6a, which are cyclized to 1-substituted chloro-benzo-imidazoquinoxalines 7.
Suitable primary amines are reacted with 7 to give compounds of formula Ib.
Alternatively, the order of reactivity can be adjusted, wherein dichloro compounds 3 are first reacted with suitable primary amines to give derivatives 4b, as in Scheme I, and then reacted with propargyl amines to amino derivatives 6b, which can be cyclized as above to give compounds of formula Ib.
Scheme III
Benzo-Pyrazolo-Quinazolines R I ~N
\ \ \ Ns / / 0 ~ \ , N
(R3) ~ (R4)n \ / ~ n N / (R3)m (R4)n C02Me O Ts I \\N I \\N
\ H ~ \ \
~.//~/.~ /~/~ _ _ (R3)m (R4)n C~2H (R3)m (R4)n N C U
11 ~ 11b I \N ' \N ' ~N
\ \ ~ N' \ \ ~ N' \ \ N, (R3)m (R4)n NH O (R3)m (R4)n N CI (R3)m (R4)n N NH-R2 12 13 Ic Benzo-pyrazolo-quinazolines of formula Ic (wherein Y~ of formula (I) is N, X is CHR~ and R~ is as defined above) can be prepared as shown in Scheme III. Reagents 8c and 9c are condensed in the presence of catalyst in a Stille-type reaction to give coupled product 10, which is hydrolyzed to give compound 11. Treatment of 11 with, for example, diphenyl phosphoryl azide followed by heat, produces an intermediate isocyanate 11 b, which will spontaneously cyclize under the reaction conditions to give compound 12.
Treatment of 12 with a chlorinating agent gives chloro compound 13, which can be reacted with suitable primary amines (R2-NH2) to give compounds of formula Ic.
Scheme Illa \ \ NH2 \ \ ~ \ \
~R3) ~~/~R4 n OH R ~~~~ ~ OH ~R3~ ~~~~ ~ O\
31m ~R4O ~ ~ 4~n 8a gb 8 Rq R~ ~ \N R~
~N ~ O; S ~ Sn / \N
H p ~ \ ~ N
/ Ts ga 9b 9 Reagents 8 and 9 for Scheme III above can be prepared as shown in Scheme Illa. Substituted 3-amino-2-naphthoic acids 8a can be converted to substituted 3-iodo-2-naphthoic acids 8b by, for example, diazotization followed by treatment with an iodide salt. Esterification of compound 8b produces 3-iodo-2-napthoic acid esters 8. 4-Substituted pyrazoles 9a can be treated with a p-toluenesulfonating agent, such as p-toluenesulfonyl chloride, to give p-toluenesulfonamide 9b. Deprotonation of compound 9b with a strong base, such as t-butyl lithium, and treatment with a stannylating agent, such as trimethyl chloro stannane, gives reagent 9.
Scheme IV
Benzo-imidazo-quinolines O N
\ \ ~ ~ \ \ B\O ~ \ \ ~N
W ~~~/ Ow ( 3)m (R4)n p~ (Ra)n (~s)m ~R4)n (~3 m O C~ O
8 ~OB~B p~ 14 ~('N\ N 15 \N~ N~ \N~
\ \ ~N ~ \ \ N ~ ~ \ \ N
// ~/ OH R / R// N.Boc // //
(R4)n (Rs)m ~ ( 4)n ( 3)m ~ (R4)n (R3)m NH2 O H
16 1~ 18 N~ \N~ \N~
N
\ \ ~ ~ \ \ ~ N ~ \ \ \ N
/ N O ~// /~/~ ~ CI // ° / ~ R
(R4)n (Rg)m ~ (R4)n ~R3~\N (R4)n ~~R~ ~N~\[vJH' O H
~ N-a N~ 'N 19 2p Id Benzo-imidazo-quinolines of formula Id (wherein X of formula (I) is NR~ and R~ is methyl) can be prepared as shown in Scheme IV. Substituted 3-iodo-2-naphthoic acid esters 8 prepared as in Scheme Illa are converted to boronate derivatives 14 using catalyst and a reagent such as bis(pinacolato)diboron. Condensation of compound 14 with 1-methyl-5-bromoimidazole and catalyst in a Suzuki-type reaction gives coupled ester 15. Ester 15 is hydrolyzed to give acid 16, which is converted via treatment with diphenylphosphoryl azide (through an intermediate isocyanate -- see 11 b) and t-butanol into protected amine 17. Acid treatment converts 17 to free amine 18, which is heated in a high-boiling point inert solvent such as 1,2-dichlorobenzene with carbonyldiimidazole to give cyclized product 19.
Treatment with a chlorinating agent converts compound 19 to the chloro derivative 20, which can be converted by treatment with suitable primary amines (R2-NH2) to give compounds of formula Id.
Scheme V
BENZO(G)THIAZOLO(4,5-C)QUINOLINES
O SAN
\ \ B~O ~ \ \
O
(R4)n~~~~ \ S~ (R4)n( ) /~COOCH3 N
s~ s~ s~
N ~ N ~ N
a R ~~~/~COOH ~ R ~~ ~ /~ NH'Boc R ~/ ~ /~ NHZ
( a) (R3)m ( a) (R3)m ( a) (R3)m S~ S-N N
O R ~/ / NH O R ~/ /~ N CI
_ ( a) (R3)m ( a) (R3)m N~ N 25 26 N
~~~ / \~
(R4)n (R3)m N NH-R
1e Benzo-thiazolo-quinolines can be prepared as shown above in Scheme V. Substituted 3-boronato-2-naphthoic acid ester 14 is condensed with 5-bromothiazole in a Suzuki-type reaction, catalyzed by a metal such as Pd, to give coupled product 21. The ester 21 is hydrolyzed under standard conditions to give acid 22, which is then converted via treatment with diphenylphosphoryl azide (through an intermediate isocyanate similar to 11 b) and t-butanol into the protected amine 23. Acid treatment can convert compound 23 to the free amine 24, which is heated in a high-boiling inert solvent such as 1,2-dichlorobenzene with carbonyldiimidazole to give cyclized product 25. Compound 25 can be converted to the chloro derivative 26 by treatment with a chlorinating agent, and compound 26 is converted by treatment with suitable primary amines (R2-NH2) to give the compound of formula 1e.
The.following preparations illustrate embodiments of the invention and are not intended to limit the scope of the claims. The reagents and starting materials of Preparations 1-19 are useful in synthesizing compounds of formula (I), or salts thereof, such as illustrated in Schemes I-V. In the following preparations, anhydrous reactions were performed under an atmosphere of nitrogen or argon using either commercially available dry solvents or freshly distilled solvents. Melting points were determined in an open capillary tube with a Thomas-Hoover melting point apparatus. Column chromatography was performed using EM Soience silica gel 60 (230-400 mesh) with the designated solvent system as eluant. Thin-layer chromatography was done on E. Merck silica gel 60 F2sa plates (0.5 mm).
HPLC purity determinations were done using either an HP 1090 DR5 with a diode array detector and a Waters Nova-Pak C18 column (3.9 x 150 mm), or a Shimadzu LC-10AS with a SPD-10AV UV-Vis detector and one of the following columns: YMC Combiscreen ODS-A (4.6 x 50 mm); HP Zorbax SB-C18 (4.6 x 750 mm). Infrared spectra and ~HNMR spectra were recorded and chemical shifts are expressed in parts per million (ppm or 8) with the solvent in use as internal standard. Coupling constants are given in Hertz and multiplets are designated as follows; singlet (s), doublet (d), triplet (t), quartet (q), muliplet (m), and broad (br). Low resolution mass spectra were determined on a Finnigan Matt TSQ-7000 triple stage quadrapole spectrometer (positive/negative ESI) operated in the negative ion mode.
Preparation of Reagents and Starting Materials for the Preparation of Compounds of Formula (I) Preparation 1 1,4-Dihydrobenzo[g]guinoxalin-2,3-dione H
N O
/ /
N O
H
A mixture of 2,3-diaminonaphthalene (2.87 g, 18.14 mmol) and diethyl oxalate (30 mL, 223 mmol) was heated to reflux for 14 hours, cooled to RT and filtered. The residue was washed with EtOH and dried in vacuo to give the title compound as a brown solid (3.15 g, 82%); mp > 350 °C;
IR
(KBr, cm -~) 3045, 2942, 2869, 1716, 1642, 1406, 877; ~H NMR (DMSO) s 12.11 (s, 2H), 7.84-7.81 (m, 2H), 7.54 (s, 2H) 7.39 (dd, J = 6.3, 3.0, 2H);
LC/MS 92.5% (220 nm), m/z (M + H+) 213.
Preparation 2 2,3-Dichlorobenzo[g]'auinoxaline NCI
/ /
N CI
One gram (1 g; 4.72 mmol) of 1,4-dihydrobenzo[g]quinoxalin-2,3-dione was stirred in 2 ml of phosphorus oxychloride for 5 hours at reflux.
The mixture was concentrated by evaporation and dried under high vacuum.
A saturated K2C03 solution was carefully added to the residue, and the solid was filtered off and washed with water to afford the title compound as a brown solid (1.00 g, 85%); mp 239-242 °C; IR (KBr, cm ~) 1200, 1109, 998, 886, 748; ~H NMR (DMSO) b 8.78 (s, 2H), 8.31-8.28 (m, 2H), 7.75-7.73 (m, 2H).
Preparation 3 2-Chloro-3-(hroparqylamino benzo[g]Ig~uinoxaline \ \ N\ N
/ /
N~ CI
A mixture of 2,3-dichlorobenzo[g]quinoxaline (0.634 g, 2.55 mmol), propargylamine (0.21 ml, 3.05 mmol) and TEA (0.53 mL, 3.83 mmol) in 15 mL of dioxane was heated to reflux for 4.5 hours. After evaporating the resulting mixture under vacuum, the crude product was chromatographed (CH2C12) to afford the title compound as a yellow solid (0.496 g, 73%); mp 169-172 °C; IR (KBr, cm -~) 3412, 3283, 3235, 1570, 1508, 1335; ~H NMR
(DMSO) 8 8.44 (s, 1 H), 8.26 (s,1 H), 8.16-8.06 (m, 3H), 7.58-7.54 (m, 1 H), 7.51-7.48 (m, 1 H), 4.28 (dd, J = 6.1, 2.5, 2H), 3.12 (t, J = 2.5, 1 H); LC/MS
97.8% (220 nm), m/z (M + H+) 268.
Preparation 4 4-Chloro-1-methylbenzo[aJimidazo[1,2-a]quinoxaline \ \ N rN
N CI
2-Chloro-3-(propargylamino)benzo[g]quinoxaline (0.420 g, 1.57 mmol) was treated with 4 mL of concentrated HZS04 and the mixture was stirred at 80 °C for 1 hour, cooled to RT and poured into ice water.
The mixture was cautiously neutralized with aqueous NaOH, and the resulting precipitate was filtered, washed with water, and dried in vacuo to give the title compound as a beige solid (0.124 g, 30%); mp 221-223° C; IR
(ICBr, cm -~) 1538, 1479, 1456, 1398, 1101, 919;'H NMR (DMSO) 8 8.79 (s, 1H), 8.53 (s, 1 H), 8.23 (d, J = 8.1, 1 H), 8.13 (d, J = 8.5, 1 H), 7.69-7.59 (m, 3H), 3.04 (s, 3H); LC/MS 100% (220 nm), m/z (M + H+) 268.
Preparation 5 3-lodo-2-napthoic acid I
/ / OH
I
O
To a beaker of 3-amino-2-napthoic acid (6.01 g, 80% pure; 25.69 mmol), was added a solution of concentrated HCI (10.0 mL) and water (15.0 mL). After the resulting pink paste was stirred for 17 min, it was cooled to 0°C and treated with a solution of water (10 mL) and NaNO2 (2.54 g, 36.81 mmol) drop-wise (over 8 min). One minute later, the brown reaction mixture was treated with a cooled (0°C) water (10.0 mL) solution of KI (10.0 g, 60.24 mmol) drop-wise (over 12 min). The cooling bath was removed, water (15 mL) was added, and the reaction mixture was stirred for 10 min at RT and heated at 95°C for 65 min. It was then diluted with water (50 mL) and extracted with EtOAc (250 mL). The organic layer was washed with water (50 mL) and brine, dried (MgS04), filtered, and evaporated in vacuo. The resultant crude material was submitted to flash chromatography (sample was loaded as a silica gel mesh; EtOAc) to afford the title compound as an iodine colored fluffy solid weighing 6.50 g. ~H NMR (DMSO, 8 = 2.50):
13.36 (br s, 1 H), 8.63 (s, 1 H), 8.37 (s, 1 H), 8.05 (d, J = 7.9, 1 H), 7.93 (d, J =
8.0, 1 H), 7.67-7.60 (m, 2H).
Preparation 6 Methyl 3-lodo-2-napthoate / / o w To 3-iodo-2-napthoic acid (Preparation 5) (6.50 g), were added MeOH (100 mL) and concentrated H2S04 (2 mL), and the resultant heterogeneous mixture was refluxed for 13 hr. The reaction mixture was allowed to cool to RT, then neutralized with NaHC03 (6.0 g), and the volatile component was removed in vacuo. The residue was partitioned between water (50 mL) and EtOAc (300 mL). The organic layer was washed with Na2S203 solution (4.2 g + 50 mL of water) and brine, dried (MgS04), filtered and evaporated in vacuo. The resulting crude material was submitted to flash chromatography (sample was loaded as a silica gel mesh, 10%
EtOAc/hexanes) to isolate the title compound as a light-yellow solid (5.50g, 2 steps combined yield of 69%). ~H NMR (DMSO, ~ = 2.50): 8.66 (s, 1 H), 8.39 (s, 1 H), 8.06 (d, J = 8.0, 1 H), 7.95 (d, J = 8.0, 1 H), 7.69-7.62 (m, 2H), 3.91 (s, 3H). (DGI) m/z (M+H)+ = 313Ø Anal. calculated for C~2HgIO2: C, 46.18; H, 2.91. Found: C, 46.28; H, 2.85.
Preparation 7 4-Methyl-1-(4-tolunesulfonyl)pyrazole \N
N
~~S
p-TsCI (9.81g,51.46 mmol) was added in batches over a few minutes to a CH2C12 (100 mL) solution of 4-methylpyrazole (4.00 g, 48.72 mmol) and pyridine (6.0 mL, 74.18 mmol). The reaction mixture was stirred for 95 min, then diluted with CH2C12 (250 mL) and washed with NaHC03 solution [a mixture of sat'd NaHC03 solution (20 mL) and H20 (40 mL)], and water (60 mL). The organic layer was dried (MgS04), filtered and evaporated in vacuo.
The resulting crude material was purified by flash chromatography (sample was loaded as a silica gel mesh; CH2C12) to afford the title compound as a white solid (10.88 g, 95%). ~H NMR (CDC13, 8 = 7.26): 7.87 (d, J = 8.4, 2H), 7.84 (s, 1 H), 7.54 (s, 1 H), 7.32 (d, J = 8.40, 2H), 2.41 (s, 3H), 2.06 (s, 3H).
(ESI) m/z (M+H)+ = 236.7. Anal. calculated for C~~H~2N202S: C, 55.91; H, 5.12; N, 11.86. Found: C, 55.81; H, 4.94; N, 11.76.
Preparation 8 4-Methy~4-tolunesulfonyl~5-trimethylstannylp razole ~Sn NON
I
TS
t-BuLi (1.7 M/pentane) was added over 10 min to a cooled (-78 °C) THF (60 mL) semi-suspension of 4-methyl-1-(4-tolunesulfonyl)pyrazole (Preparation 7) (6.01 g, 25.43 mmol). After the mixture.was stirred for 10 min, it was treated drop-wise (over 20 min) with Me3SnCl (28.0 mL of 1.0 M/THF, 28.0 mmol). The resulting mixture was stirred for 4.3 hr while the bath was allowed to thaw to -55 °C, and then for 70 min. at RT. The reaction mixture was diluted with EtOAc (250 mL) and washed with water (50 mL) and brine, dried (MgS04), filtered, and evaporated in vacuo. The crude material was submitted to flash chromatography (sample was loaded as a silica gel mesh; 15-20% EtOAc/hexanes) to afFord the title compound as a dense white solid (4.406 g, 43%). Non-consumed pyrazole of Preparation 7, above, was also retrieved (1.954 g, 33%). ~H NMR of the title compound (DMSO, 8 = 2.50): 7.74 (s, 1 H), 7.70 (d, J = 8.3, 2H), 7.45 (d, J =
8.3, 2H), 2.38 (s, 3H), 2.08 (s, 3H; satellite peaks due to Sn-H with J =
4.5), 0.45 (s, 9H; satellite peaks due to Sn-H with J = 59.8 and 57.3). (ESI) m/z (M+H)+ = 400.9.
Preparation 9 Methyl 3-(4-meth I-1- 4-toluenesulfonyl~pyrazol-5-yl)-2-naphthoate I \N
\ \ N~
TS
C02Me DMF (26.0 mL) was added into a mixture of methyl-3-iodo-2-napthoate (Preparation 6) (2.017 g, 6.463 mmol), 4-methyl-1-(4-tolunesulfonyl)-5-trimethylstannylpyrazole (Preparation 8) (2.895 g, 7.254 mmol), Pd2dba3 (236 mg, 0.258 mmol), Ph3As (317.2 mg, 1.036 mmol), and Cul (130.7 mg, 0.686 mmol). After nitrogen was bubbled through the heterogeneous mixture for a few minutes, it was stirred at RT for 7 min and at 90°C for 12 hr. The volatile component was removed in vacuo, and the resultant viscous residue was submitted to flash chromatography (sample was loaded as a silica gel mesh; 0-10 % EtOAclCH2Cl2) to afford the titled compound as a yellow solid (1.485 g, 55%). ~H NMR (DMSO, 8 = 2.50): 8.73 (s, 1 H), 8.23 (d, J = 7.7, 1 H), 8.05 (d, J = 7.7, 1 H), 7.83 (s, 1 H), 7.81 (s, 1 H), 7.77-7.71 (m, 2H), 7.50 (d, J = 8.2, 2H), 7.38 (d, J = 8.2, 2H), 3.66 (s, 3H), 2.38 (s, 3H), 1.77 (s, 3H). (ESI) m/z (M+H)+ = 421Ø
Preparation 10 3-(4-methypyrazol-5-yl -2-na~hthoic acid THF (12.0 mL), MeOH (8.0 mL) and NaOH solution (7.5 mL of 1.0 N/H20) were added to methyl-3-(4-methyl-1-(4-tolunesulfonyl)pyrazol-5-yl)-2-napthoate (Preparation 9) (1.240 g, 2.949 mmol), and the reaction mixture was heated at 80°C for 4.2 hr. It was then diluted with water (20 mL), acidified to pH ~ 4.5 with 1 N HCI, and extracted with EtOAc (75 ml, 2x). The combined organic layer was washed with brine, dried (MgS04), filtered, and evaporated in vacuo. The resulting crude material was submitted to flash chromatography (sample was loaded as a silica gel mesh; 10%
I \N
Hi / /
MeOH/CH~C12) to isolate the title compound as faint-yellow solid (300 mg, 40%). ~ H NMR (DMSO, 8 = 2.50; one tautomer was observed): 12.70 (br s, 2H), 8.37 (s, 1 H), 8.08 (d, J = 7.9, 1 H), 8.01 (d, J = 8,0, 1 H), 7.93 (s, 1 H), 7.65-7.58 (m, 2H), 7.47 (s, 1 H), 2.01 (s, 3H). (ESI) mlz (M+H)+ = 252.99.
Preparation 11 1-Methylbenzo(g)pyrazolo(1,5-c)quinazolin-5-one \N
\ \ ~ N' N ~O
H
Et3,N (300 p,L, 2.152 mmol) and (Ph0)2PON3 (440 pL, 2.064 mmol) were added to a C6H6 (10.0 mL) suspension of 3-(4-methylpyrazol-5-yl)-2-naphthoic acid (Preparation 10) (257 mg, 1.019 mmol), and the mixture was heated at 50°C for 2 hr. The volatile component was removed in vacuo, and the resulting yellow solid was dissolved in o-dichlorobenzene (8.0 mL) and heated at 150°C for 4 hr. During the latter heating, there was a gradual evolution of gas accompanied by the formation of a suspension. The reaction mixture was allowed to cool to RT, and the precipitate was filtered and washed with copious ether to afford the title compound as a fluffy light-yellow solid (170.8 mg, 67%).'H NMR (DMSO, s = 2.50): 11.86 (s, 1H), 8.57 (s, 1 H), 8.13 (d, J = 8.2, 1 H), 7.99 (s, 1 H), 7.92 (d, J'= 8.3, 1 H), 7.22 (s, 1 H), 7.56 (app t, J = 7.21, 1 H), 7.49 (app t, J = 7.48, 1 H), 2.60 (s, 3H):
(ESI) m/z (M+H)+ = 250.00.
Preparation 12 1-Methyl-5-chlorobenzo(g)pyrazolo 1,5-c)auinazoline \N
\ \ ~ N' N "CI
PhNEt2 (1.50 mL) and POC13 (15.0 mL) were added to 1-methylbenzo(g)pyrazolo(1,5-c)quinazolin-5-one (Preparation 11) (184.7 mg, _78-0.741 mmol), and the resulting heterogeneous mixture was heated at reflux for 46 hr. During heating, the suspension (the starting material), gradually started to dissolve. The dark-green reaction mixture was filtered to remove non-consumed starting material (16.2 mg, 8.8%), and the filtrate was exposed to high vacuum to remove most of the POC13. The residue was partitioned between water (30 mL) and EtOAc (70 mL). The organic layer was washed with brine, dried (MgS04), filtered, and evaporated in vacuo.
The crude material was submitted to flash chromatography (sample was loaded as a silica gel mesh; 20% EtOAc/hexanes) to afford the title chloride as an off-white solid (153 mg, 77%).'H NMR (DMSO, s= 2.50): 8.80 (s, 1H), 8.46 (s, 1 H), 8.29-8.27 (m, 1 H), 8.19 (s, 1 H), 8.17-8.15 (m, 1 H), 7.70-7.65 (m, 2H), 2.70 (s, 3H). (ESI) m/z (M+H)+ = 267.98.
Preparation 13 Methy~4,4,5,5-tetramethyl-1,3.2-dioxaborolan-2-yl)-2-naphthoate o~
To a solution of 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi-1,3,2-dioxaborolane (30.0 g, 0.118 mol) and methyl 3-iodo-2-naphthoate (Preparation 6) (33.5 g, 0.107 mol) in DMSO (600 mL) were added PdCl2(dppf) (2.62 g, 0.21 mmol) and KOAc (31.51 g, 0.321 mol). The mixture was degassed and purged with N2, and then heated at 85°C for 18 hours. The brown reaction mixture was cooled to RT, diluted with water (1.5 L), and extracted with EtOAc (2.5 L, then 2x500 mL). The combined organic layer was washed with brine (9x500 mL), dried over MgS04, filtered and evaporated in vacuo. The resulting crude material was submitted to flash chromatography (2.0% MeOH/CHC13), affording the title compound as a yellow solid (19.5 g, 58%). ~ H NMR (CDC13): 8.50(s, 1 H), 7.99(s, 1 H), 7.90(d, J=8.1, 1 H), 7.86(d, J=8.1,1 H), 7.57(m, 1 H), 7.54(m, 1 H), 3.98(s, 3H), 1.47(s, 12H). (ESI) m/z (M+H)+ = 313.16 Preparation 14 Meth rLl-3-~1-methyl-imidazol-5-~ -2-naphthoate N-l \ .~ ~ N
/ O~
O
To a mixture of methyl-3-(4,4,5,5,-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-naphthoate (Preparation 13) (15.37 g, 49.3 mmol) and 5-bromo-1-methyl-1 H-imidazole (9.06 g, 49.3 mmol) in toluene/EtOH (350 mL/36 mL) were added Pd(PPh3)4 (11.37 g, 9.84 mmol), Na2C03 (20.9 g, 197.2 mmof) and water (106 mL). The mixture was degassed, purged with N2, and heated to reflux for 20 hours. It was then cooled to RT, neutralized with HCI
(1.0 N, 100 mL), and concentrated in vacuo. The residue was partitioned between water (300 mL) and EtOAc (1 L). The organic layer was washed with water (2 L) and brine, dried over MgSO4, filtered and evaporated in vacuo. The resulting crude material was submitted to flash chromatography (1.5% MeOH/CHC13), furnishing the title compound as a light-yellow solid (9.5 g, 72%). ~ H NMR(CDCI3): 8.53(s, 1 H), 7.99(d, J=8.1, 1 H), 7.80(d, J=8.1, 1 H), 7.77(s, 1 H), 7.56(m, 1 H), 7.54(m, 1 H), 7.54(s, 1 H), 6.94(s, 1 H), 3.73(s, 3H), 3.29(s, 3H). (ESI) m/z (M+H)+ = 267.11.
Preparation 15 3-(1-Methyl-imidazol-5-yl -2-naphthoic acid N
\ \ \ N
/ OH
O
A solution of methyl-3-(1-methyl-imidazol-5-yl)-2-naphthoate (Preparation 14) (8.5 g, 32 mmol) in THF/MeOH (3/2, 120 mL) was treated with aqueous NaOH (1.0 N, 48 mL). After 20 hours at RT, it was neutralized with aqueous HCI (1.0 N, 20 mL). The solvent was evaporated in vacuo.
The solid residue was treated with MeOH (5 mL), then evaporated again.
The resulting crude material was purified by flash chromatography (5%
MeOH/EtOAc) affording the title compound as a pale-yellow solid (6.0 g, 74%). ~ H NMR(CDC13): 8.34(s, 1 H), 7.95(d, J=8.1, 1 H), 7.90(d, J=8.1, 1 H), 7.72(s, 1 H), 7.53(s, 1 H), 7.52(m, 1 H), 7.50(m, 1 H), 6.83 (s, 1 H), 3.16(s, 3H).
(ESI) m/z (M+H)+ = 253.10.
Preparation 16 1,1-Dimethylethy~(1-methylimidazol-5-y,-2-naphthyl~carbamate N-\ \ \ N
_ BOC
N
I
H
To a mixture of 3-(1-methyl-imidazol-5-yl)-2-naphthoic acid (Preparation 15) (1.0 g, 3.95 mmol) and Et3N (1.1 mL, 7.91 mmol) in 20m1 t BuOH was added diphenylphosphorylazide (1.63 g, 5.93 mmol). After 40 minutes at 80°C, the mixture was cooled to RT. The slurry was diluted with EtOAc (300 mL), and washed once with water (50 mL) and three times with brine. The organic layer was dried over MgS04, filtered, and evaporated in vacuo. The crude material was submitted to flash chromatography (0.5%
MeOH/EtOAc) afFording the title compound as a pale-yellow solid (0.67 g, 51 %). ~ H NMR(CDC13): 8.34(s, 1 H), 7.95(d, J=8.1, 1 H), 7.90(d, J=8.1, 1 H), 7.72(s, 1 H), 7.53(s, 1 H), 7.52(m, 1 H), 7.50(m, 1 H), 6.83 (s, 1 H), 3.16(s, 3H), 1.43(s, 9H). (ESI) m/z (M+H)+ = 324.15 Preparation 17 5~3-Amino-2-nalahth~rl)-1-methylimidazole N
A solution of 1,1-dimethylethyl-3-((1-methylimidazol-5-yl)-2-naphthyl)carbamate (Preparation 16) (1.0 g, 2.98 mmol) in TFA/CH2C12 (1:10, 50 mL) was stirred at RT for 18 hours. After concentration, the residue was diluted with EtOAc (200 mL), washed with aqueous NaHC03 (100 mL) and brine. The organic layer was then dried over MgS04, filtered and evaporated in vacuo. .The crude material was submitted to flash chromatography (5% MeOH/EtOAc) affording the title compound as a light yellow solid (0.49 g, 70%). ~H NMR(CDC13): 7.65(d, J=8.1, 1H), 7.59(d, J=8.1, 1 H), 7.57(s, 1 H), 56(s, 1 H), 7.36(m, 1 H), 7.22(m, 1 H), 7.13(s, 1 H) 7.03 (s, 1 H), 3.96(b, 2H), 3.46(s, 3H). (ESI) m/z (M+H)+ = 224.08 Preparation 18 1-methyl-4,5-dihydrobenzo~g~imidazo 4,5-c)guinolin-4-one N
N
N O
H
A mixture of 5-(3-amino-2-naphthyl)-1-methylimidazole (Preparation 17) (0.48 g, 2.14 mmoi) and 1,1'-carbonyldiimidazole (0.42 g, 2.57 mmol) in o-dichlorobenzene (22 mL) was heated at 180°C for 5 hours. The suspension was cooled to RT, filtered, and dried under vacuum, affording the title compound as a light yellow solid (0.22 g, 42%). ~ H NMR(DMSO):
11.57(s, 1 H), 8.71 (s, 1 H), 8.15(s, 1 H), 8.10(d, J=8.4, 1 H), 7.89(d, J=8.4, 1 H), 7.84(s, 1 H), 7.53(m, 1 H), 7.46(m, 1 H), 4.30(s, 3H). (ESI) m/z (M+H)+
_ 250.08.
Preparation 19 1-Meth~~l-4-chlorobenzo(g)imidazo 4,5-c)auinoline N-~ \ ~ N
/ N CI
To a mixture of 1-methyl-4,5-dihydrobenzo(g)imidazo(4,5-c)quinolin-4-one (Preparation 18) (200 mg, 0.80 mmol) and PhNEt2 (2.5 mL, 1.6 mmol) was added POC13 (8 mL). The mixture was then heated to reflux for 4 hours.
After cooling, excess POC13 was removed under vacuum. The residue was diluted with EtOAc (150 mL), and treated with NaHC03 (1 g) to neutralize the acid. The organic layer was washed with brine, dried over MgS04, filtered and evaporated in vacuo. The crude material was submitted to flash chromatography (EtOAc) affording the title compound as a light yellow solid (0.18 g, 90°l°). ~ H NMR(CDC13): 8.61 (s, 1 H), 8.57(s, 1 H), 8.01 (d, J=8.8, 1 H), 7.98(d, J=8.8, 1 H), 7.89(s, 1 H), 7.57(m, 1 H), 7.54(m, 1 H), 4.35(s, 3H).
(ESI) m/z (M+H)+ = 268.08.
Examples 12-19 provide compounds as described herein.
1-METHYL-4-METHYLAMINOBENZO[G]IMIDAZO[1,2-A]QUINOXALINE
\ \ N iN
/ ~ i N N
H
To a solution of 4-chloro-1-methylbenzo[g]imidazo[1,2-a]quinoxaline (0.063 g, 0.236 mmol) (Preparation 4 in Example 11) in 4 mL of THF was added MeNH2 (40% in H20, 0.16 mL, 1.88 mmol). The reaction tube was sealed and the mixture stirred at 80°C for 18 hours. The cooled mixture was then taken up in EtOAc, washed with water and brine, dried (Na2S04) and evaporated. The resulting residue was recrystallized using i-PrOH to give Example 12 as beige needles (0.043 g, 69%); mp 201-202 °C, IR
(KBr, cm -~) 3324, 1575, 1557, 1411, 1121; ~H NMR (DMSO) 8 8.62 (s, 1H), 8.10 (s, 1 H), 8.08 (d, J = 8.1, 1 H), 7.94 (d, J = 8.1, 1 H), 7.77 (br d, J = 4.5, 1 H), 7.49-7.45 (m, 2H), 7.35 (s, 1 H), 3.06 (d, J = 4.6, 3H), 2.98 (s, 3H); MS
(~ESI, M + H+) m/z 263; HPLC: 99.5% (230 nm); HRMS calculated for C~6H~4N4:
262.1219; found 262.1226. Inhibition of IKK-1 activity was measured using the assay of Example 2, where the inhibitory potential of the compound of Example 12 resulted in an IC5o of 0.23 p,M.
1-METHYL-4-(2-N-METHYLAMINOETHYLAMI NO)BENZO[G]IM IDAZO[1,2 A]QUINOXALINE HYDROCHLORIDE
\ \ N rN
~NHMe.HCI
N N
H
To a solution of 4-chloro-1-methylbenzo[g]imidazo[1,2-a]quinoxaline (0.075 g, 0.281 mmol) (Preparation 4 in Example 11) in 4 mL of THF was added N-methylethylene diamine (0.20 mL, 2.25 mmol). The reaction tube was sealed and the mixture stirred at 80°C for 18 hours. The resulting cooled mixture was then taken up in EtOAc, washed with water and brine, dried (Na2S04) and evaporated. Purifying the residue by preparative TLC
(CH2C12:MeOH, 8:2) yielded 1-methyl-4-(2-N-methylaminoethylamino)benzo[g]imidazo[1,2-a] quinoxaline. This solid was dissolved in CH2CI2/EtOH and a solution of 1 N HCI in EtOH was added to form the hydrochloride salt, which was filtered, washed with EtOH and dried in vacuo to afford the above titled salt as an off-white solid (0.025 g, 26%);
mp 265-275 °C dec; IR (KBr, cm-~) 3448, 2958, 2780, 1656, 1532, 1420;
~H
NMR (CD30D) 8.72 (s, 1 H), 8.42 (s, 1 H), 8.13-8.11 (m, 1 H), 8.01-7.98 (m, 1 H), 7.63-7.57 (m, 3H), 4.23-4.20 (m, 2H), 3.54-3.51 (m, 2H), 3.07 (s, 3H), 2.86 (s, 3H); MS (+ESI, M + H+) m/z 306; HPLC: 98.3% (230 nm); HRMS
calculated for C~sH~9N5: 306.1719; found 306.1708. Inhibition of IKK-1 activity was measured using the assay of Example 2, where the inhibitory potential.of the~compound of Example 13 resulted in an IC5o of 0.35 p.M.
1-METHYL-4-METHYLAMINOBENZO[G]PYRAZOLO[1,5-C]QU INAZOLI NE
\N
\ \ wN~
N~N~
H
A mixture of 4-methyl-1-(4-tolunesulfonyl)-5-trimethylstannylpyrazole (Preparation 8 in Example 11) (24.0 mg, 0.0896 mmol) and MeNH2 (3.0 mL
of 2.0 M/THF, 6.0 mmol) in a pressure tube was heated at 60°C for 5 hr.
After the reaction mixture was cooled to RT, it was treated with NaHC03 (57 mg) and water (2 pipet-drops) and stirred for 5 min. Silica gel was added and the volatile component was removed in vacuo. The resulting silica gel mesh was submitted to flash chromatography (20% EtOAc/hexanes) to afford the title compound as a light yellow solid (23.0 mg, 98%).'H NMR
(DMSO, b = 2.50): 8.60 (s, 1 H), 8.10 (s, d, J = 8.3, 1 H), 8.03 (s, 1 H), 8.01 (s, 1 H), 7.95 (d, J = 8.01, 1 H), 7.92 (q, J = 4.7, 1 H), 7.50 (t, J = 7.5, 1 H), 7.44 (t, J = 7.4, 1 H), 3.09 (d, J = 4.7, 3H), 2.66 (s, 3H). (ESI) m/z (M+H)+ = 263.02.
Inhibition of IKK-1 activity was measured using the assay of Example 2, where the inhibitory potential of the compound of Example 14 resulted in an ICSO of 0.67 p,M.
1-M ETHYL-4-(2-N-METHYLAMINOETHYLAMINO)BENZO[G]PYRAZOLO[1,5-C]QUINAZOLINE
wN~
I H
/ /
N~N~N\
H
N-methyl-ethylenediamine (250 ~,L, 2.836 mmol) was added rapidly to a THF (2.0 mL) semi-suspension of 4-methyl-1-(4-tolunesulfonyl)-5-trimethylstannylpyrazole (Preparation 8 in Example 11 ) (30.5 mg, 0.114 mmol). The reaction mixture was stirred at RT for 1 hr and at 75°C for 2.3 hr.
After the reaction mixture was cooled to RT, it was treated with NaHCO3 (57 mg) and water (2 pipet-drops) and stirred for a few minutes. The volatile components, including the excess diamine, were removed in vacuo. The crude material was submitted to flash chromatography (sample was loaded as a silica gel mesh; 0-100% MeOH/EtOAc) to afford the title compound as a yellow waxy-solid (43.4 mg; the weight is 8.6 mg more than the theoretical yield). ~ H NMR (DMSO, 8 = 2.50): 8.60 (s, 1 H), 8.10 (d, J = 8.1, 1 H), 8.02 (s, 2H, signal overlap), 7.95 (d, J = 8.1, 1 H), 7.73 (t, J = 5.5, 1 H), 7.51 (ddd, J =
8.2, 6.8, 1.1, 1 H), 7.45 (ddd, J = 8.0, 6.9, 1.0, 1 H), 3.66 (apt q, J = 6.1, 2H), 2.82 (t, J = 6.3, 2H), 2.66 (s, 3H), 2.35 (s, 3H), 1.81 (s, 1 H). (ESI) m/z (M+H)+ = 306.05.
1-METHYL-4-METHYLAMINOBENZO(G)IMIDAZO(4,5-C)QUINOLINE
N N
\ \ \~
/ /
A mixture of 1-methyl-4-chlorobenzo(g)imidazo(4,5-c)quinoline (Preparation 19 in Example 11) (130 mg, 0.49 mmol) and MeNH2 (2.OM/THF, 1.5 mL, 2.92 mmol) was heated in a pressure tube at 80°C for 18 hours. After the reaction mixture was cooled to RT, it was diluted with EtOAc (100 mL), washed with saturated NaC03 (50 mL), and brine. The organic layer was dried over MgS04, filtered and evaporated in vacuo. The crude material was submitted to flash chromatography (5% MeOH/EtOAc) affording the title compound as a pale white solid (5.2 mg, 4%). ~H
NMR(CDCI3): 8.44(s, 1 H), 8.35(s, 1 H), 7.94(d, J=8.3, 1 H), 7.90(d, J=8.3, 1 H), 7.72(s, 1 H), 7.46(m, 1 H), 7.40(m, 1 H), 5.95(b, 1 H), 4.28(s, 3H), 3.31 (s, 3H). (ESI) m/z (M+H)~ = 263.14. Inhibition of IKK-1 activity was measured using the assay of Example 2, where the inhibitory potential of the compound of Example 16 resulted in an IC5° of 0.80 ~,M.
1-METHYL-4-(2-N-METHYLAMINOETHYLAMINO)BENZO(G)IM1DAZ0(4,5-?0 C)QUINOLINE
N
N
\ \
/ /
NH-CHyCH2NH2 A solution of 1-methyl-4-chlorobenzo(g)imidazo(4,5-c)quinoline (Preparation 19 in Example 11) (130 mg, 0.49 mmol) in NH2CH2CH2NH2 (3.2 mL, 49 mmol), was heated at 60°C for 18 hours. The solvent was evaporated in vacuo. The residue was diluted with EtOAc (50 mL) and washed with brine (20 mL). The organic layer was dried over MgS04, filtered, and concentrated. The crude material was submitted to flash chromatography (MeOH) affording the title compound as a pale white solid (6.9 mg, 5%). ~ H NMR(CDC13): 8.52(s, 1 H), 8.33(s, 1 H), 7.96(d, J=8.3, 1 H), 7.94(d, J=8.3, 1 H), 7.77(s, 1 H), 7.46(m, 1 H), 7.42(m, 1 H), 6.22(b, 1 H), 4.36(s, 3H), 3.85(m, 2H), 3.10(m, 2H), 1.60(b, 1 H). (ESI) m/z (M+H)+ _ 292.18. Inhibition of IKK-1 activity was measured using the assay of Example 2, where the inhibitory potential of the compound of Example 17 resulted in an IC5° of 1.0 ~,M.
1-METHYL-4-(2-HYDROXYETHYLAMINO)BENZO[G]IMIDAZO[1,2 A]QUINOXALINE
~N
N i / / ~ OOH
N N
To a solution of 4-chloro-1-methylbenzo[g]imidazo[1,2-a]quinoxaline (0.060 g, 0.225 mmol) (Preparation 4 in Example 11) in 2 mL of THF was added 2-aminoethanol (0.11 mL, 1.80 mmol). The reaction tube was sealed and the mixture stirred at 80°C for 16 hours. The resulting cooled mixture was then taken up in EtOAc, washed with water and brine, dried (Na~S04) and evaporated. The resulting residue was recrystallized using i-PrOH to give Example 18 (0.062 g, 94%); mp 186-188 °C; IR (KBr, cm-') 3370, 3147, 1549, 1485, 1414; ~H NMR (DMSO-d6) 8.64 (s, 1H), 8.10-8.09 (m, 2H), 7.96 (d, J = 7.5, 1 H), 7.51-7.46 (m, 3H), 7.37 (s, 1 H), 4.91 (t, J = 5.2, 1 H), 3.70-3.66 (m, 4H), 3.00 (s, 3H); MS (+ESI, M + H+) m/z 293; HPLC: 98.8% (230 nm). Inhibition of IKK-1 activity was measured using the assay of Example _$$_ 2, where the inhibitory potential of the compound of Example 18 resulted in an ICSO of 0.87 M.
1-METHYL-4-(2-PIPERIDIN-1-YL-ETHYLAMINO)BENZO[G]IMIDAZO[1,2-A]QUINOXALINE
/N
I / /
N N~
H
To a solution of 4-chloro-1-methylbenzo[g]imidazo[1,2-a]quinoxaline (0.055 g, 0.206 mmol) (Preparation 4 in Example 11) in 5 mL.of THF was added 1-(2-aminoethyl)piperidine (0.24 mL, 1.65 mmol). The reaction tube was sealed and the mixture stirred at 80°C for 17 hours. The resulting cooled mixture was then taken up in EtOAc, washed with water and brine, dried (Na2S04) and evaporated. The resulting residue was recrystallized using i-PrOH to give Example 19 (0.063 g, 84%); mp 170-172 °C; IR (KBr, crri ~) 3300, 2932, 1557, 1483, 1408; ~H NMR (DMSO-d6) 8.61 (s, 1H), 8.07-8.06 (m, 2H), 7.94 (d, J = 7.6, 1 H), 7.49-7.34 (m, 4H), 3.66 (br q, J = 6.5, 2H), 2.97 (s, 3H), 2.59 (br t, J = 6.5, 2H), 2.44 (br s, 4H), 1.54-1.39 (m, 6H);
MS (+ESI, M + H+) m/z 360; HPLC: 97.6% (230 nm). Inhibition of IKK-1 activity was measured using the assay of Example 2, where the inhibitory potential of the compound of Example 19 resulted in an IC5o of 1.7 ~,M.
The contents of all patents, patent applications, published PCT
applications and articles, books, references, reference manuals and abstracts cited herein are hereby incorporated by reference in their entirety to more fully describe the state of the art to which the invention pertains.
As various changes can be made in the above-described subject matter without departing from the scope and spirit of the present invention, it _89_ is intended that all subject matter contained in the above description, or defined in the appended claims, be interpreted as descriptive and illustrative of the present invention. Many modifications and variations of the present invention are possible in light of the above teachings.
In addition, in vitro studies have demonstrated that the full length IKK~ can autophosphorylate and phosphorylate its substrate, IKBa, as well;
however, neither the N-terminal kinase domain-containing form, nor the C-terminal HLH domain-containing form of IKK was capable of autophosphorylation (U.S. Patent No. 6,077,701 to Chu et al.). U.S. Patent 6,077,701 discloses that compounds which increase IKK~i activity and/ or binding to I~cB can be potential therapeutic targets for inflammatory disease.
Evidence that IKK is involved in the signal inducible degradation of IKB-a was provided by both anti-sense inhibition of IKK-1 and the use of dominant-negative, catalytically-inactive mutants of IKK-1 and IKK-2 (DiDonato et al. Nature 388:548-554, 1997; Mercurio et al. Science 278:860-866, 1997; Woronicz et al. Science 278:866-869, 1997). Both approaches abrogated cytokine- and lipopolysaccharide (LPS)-induced activation of NF
xB. These in vitro assays implicate a role for IKK in activating NF-xB.
There are other kinases which can phosphorylate I~cB and which have been implicated in the activation of NF-~cB. For example, two kinases (pp90rsk and IKK-s) have been demonstrated to phosphorylate hcB-a at serine-32 and! or serine-36. The overexpression of these kinases, and the use of dominant negative mutants to these kinases, have indicated a role for them in the phosphorylation of IoB in cells (Ghoda et al., J. Biol. Chem.
272:21281-21288, 1997; Peters et al., Mol. Cell. 5:513-522, 2000). The existence of multiple hcB kinases is indicative of redundant signaling pathways. Therefore, it is possible that an inhibitor of IKK-1 and/ or IKK-2 can not necessarily show anti-inflammatory or immunosuppressive effects due to redundant signaling pathways in at least some cells.
Several in vitro types of studies have been performed to further investigate IKK and its properties. The in vitro types of cell biology studies (for example, overexpression of either IKK-1 or IKK-2, or of dominant negative versions of these kinases (DiDonato et al. Nature 388:548-554, 1997; Mercurio et al. Science 278:860-866, 1997; Woronicz et al. Science 278:866-869, 1997; Regnier et al. Cell 90:373-383; Zandi et al: Cell 91:243-252)) that appear to implicate IKK-1 and IKK-2 in NF-~cB activation are sometimes artifactual. A particular example of such an artifactual study involves a kinase known as NF-~cB-inducing kinase, NIK.
Overexpression of NIK in cells activated IKK and NF-KB, while expression of kinase-inactive forms of the enzyme blocked the stimulated activation of IKK and NF-~cB (Malinin et al., Nature 385:540-544, 1997; Song et al., Proc. Nat. Acad. Sci. USA 94:9792-9796, 1997). Based on the foregoing, as well as on yeast two-hybrid studies showing a strong interaction between NIK and IKK (Regnier et al., Cell 90:373-383, 1997), NIK is suggested to be essential for the activation of IKK and, subsequently, N F-~cB.
Additional studies have demonstrated that the NIK-IKK protein-protein interaction is important for NF-oB-dependent responses (W099/43704; Publication Date: Sept. 2, 1999; Goeddel et al., U.S. Patent Nos.: 5,851,812; 5,916,760; and 5,939,302). Goeddel et al. show that transient IKK~i overexpression induces luciferase reporter gene activity in both HeLa and 293 cells and overexpression of kinase-inactive IKK(i, which still associates with NIK, blocks activation. However, it was further determined that cells derived from mice deficient in NIK had no abrogated NF-~cB activation (Karin and Ben-Nariah, Ann. Rev. Immunol., 18:621-663, 2000). Therefore, although some studies suggest the importance of NIK as a potential target for inhibiting NF-~cB activation, the experimental results were not demonstrable in vivo, as reported by Karin and Ben-Nariah (supra).
Thus, it is very important that in vitro-based and strictly cell biology-based experiments using overexpressed proteins always be cautiously interpreted.
Although there are several known synthetic inhibitors of IKK, none of these have played a successful role in vivo in disease inhibition. For example, aspirin (acetylsalicyclic acid) and salicylate have been demonstrated to be inhibitors of IKK-1 and IKK-2, but only at high, non-physiological concentrations which are much higher than those required to block prostaglandin synthesis through the inhibition of cyclooxygenase (Yin et al., Nature 396:77-80, 1998). Therefore, these agents are inappropriate for use in treatments or for testing the role of IKK in disease.
Similar to aspirin, 5-aminosalicyclic acid has been shown to inhibit IKK (Yan and Polk, J. Biol. Chem. 274:36631-36636, 1999), but this compound has several other activities, including the inhibition of prostaglandin and leukotriene synthesis (Peskar et al., Deg. Disc. Sci., 32:51 S-56S, 1987; Horn et al., Scand. J. Gastroenterol. 26:867-879, 1991 ) which thereby precludes its use in testing the role of IKK in disease.
Sulindac is a cyclooxygenase inhibitor that has been demonstrated to also inhibit IKK-2 (Yamamoto et al., J. Biol. Chem. 274:27307-27314, 1999).
However, in studies similar to those using aspirin, the concentrations of sulindac necessary for inhibiting IKK were much greater than those needed to inhibit cyclooxygenase. Therefore, this agent is also inappropriate for testing the role of IKK in disease.
Other inhibitors of IKK, more specifically of IKK-2, are cyclopentenone prostaglandins, such as 15dPGJ2 (Rossi et al., Nature 403:103-108, 2000). However, 15dPGJ2, can also activate peroxisome proliferator-activated receptor-gamma (PPAR-y), a nuclear receptor that interferes with NF-~cB transcriptional activity. Therefore, any anti-inflammatory effect could be explained by PPAR-y activity rather than IKK
inhibition. Thus, this inhibitor is not specific for inhibiting the downstream effects of NF-oB-induced inflammation via IKK.
Arsenite, another IKK inhibitor, is a reactive environmental toxin that has been shown to inhibit both IKK-1 and IKK-2 (Kapahi et al., J. Biol.
Chem., 275:36062-36066, 2000). Due to its toxic effects, the therapeutic benefits or in vivo treatment utility of arsenite would therefore preclude its use in patients.
_$_ U.S. Patent Nos. 4,229,452 and 4,200,750 to Warner et al., Colotta et al. (Eur. J. Med. Chem. 30:133-139, 1995) and Ceccarelli et al. (Eur. J. Med.
Chem. 33:943-955, 1998; W097/17079; May 29, 1997) disclose compounds that are structurally different from compound 6 as described herein.
The Aventis Pharma Deutschland GMBH (WO 01/68648) publication discloses particular substituted beta-carboline compounds. The WO
01/68648 publication does not disclose the IKK inhibitor compounds) of the present invention, which have been shown to function and have proven to be effective in a variety of in vivo animal models of diseases or pathologies associated with inflammation, e.g. animal models of arthritis, inflammatory bowel disease, and pulmonary inflammation, and graft survival.
The Astrazeneca AB (WO 01/58890) publication discloses particular heteroaromatic carboxamide derivatives that are structurally different from the compounds of the present invention. The compounds of the WO
01/58890 publication do not demonstrate in vivo efficacy of the IKK inhibitor compounds of the present invention in animal models of disease associated with inflammation and/or the immune system.
In animal models of disease (i.e. knock-out mice) designed to test inhibition of IKK, the deletion of IKK-1 or IKK-2 has been demonstrated to be embryonic lethal (Li et al. Science 284:321-325, 1999; Hu et al. Science 284:316-320, 1999). Therefore, the use of IKK knockout mice to demonstrate a role of IKK in disease is neither practical nor feasible. In contrast, the present invention demonstrates for the first time that inhibitors of the catalytic activity of IKK-1 and IKK-2 are effective in murine models of disease. Such models are believed to be predictive of similar effects in human patients. Therefore, the treatment methods, in vivo models, and effectiveness of IKK inhibitors as described herein, are extremely beneficial and advantageous for the advancement of discovering and employing therapeutics for inflammation and immune system diseases. These animal models are therefore important tools for studying human diseases, specifically inflammatory and immune-related diseases.
_g_ Lactam-based tetracyclic compounds useful as antagonists of NMDA
(N-methyl-D-aspartate) and AMPA (a-3-hydroxy-5-methylisoxazole-4-propionate) receptors are disclosed in WO 94/07893, Preparation of 5H, 10H-imidazo[1,2-a]indeno[1,2-a]pyrazine-4-one AMPA/KA Receptor Antagonist, filed by Aloup et al ; and in articles by Mignani, Aloup, et al., "Synthesis and Pharmacological Properties of 5H, 10H-imidazo[1,2-a]indeno[1,2-a]pyrazine-4-one, a New Competitive AMPA/KA Receptor Antagonist," Drug. Dev. Res., Vol. 48 (3) (1999), at pp. 121-29, and "An Efficient Preparative Route to Fused Imidazo[1,2-a]-Pyrazin-4-one Derivatives," Heterocycles, Vol. 50, No. 1 (1999), at pp. 259-267.
Compounds such as lactams that are claimed to be useful for blocking excitatory amino acid receptors found in the brain and spinal cord are shown in U.S. Pat. Nos. 5,153,196 and 5,196,421, both assigned to Eli Lilly and Company. Tricyclic compounds having amino-substituents claimed to be useful as brain receptor ligands are disclosed in U.S. Pat. No. 5,182,386, assigned to Neurogen Corp., and in U.S. Patents Nos. 4,160,097;
4,172,947; 4,191,766; 4,191,767; 4,198,508; 4,200,750; 4,225,724; and 4,236,015 in W097/19,079, and in S. Ceccarelli et al, "Imidazo[1,2-a]quinoxalin-4-amines: A Novel Class of Nonxanthine A1-Adenosine Receptor Antagonists," European Journal of Medicinal Chemistry Vol. 33, (1998), at pp. 943-955. To applicants' knowledge, 4-amino substituted tetracyclic compounds according to formula (I) have not been previously described.
As can be appreciated, those in the field of pharmaceutical research continue to seek to develop new compounds and compositions having increased effectiveness, bioavailability, and solubility, having fewer side effects, and/or providing the consumer with a choice of options. Particularly in the area of immune response, many individuals respond differently depending upon the type of treatment and chemical agent used.
Mechanisms of action continue to be studied to aid in understanding the immune response and in developing compounds effective for treating immune-related disorders.
In view of the dearth of safe, effective, and novel therapeutics for treating inflammatory or immune-related diseases, there is a need for new anti-inflammatories and agents that reduce, eliminate, and/ or ameliorate inflammation and immune-related disease. In addition, the discovery of additional proteins involved in the processes of inflammation and immune-related diseases and disorders is important for controlling inflammation and adverse immune responses, processes, and the diseases and disorders related thereto. Thus, the identification and characterization of the proteins involved in IKK-mediated cellular processes would benefit the art and be advantageous for providing therapies for those suffering from such disorders and diseases.
SUMMARY OF THE INVENTION
The present invention relates to methods of preventing and treating inflammatory and immune-related diseases or disorders using IKB kinase (IKK) inhibitors, compounds of formula (I) as described herein. Also provided is the IKK inhibitor4(2'-aminoethyl)amino- 1,8-dimethylimidazo(1,2-a) quinoxaline used to prevent and treat inflammatory and immune-related diseases or disorders.
It is an object of the present invention to provide methods of preventing and treating inflammatory and immune-related diseases or disorders using IKK inhibitors either alone, or optionally, in combination with at least one biologically active agent.
It is also an object of the present invention to provide IKK inhibitors for the prevention and treatment of inflammatory and immune-related diseases or disorders.
It is another object of the present invention to provide pharmaceutical compositions comprising IKK inhibitors in a pharmaceutically-acceptable carrier, excipient, or diluent for use in preventing and treating inflammatory and immune-related diseases or disorders.
It is a further object of the present invention to provide methods of preventing and treating diseases and disorders involving inflammation and the immune system. Preferably, the methods comprise the use of IKK
inhibitors for the prevention and treatment of inflammatory and immune-related diseases, non-limiting examples of which include, rheumatoid arthritis, transplant rejection, inflammatory bowel disease, osteoarthritis, asthma, chronic obstructive pulmonary disease, atherosclerosis, psoriasis, multiple sclerosis, stroke, systemic lupus erythematosus, Alzheimer's disease, brain ischemia, traumatic brain injury, Parkinson's disease, amyotrophic lateral sclerosis, subarachnoid hemorrhage or other diseases or disorders associated with excessive production of inflammatory mediators in the brain and central nervous system. , Yet another object of the present invention is to provide methods of inhibiting i) the catalytic activity of IKK; ii) the phosphorylation of IKB;
and/or iii) NF-oB gene expression using IKK inhibitors for the prevention and treatment of inflammatory and immune-related diseases or disorders. .
A more particular object of the present invention is to provide an IKK
inhibitor, 4(2'-aminoethyl)amino- 1,8-dimethylimidazo(1,2-a) quinoxaline, also known as compound 6 herein, or a pharmaceutically-acceptable salt thereof, useful as a preventative and/or therapeutic agent and in methods of treating inflammatory and immune diseases. In accordance with the present invention, compound 6 is shown by the below formula, Me~
Me N ~ N
i NHZ
N N~
H
Yet another embodiment of the present invention relates to 4-amino substituted benzoquinoline, benzoquinoxaline, and benzoquinazoline compounds having five-membered heterocycles (e.g., pyrazolyl, imidazolyl, and thiazolyl rings) fused thereto. The compounds are useful as anti-inflammatory agents and/or for treating conditions associated with TNF-a and NF-~cB activity.
It is a further object of the present invention to provide 4-amino substituted benzoquinoline, benzoquinoxaline, and benzoquinazoline compounds having five-membered heterocycles (e.g., pyrazolyl, imidazolyl, and thiazolyl rings) fused thereto, more specifically, the compounds of formula (I), as described herein. The compounds are useful as anti-inflammatory agents and/or for preventing and treating conditions associated with TNF-a and NF-rcB.
One embodiment of the present invention is further directed to a compound of the formula (I), useful in treating inflammatory diseases or disorders:
X__ ~ A ' / / Y~:YZ N
N NHRZ
C 4~n (R3~m 2~
(I), or a pharmaceutically-acceptable salt thereof, wherein X is NR~, CRS, or S;
Y~ and Y2 are nitrogen or carbon, provided that a) when X is CRS, at least one of Y~ and Y2 is nitrogen; and b) when one of Y~ and Y2 is carbon, the other of Y~ and Y2 is nitrogen and/or X is NR~ or S, so that ring A defines a five-membered heteroaryl ring having at least two heteroatoms;
R~ is hydrogen, halogen, alkyl, substituted alkyl, cyano, OR5, NR5R6, C(=O)R5, C02R5, or aryl;
R2 is alkyl, substituted alkyl, alkenyl, alkynyl, alkoxy, alkylthio, aryl, heteroaryl, heterocyclo, cycloalkyl, or substituted cycloalkyl;
R3 and R4 are independently selected from halogen, alkyl, substituted alkyl, nitro, cyano, ORS, NR7R8, C(=O)R~, CO~R~, C(=O)NR~R8, NR~C(=O)R8, NR7C(=O)OR8, S(O)qR~, NR~SO~R8, and S02NR~R8;
R5, R6, R7, and R$ are independently selected from hydrogen, alkyl, substituted alkyl, and phenyl, or when attached to the same nitrogen atom (as in NR5R6 or NR~R$) can join together to form a heterocycle or heteroaryl;
and m, n and q are independently 0, 1, or 2.
Advantageously, R2, as specified above, is an alkyl optionally substituted with OR' or NR'R", as defined in the specification.
The invention also relates to pharmaceutical compositions containing at least one compound of formula (I) and a pharmaceutically-acceptable carrier or diluent. Also included within the invention are methods of~
preventing and treating inflammatory and immune-related diseases and disorders comprising administering to a mammal in need of such prevention and/or treatment an efiFective amount of at least one compound of formula Another object of the present invention is to provide kits for treating inflammatory and immune-related diseases and disorders, comprising one or more IKK inhibitors, compound 6, and/or compounds of formula (!) as described herein.
BRIEF DESCRIPTION OF THE FIGURES
FIGURE 1 shows the effect of 4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a) quinoxaline (compound 6) on disease incidence in the murine model of collagen-induced arthritis. The compound was administered once daily in a preventative dosing mode. *p<0.05, Fisher's Exact test.
FIGURE 2 shows the effect of 4(2'-aminoethyl)amino- 1,8-dimethylimidazo(1,2-a) quinoxaline (compound 6) on the average gross clinical score for all mice within each treatment in the murine model of collagen-induced arthritis based on clinical scores corresponding to the study day. The test compound was administered once daily in the preventative dosing mode. *p<0.05, Mann-Whitney U-test.
FIGURE 3 shows the effect of 4(2'-aminoethyl)amino- 1,8-dimethylimidazo(1,2-a) quinoxaline (compound 6) on disease incidence in the murine model of collagen-induced arthritis based on the clinical score corresponding to the days after disease onset. The test compound was administered once daily in the established disease dosing mode. *p<0.05, Mann-Whitney U-test.
DESCRIPTION OF THE INVENTION
The present invention describes methods of preventing and treating inflammatory and immune-related diseases or disorders using inhibitors of hcB kinase (IKK). Such methods are efficacious in vivo in inhibiting IKK
activity in mammalian, including human and biological systems, e.g. animal models of disease.
In one of its aspects, the present invention relates to methods of inhibiting the catalytic activity of IKK using inhibitors. The inhibitors of the present invention preferably inhibit the catalytic activity of the IKKs (see, Example 2). For example, inhibitors can include small molecule enzyme inhibitors which bind directly to the enzyme, preferably IKK, and more preferably IKK-2. Without wishing to be bound by theory, it is believed that the binding of the inhibitor to the active site of IKK also inhibits binding of substrate, such as, for example, hcB or ATP.
One embodiment of the present invention provides a novel IKK
inhibitor, 4(2'-aminoethyl) amino-1,8-dimethylimidazo(1,2-a) quinoxaline (compound 6), wherein the compounds of the present invention can be used in methods for the prevention and treatment of inflammatory and immune-related diseases or disorders.
Another embodiment of the present invention provides 4-amino substituted benzoquinoline, benzoquinoxaline, and benzoquinazoline compounds having five-membered heterocycles (e.g., pyrazolyl, imidazolyl, and thiazolyl rings) fused thereto. The compounds are useful as anti-inflammatory agents and/or for treating conditions associated with TNF-a and NF-~cB.
Also provided are pharmaceutical compositions comprising IKK
inhibitor compounds or salts thereof, and kits comprising IKK inhibitor compounds or salts thereof.
Definitions The following definitions are provided to more fully describe the present invention in its various aspects. The definitions are intended to be useful for guidance and elucidation, and are not intended to limit the disclosed invention and its embodiments.
The term "IoB" as used herein, is defined as Inhibitor KB. The IKB
family comprises IoBa, IoB~i, and IoB~, all of which contain ankyrin repeats for complexing to NF-~sB.
The term "IKK" as used herein, refers to hcB-kinase (IKK). IKK
comprises two catalytic subunits, IKK-1 and IKK-2, also known as IKKa and IKK~i, respectively.
"Activation of IKK" as used herein means changing an inactive IKK
protein into an active IKK protein that functions as an IKB kinase. Activated IKK phosphorylates serine-32 and serine-36 of I~cB, which thus marks the IKB for ubiquitination and degradation.
"IKK inhibitors" according to the invention refer to those compounds or molecules which prevent, block, abolish, antagonize, suppress, or reduce the activation of IKK as defined above. In addition, IKK inhibitors inhibit the activity of IKK, preferably the in vivo activity of IKK, such that one or more of the following occurs: 1) inhibition of IKK catalytic activity; 2) inhibition of IKB
phosphorylation, preferably catalyzed phosphorylation of I~cB; and/or 3) inhibition of NF-~cB-dependent gene expression activation.
A "selective inhibitor", as referred to herein, inhibits one protein at a higher level or degree than another protein. An inhibitor is considered to be selective for one protein over another protein when there is preferably at least about a 5-fold or greater difference in inhibition of one protein compared with another protein. More preferably, there is at least about an 8-fold or greater difference in inhibition of one protein compared with another protein.
"Nuclear factor-oB" or "NF-KB" as used herein, is defined as a ubiquitously expressed family of eukaryotic transcription factors. This family comprises a homo- or hetero-dimer of DNA-binding proteins related to c-Rel, a proto-oncogene that controls the expression of many ~cB-dependent immune, inflammatory, and anti-apoptotic response genes.
The phrase "NF-~cB-dependent gene expression" as used herein, is defined as those immune-related and inflammatory genes that are under the regulatory control of the KB-enhancer. In most cells, NF-~cB exists in a dormant state in the cytoplasm bound to inhibitory proteins, collectively called hcB, that conceal the nuclear localization signal, thereby preventing nuclear translocation. Activation of NF-oB can be induced by cytokines, such as TNFa, and IL-1, where both TNF-a and IL-1 signaling results in sequential phosphorylation and activation of a cascade of proteins.
Specifically, activation of IKK or modification of the catalytic action of IKK
results in phosphorylation, ubiquitination, and degradation of IKB.
The term "treat", "treating", or "treatment" refers to the prevention, reduction, or amelioration, partial or complete alleviation, or cure of a disease, disorder, or condition. NF-~cB plays an important role in inflammation and immune response; therefore, the inhibition of hcB
phosphorylation can also be an important target for novel anti-inflammatory and immune-related agents.
The phrase "NF-~cB-associated condition" refers to diseases that are characterized by release of NF-ICB from the cytoplasm (e.g., upon phosphorylation of I~cB).
The phrase "TNF-a-associated condition" is a condition characfierized by enhanced levels of TNF-a. In the instant specification, the term NF-KB-associated condition includes a TNF-a-associated condition but is not limited thereto as 'NF-~cB is involved in the activity and upregulation of other pro-inflammatory proteins and genes.
The term "inflammatory or immune diseases or disorders" is used herein to encompass both IKK-associated conditions, NF-~cB-associated conditions, TNF-a-associated conditions, e.g., any condition, disease, or disorder that is associated with release of NF-KB and/or enhanced levels of TNF-a, including each of the conditions specifically referenced below.
"Bioavailability" as referred to herein is the rate and extent to which an active ingredient or moiety is absorbed from a pharmaceutical composition and becomes available at the site of action. For drug products that are not intended to be absorbed into the bloodstream, bioavailability may be assessed by measurements intended to reflect the rate and extent to which the active ingredient or active moiety becomes available at the site of action.
The term "prodrug" denotes a therapeutic agent that is prepared in an inactive form, which upon administration to a subject, undergoes chemical conversion by metabolic or chemical processes by the action of endogenous enzymes or other chemicals and/or conditions, to yield the active compounds of the present invention, and/or salt and/or solvate thereof. For example, compounds containing a carboxy group can form physiologically hydrolyzable esters which serve as prodrugs by being hydrolyzed in the body to yield formula I-II compounds per se.
The term "alkyl" refers to straight or branched chain hydrocarbon groups having 1 to 12 carbon atoms, preferably 1 to 8 carbon atoms. Lower alkyl groups, that is, alkyl groups of 1 to 4 carbon atoms, are most preferred.
When numbers appear in subscript after the symbol "C", the subscript defines with more specificity the number of carbon atoms that a particular group can contain. For example, "C~_6alkyl" refers to straight and branched chain alkyl groups with one to six carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, and so forth.
The term "substituted alkyl" refers to an alkyl group as defined above having one, two, or three substituents selected from the group consisting of halo, amino, cyano, hydroxy, alkoxy, alkylthio, -C(=O)H, -C02H, -(C=O)alkyl, -CO~alkyl, cycloalkyl, substituted cycloalkyl, aryl, heteroaryl, or heterocycle.
Thus, the term "substituted alkyl" includes a polyfluoroalkyl, i.e., where two or more hydrogen atoms of an alkyl chain are replaced by a fluorine atom, such as with trifluoromethyl. The term "substituted alkyl" also includes an alkyl group as defined above having the substituent NR'R", wherein each of R' and R" are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, hydroxy, alkoxy, -C(=O)H, -COSH -(C=0)alkyl, -C02-alkyl, cycloalkyl, substituted cycloalkyl, aryl, heteroaryl, and heterocycle.
Alternatively, R' and R" can together form a heterocyclo or heteroaryl ring.
A substituted lower alkyl or substituted C~_4alkyl refers to an alkyl group of 4 carbon atoms having one to three substituents selected from those recited above for alkyl groups generally.
The term "alkoxy" refers to an alkyl group as defined above bonded through an oxygen atom (-O-), and the term "alkylthio" refers to an alkyl group as defined above bonded through a sulfur atom (-S-). For example, such groups include methoxy, methylthio, ethoxy, ethylthio, n-propoxy, n-propylthio, isopropoxy, isopropylthio, n-butoxy, n-butylthio, tert-butoxy, tert-butylthio, n-pentoxy, n-pentylthio, and so forth.
The term "alkenyl" refers to straight or branched chain hydrocarbon groups having 2 to 12 carbon atoms and at least one double bond. Alkenyl groups having 2 to 6 carbon atoms and one double bond are most preferred.
Exemplary alkenyl groups include ethenyl, 1-methyl-ethenyl, 1- or 2-propenyl, 1-methyl-1-propenyl, 1-methyl-2-propenyl, 1,1-dimethyl-2-propenyl, 2-methyl-2-propenyl, 1- , 2- or 3-butenyl, 1-methyl-1-butenyl, 2-methyl-1-butenyl, 3-methyl-1-butenyl, 3,3-dimethyl-1-butenyl, 2,3-dimethyl-1-butenyl, 1-methyl-2-butenyl, 1,1-dimethyl-2-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 1,3-butadienyl, 1,3-dimethyl-1,3-butadienyl, 1-, 2-, 3- or 4-pentenyl, and so forth.
IS The term "alkynyl" refers to straight or branched chain hydrocarbon groups having 2 to 12 carbon atoms and at least one triple bond. Alkynyl groups of 2 to 6 carbon atoms and having one triple bond are most preferred. Exemplary alkynyl groups include ethynyl, 1- or 2-propynyl, 1-methyl-2-propynyl, 1,1-dimethyl-2-propynyl, 1-, 2- or 3-butynyl, 3-methyl-1-butynyl, 3,3-dimethyl-1-butynyl, 1-methyl-2-butynyl, 1,1-dimethyl-2-butynyl, 1-, 2- 3, or 4-pentynyl, and so forth.
The term "amino" when used alone refers to NH2. When used to define a substituent, as in 4-amino substituted tetracycles, the term "amino"
refers to the group NR'R", wherein R' and R" are as defined above for alkyl.
The term "carbonyl" refers to -C(=O)-, and "carboxy" refers to -C02-.
Thus, carbonylC~_4alkyl refers to the group -C(=O) linked to a C~_4 alkyl.
The term "halo" or "halogen" refers to chloro, bromo, fluoro and iodo.
The term "cycloalkyl" refers to fully saturated and partially unsaturated hydrocarbon rings of 3 to 9, preferably 3 to 7, carbon atoms as well as such rings having a fused aryl ring such as indan or a bridge of three to four carbon atoms as in bicycloheptane.
The term "substituted cycloalkyP' refers to such rings having one, two, or three substituents, preferably one, selected from the group consisting of alkyl, substituted alkyl, alkoxy, alkylthio, halo, hydroxy, cyano, amino, -NH(alkyl), -NH(cycloalkyl), -N(alkyl)2, -C02H, -C021ower alkyl, aryl, heterocyclo, heteroaryl, keto (=O), =N-OH, =N-O-lower alkyl, and a five or six membered ketal, i.e., 1,3-dioxolane or 1,3-dioxane.
The term "aryl" refers to phenyl, 1-naphthyl and 2-naphthyl, with phenyl being preferred. When the term "aryl" is used, it encompasses such rings having from zero, one, two or three substituents selected from the group consisting of alkyl, substituted alkyl, alkoxy, alkylthio, halo, hydroxy, nitro, cyano, amino, -NH(alkyl), -NH(cycloalkyl), -N(alkyl)2, -CO2H, -(C=O)alkyl, -C02-alkyl, cycloalkyl, substituted cycloalkyl, -(C=0)NH2, -(C=O)NH(alkyl), -(C=O)NH(cycloalkyl), -(C=O)N(alkyl)2, -NH-CH2-C02H, -NH-CHI-C02-alkyl, phenyl, benzyl, phenylethyl, phenyloxy, phenylthio, heterocyclo, and heteroaryl.
The term "heterocyclo" or "heterocycle" refers to substituted and unsubstituted non-aromatic 3 to 7 membered monocyclic groups, 7 to 11 membered bicyclic groups, and 10 to 15 membered tricyclic groups which have at least one heteroatom (O, S, or N) in at least one of the rings. When the heterocyclo is monocyclic, five- or six-membered rings are preferred;
when bicyclic, fused 5,6- or 6,6-membered ring systems are preferred; and when tricyclic, ring systems having one five and two six membered rings, or three six membered rings, are preferred. Each ring of the heterocyclo group containing a heteroatom can contain one or two oxygen or sulfur atoms and/or from one to four nitrogen atoms provided that the total number of heteroatoms in each ring is four or less, and further provided that the ring contains at least one carbon atom. The fused rings completing the bicyclic and tricyclic groups can contain only carbon atoms and can be saturated, partially saturated, or unsaturated. The nitrogen and sulfur atoms can optionally be oxidized and the nitrogen atoms can optionally be quaternized.
The heterocyclo group can be attached at any available nitrogen or carbon atom.
Whenever the term "heterocyclo" or "heterocyc(e" is used, any ring of the heterocyclo group can optionally contain one, two, or three substituents selected from the group consisting of halo, amino, cyano, alkyl, substituted alkyl, -NH(alkyl), -NH(cycloalkyl), -N(alkyl)2, alkoxy, alkylthio, hydroxy, nitro, phenyl, benzyl, phenylethyl, phenyloxy, phenylthio, -C02H, -C02-alkyl, cycloalkyl, substituted cycloalkyl, -(C=O)NH2, -(C=O)NH(alkyl), -(C=O)NH(cycloalkyl), -(C=O)N(alkyl)2, -NH-CH2-C02H, -NH-CH2-C02-alkyl, heterocyclo, heteroaryl, keto, =N-OH, =N-O-lower alkyl, and a five or six membered ketal, i.e., 1,3-dioxolane or 1,3-dioxane.
Exemplary monocyclic groups include tetrahydrothienyl, tetrahydrofuryl, azetidinyl, pyrrolidinyl, oxetanyl, imidazolinyl, oxazolidinyl, isoxazolinyl, thiazolidinyl, isothiazolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl, 4-piperidonyl, tetrahydropyranyl, morpholinyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, 1,3-dioxolane and tetrahydro-1,1-dioxothienyl and the like. Exemplary bicyclic heterocyclo groups include quinuclidinyl.
The term "heteroaryl" refers to substituted and unsubstituted aromatic 5 or 6 membered monocyclic groups, 9 or 10 membered bicyclic groups, and 11 to 14 membered tricyclic groups which have at least one heteroatom (O, S or N) in at least one of the rings. When the heteroaryl is monocyclic, five- or six membered rings are preferred; when bicyclic, fused 5,6- or 6,6-membered ring systems are preferred; and when tricyclic, ring systems having one five and two six membered rings, or three six-membered rings, are preferred. Each ring of the heteroaryl group containing a heteroatom can contain one or two oxygen or sulfur atoms and/or from one to four nitrogen atoms provided that the total number of heteroatoms in each ring is four or less and each ring has at least one carbon atom. The fused rings completing the bicyc(ic and tricyclic groups can contain only carbon atoms and can be saturated, partially saturated, or unsaturated. The nitrogen and sulfur atoms can optionally be oxidized and the nitrogen atoms can optionally be quaternized. Heteroaryl groups which are bicyclic or tricyclic include at least one fully aromatic ring but the other fused ring or rings can be aromatic or non-aromatic. The heteroaryl group can be attached at any available nitrogen or carbon atom of any ring.
Whenever the term "heteroaryl' is used herein, any ring of the heteroaryl group can optionally contain one, two or three substituents selected from the group consisting of halo, amino, cyano, alkyl, substituted alkyl, -NH(alkyl), -NH(cycloalkyl), -N(alkyl)2, alkoxy, alkylthio, hydroxy, nitro, phenyl, benzyl, phenylethyl, phenyloxy, phenylthio, -C02H, -C02-alkyl, cycloalkyl, substituted cycloalkyl, -(C=O)NH~, -(C=O)NH(alkyl), -(C=O)NH(cycloalkyl), -(C=O)N(alkyl)2, -NH-CH2-C02H, -NH-CH2-C02-alkyl, heterocyclo, and heteroaryl.
Exemplary monocyclic heteroaryl groups include pyrrolyl, pyrazolyl, pyrazolinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, furanyl, thienyl, oxadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, triazolyl, and the like.
Exemplary bicyclic heteroaryl groups include indolyl, isoindolyl, benzothiazolyl, benzodioxolyl, benzoxaxolyl, benzothienyl, quinolinyl, tetrahydroisoquinolinyl, isoquinolinyl, benzimidazolyl, benzopyranyl, indolizinyl, benzofuranyl, isobenzofuranyl, chromonyl, coumarinyl, benzopyranyl, cinnolinyl, quinoxalinyl, quinazolinyl, indazolyl, pyrrolopyridyl, furopyridinyl, dihydroisoindolyl, tetrahydroquinolinyl, napthyridinyl, pteridinyl, and the like.
Exemplary tricyclic heteroaryl groups include carbazolyl, benzidolyl, phenanthrollinyl, acridinyl, phenanthridinyl, xanthenyl and the like.
DETAILED DESCRIPTION OF THE INVENTION
Since activation of NF-~cB-dependent gene expression is associated with the activation of IKK-dependent phosphorylation of IKB and genes involved in inflammatory and immune-related diseases or disorders, one emobidment of the present invention generally relates to the prevention and treatment of inflammatory and immune-related diseases, disorders, or conditions using IKK inhibitors. More specifically, embodiments of the present invention relate to: 1 ) methods of inhibiting IKK to prevent and/or treat inflammatory and immune-related diseases, disorders, or conditions; 2) methods of inhibiting the activation of NF-~cB-dependent gene expression by inhibiting the IKK-dependent phosphorylation of IKB for preventing and treating inflammatory and/or immune-related diseases, disorders, or conditions; 3) inhibitors of IKK; 4) the use of inhibitors of IKK in the methods of the present invention; and 5) exemplary IKK inhibitor compounds which inhibit IKK.
As described herein, an embodiment of the present invention demonstrates the in vivo employment of an IKK inhibitor for use in methods for treating and preventing inflammatory and immune-related diseases or disorders (Examples 4-7). Prior to the present invention, there have been no demonstrations of the actual in vivo therapeutic effectiveness of IKK
inhibitors in treating and preventing inflammatory or immune-related diseases, such as, for example, asthma, inflammatory bowel disease, tissue/organ transplant rejection, e.g., graft versus host rejection, and pulmonary diseases, for example, involving inflammatory cell infiltration in the lung.
Accordingly, an aspect of the present invention provides therapeutic and prophylactic methods of treating and preventing inflammatory or immune-related diseases, disorders, or conditions by administering an effective amount of one or more IKK inhibitors, or salt thereof, alone, or optionally, in combination with another IKK inhibitor, to a subject, preferably a mammal, in need thereof. In addition, other therapeutic or biologically active agents can be used in combination with the IKK inhibitors, for example, drugs, hormones, or synthetic agents, such as those described below, for example. In the methods of the present invention, such therapeutic or biologically active agents can be administered prior to, simultaneously with, or following the administration of one or more of the IKK inhibitors of the present invention.
More specifically, IKK inhibitors can also be used in accordance with the described methods in conjunction with other drugs, such as cyclosporine A or CTLA4-Ig, to alleviate transplant rejection. Cyclosporine A is a potent immunosuppressive compound currently used therapeutically in humans to prevent graft rejection following solid organ transplantation. Most current therapeutic protocols for transplant include cyclosporine A in combination with other potent immunosuppressive drugs such as steroids and antiproliferative agents such as mycophenolic acid. When test compounds are examined for clinical efficacy in solid organ transplant, the protocols generally include treatment of the patients with test compounds in addition to standard therapeutics including cyclosporine A. Therefore, in order to progress with clinical development of new compounds, new compounds must work beneficially well with cyclosporine A.
CTLA4-Ig is an immunoglobulin fusion protein that binds to the ligands for CD28 and CTLA4 (Linsley et al. J. Exp. Med., 174:561-569, 1991 ). CTLA4-Ig is a promising agent that is effective in the treatment of transplant rejection (Larsen et al., Nature, 381:434-438, 1996). Since some form of CTLA4-Ig could become part of the standard treatment paradigm for transplantation, new compounds developed for the prevention of graft rejection would be important, particularly in conjunction with CTLA4-Ig.
Embodiments of the present invention further embrace methods of inhibiting the IKK enzyme, comprising administering to an individual suffering from an inflammatory or immune-related disease or disorder, an IKK inhibitor in an amount effective to inhibit the catalytic activity of IKK
and the IKK-dependent phosphorylation of I~cB. Without wishing to be bound by theory, the mechanism of inhibition of IKK involves inhibiting the catalytic activity of the IKKs, eifiher IKK-1 or IKK-2, preferably IKK-2, through binding to the active site of the enzyme and inhibiting the binding and/or phosphorylation of substrates such as hcB and ATP (see Example 2).
One embodiment of fihe present invention encompasses a method of inhibiting the phosphorylation of I~cB inhibitor protein which comprises the administration of IKK inhibitors in an amount effective to inhibit the phosphorylation of the hcB protein. In particular, inhibition of IKB-a phosphorylation is preferred, and the inhibition of phosphorylation of IxB-a at serine-32 and serine-36 is more preferred.
According to the present invention, compounds which inhibit IKK, i.e.
IKK inhibitors, can be used in the methods for preventing and treating inflammatory and immune system-related conditions, diseases, or disorders.
Non-limiting examples of such diseases, disorders, and conditions include arthritis, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, acute pancreatitis, chronic pancreatitis, psoriasis, glomerulonephritis, serum sickness, lupus (systematic lupus erythematosis), urticaria, scleraclerma, contact dermatitis, dermatomyositis, alopecia, atopic eczemas, ichthyosisrhinitis, inflammatory bowel disease (Crohn's and ulcerative colitis); Alzheimer's disease, brain ischemia, traumatic brain injury, Parkinson's Disease, Creutzfeldt-Jacob diseases, HIV encephalitis, cerebral malaria, and meningitis, atherosclerosis, ataxia telangiectasis, septic shock, multiple sclerosis, amyotrophic lateral sclerosis, atherosclerosis, subarachnoid hemorrhage, autoimmune diseases, systemic lupus erythematosus, multiple sclerosis, hematopoiesis, pulmonary diseases, respiratory allergies, asthma, acute respiratory distress syndrome, hayfever, allergic rhinitis, allergic respiratory disease, herpes simplex type 1 (HSV-1), herpes simplex type 2 (HSV-2), cytomegalovirus, Epstein-Barr, human immunodeficiency virus (HIV), Addison's disease (autoimmune disease of the adrenal glands), idiopathic adrenal insufficiency, autoimmune polyglandular disease (also known as autoimmune polyglandular syndrome), fungal infections, mycosis fungoides, chronic obstructive pulmonary disorder; tissue/ organ transplant rejection (e.g., kidney, liver, heart, lung, pancreas, bone marrow, cornea, small bowel, skin allografts, skin homografts, and heterografts, etc.); stroke, oncological diseases, cancer, tumors, breast cancer, prostate cancer, and Hodgkin's lymphoma.
IKK inhibitors of the present invention can be used to prevent, treat or ameliorate diseases and conditions, particularly inflammatory or immune-related diseases or conditions. Without wishing to be bound by theory, the IKK inhibitors are employed in preventing and treating diseases, disorders, or conditions characterized by NF-ICB activation via phosphorylation of IKB
by IKK. Specifically, the embodiments of the present invention further relate to IKK inhibitors that inhibit the catalytic activity of the IKK enzyme, thereby blocking phosphorylation of I~cB and downstream transcriptional activation of KB gene expression, such as NF-~cB.
In one embodiment of the present invention, an IKK inhibitor has an IC5o against IKK activity ranging from about 0.01 ~,M to about 50 p,M.
Preferably, the IKK inhibitor has an IC5o against IKK activity ranging from about 0.01 ~,M to about 10 ~,M, more preferably from about 0.01 ~,M to about 5 ~,M, and most preferably from about 0.01 ~.M to about 1 ~,M.
Yet another embodiment of the present invention encompasses IKK
inhibitors that have selectivity for IKK-2 over IKK-1 (see Example 2).
Preferably, a selective IKK inhibitor has at least about a 5-fold or greater selectivity for IKK-2 over IKK-1. More preferably, a selective IKK inhibitor has at least about an 8-fold or greater selectivity for IKK-2 over IKK-1. As a more particular guide, for example, inhibition of IKK-2 activity is about 5-to 500-fold, or about 8- to 100-fold, relative to IKK-1 activity, preferably about 10- to 100-fold, and more preferably, about 10 to 50-fold.
In a preferred aspect, according to the invention, selective inhibitors affect about 50% inhibition of IKK activity at an IC50 against IKK activity ranging from about 0.01 ~.M to about 50 ~.M. Preferably, selective inhibitors have an IC50 against IKK activity ranging from about 0.01 ~,M to about 10 p,M, and preferably, from about 0.01 p.M to about 5 pM. Most preferably, selective inhibitors have an IC50 ranging from about 0.01 ~,M to about 1 pM.
A preferred embodiment of the present invention comprises IKK
inhibitors selective for IKK-2. Preferably, the selective IKK-2 inhibitor has an IC50 against IKK-2 activity, ranging from about 0.01 ~,M to about 5 ~,M, and more preferably, an IC50 against IKK-2 activity, ranging from about 0.01 p,M
to about 1 p.M.
In another aspect, bioavailability of the inhibitor compounds was assessed. For example, the pharmacokinetics of compound 6 in mice is described in Example 3. For guidance, an effective oral bioavailability for the IKK inhibitor of the present invention ranges from about 10% to about 100%, preferably from about 50% to about 100%, and more preferably from about 80% to about 100%. From a pharmacokinetic perspective, bioavailability data for a given compound estimate the relative fraction of the orally administered dose that is absorbed into the systemic circulation when compared to the bioavailability data for a solution, suspension, or intravenous dosage form.
The present invention further relates to methods of testing the inhibitory potential of candidate IKK inhibitors. Specifically, Example 2 analyzes test compounds and their capacity to inhibit IKK activity by measuring the concentration of phosphorylated substrate, specifically IKB, and the concentration of test IKK inhibitor compound necessary to achieve 50% inhibition of IKK activity.
One embodiment of the present invention provides beneficial and advantageous in vivo animal studies using IKK inhibitors that demonstrate compound efficacy using methods of the present invention. For example, 4 (2'-aminoethyl)amino- 1,8-dimethylimidazo(1,2-a) quinoxaline, compound 6 herein, or a salt thereof, newly discovered by the present inventors, inhibits the catalytic activity of I~cB kinase by blocking the active site of IKK which is responsible for phosphorylating the IKB protein. Moreover, the examples described herein demonstrate that IKK inhibitors are particularly useful in methods of treating inflammatory and immune-related diseases or disorders in several different animal models of disease that are considered to be predictive of similar employment and effects in human patients.
The compounds and compositions of this invention are also useful in treating conditions that are characterized by release of NF-~cB and/or enhanced levels of TNF-a. Inhibition or suppression of NF-oB and/or TNF-a may occur locally, for example, within certain tissues of the subject, or more extensively throughout the subject being treated for such a disease.
Inhibition or suppression of NF-~cB and/or TNF-a may occur by one or more mechanisms, e.g., by inhibiting or suppressing any step of the pathway(s), preferably inhibition of IKK. The present invention thus provides methods for treating such conditions, comprising administering to a subject in need thereof an effective amount of at least one compound, of formula (I), compound 6, or salt thereof. Other therapeutic agents such as those described below may be employed in combination with the IKK inhibitors, compound 6, and/or compounds of formula (I). In the methods of the present invention, such other therapeutic agents) may be administered prior to, simultaneously with, or following the administration of the inventive compound.
Compound 6 is structurally represented by the following formula as shown below:
Me~
Me N s N
i NHz N N~
H
The formula of compound 6 or 4(2'-aminoethyl)amino- 1,8-dimethylimidazo(1,2-a) quinoxaline forms salts which are also within the scope of the present invention. Unless otherwise indicated, reference to an IKK compound according to this invention is understood to include reference to salts thereof, as further described below.
In another embodiment of the present invention compounds of formula (1) are useful in treating inflammatory diseases or disorders:
/ / Y~~Y;'N
( ~n (Rg~m (1), or a pharmaceutically-acceptable salt thereof, wherein X is NR~, CRS, or S;
Y~ and Y2 are nitrogen or carbon, provided that a) when X is CRS, at least one of Y~ and Y2 is nitrogen; and b) when one of Y~ and Y2 is carbon, the other of Y~ and Y2 is nitrogen and/or X is NR~ or S, so that ring A defines a five-membered heteroaryl ring having at least two heteroatoms;
R~ is hydrogen, halogen, alkyl, substituted alkyl, cyano, OR5, NR5R6, C(=O)R5, C02R5, or aryl;
R2 is alkyl, substituted alkyl, alkenyl, alkynyl, alkoxy, alkylthio, aryl, heteroaryl, heterocyclo, cycloalkyl, or substituted cycloalkyl;
R3 and R4 are independently selected from halogen, alkyl, substituted alkyl, nitro, cyano, ORS, NR~R8, C(=O)R~, C02R~, C(=O)NR7R8, NR~C(=O)R8, NR~C(=O)OR8, S(O)qR~, NR~SOZR8, and S02NR~R8;
R5, R6, R~, and R$ are independently selected from hydrogen, alkyl, substituted alkyl, and phenyl, or when attached to the same nitrogen atom (as in NR5R6 or NR7R$) can join together to form a heterocycle or heteroaryl;
and m, n and q are independently 0, 1, or 2.
Yet another embodiment of the present invention encompasses the compounds having the formula (If):
X__ ~A,N
Y ~ ' YZ
\ \ i\
N NHRZ (1.~, and pharmaceutically-acceptable salts thereof, wherein X is NR~, CRS, or S;
Y~ and Y2 are nitrogen or carbon. provided that a) when X is CRS, one of Y~ and Y2 is nitrogen, and b) when one of Y~ and Y2 is carbon, either the other of Y~ and Y2 is nitrogen or X is NR~ or S, so that ring A defines a five-membered heteroaryl ring having two heteroatoms;
R~ is hydrogen, halogen, lower alkyl, or substituted lower alkyl;
R2 is alkyl or substituted alkyl.
More preferred are the compounds of formula (If), above, and/or pharmaceutically acceptable salts thereof, wherein X is NR~ or CRS;
R~ is hydrogen, halogen, lower alkyl, or trifluoromethyl;
R2 is C~_~ alkyl optionally substituted with OR9 or NR~oR~~;
R9 is hydrogen or lower alkyl; and Rio and R~~ are (i) independently selected from hydrogen, C~_2alkyl, C~_ 2substituted alkyl, and -(C=O)C~_~alkyl, or alternatively (ii) together form a five to six membered heterocycle or heteroaryl.
Most preferred are the compounds of formula (If), above, and/or pharmaceutically acceptable salts thereof, wherein ring A is selected from:
R~ R~ R~
\N
and \ ,N
N
R~ is hydrogen, halogen, ethyl, methyl, or trifluoromethyl; and R2 is a C~_2 alkyl optionally substituted with one of:
OH, NH2, NH(C~_2alkyl), N(C~_2alkyl)2, NH(C~_~substituted alkyl), N(C~_ 2substituted alkyl)2, NH(C=O)C~_2alkyl, and piperidinyl.
Advantageously, R~ does not include hydroxy or an alkyl substituted with hyd roxy.
When reference is made herein to a bond having a solid and dashed line, such as in [ ] , it should be understood that the bonds) can be selected from a single or a double bond, as appropriate, given selections for X~B
y adjacent atoms. For example, when there is shown A , if X is sulfur or NH, the bonds linking X to adjacent atoms A and B are single bonds.
X/B
However, when in A , X is CRS or a nitrogen atom, one of the bonds linking X to A or B is a double bond and the other is a single bond.
Throughout this disclosure, groups and substituents thereof can be chosen by one skilled in the field to provide stable moieties and compounds.
The compounds of formula (I) and/or compound 6 form salts which are also within the scope of this invention. Unless otherwise indicated, reference to an inventive compound is understood to include reference to salts thereof. The term "salt(s)" denotes acidic and/or basic salts formed with inorganic and/or organic acids and bases. In addition, the term "salt(s) can include zwitterions (inner salts), e.g., when a compound of formula (I) contains both a basic moiety, such as an amine or a pyridine or imidazole ring, and an acidic moiety, such as a carboxylic acid. Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, such as, for example, acceptable metal and amine salts in which the cation does not contribute significantly to the toxicity or biological activity of the salt. However, other salts can be useful, e.g., in isolation or purification steps which can be employed during preparation, and thus, are contemplated within the scope of the invention. Salts of the compounds of the formula (I) can be formed, for example, by reacting a compound of the formula (i) with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.
Exemplary acid addition salts include acetates (such as those formed with acetic acid or trihaloacetic acid, for example, trifluoroacetic acid), adipates, alginates, ascorbates, aspartates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, cyclopentanepropionates, digluconates, dodecylsulfates, ethanesulfonates, fumarates, glucoheptanoates, glycerophosphates, hemisulfates, heptanoates, hexanoates, hydrochlorides (formed with hydrochloric acid), hydrobromides (formed with hydrogen bromide), hydroiodides, 2-hydroxyethanesulfonates, lactates, maleates (formed with malefic acid), methanesulfonates (formed with methanesulfonic acid), 2-naphthalenesulfonates, nicotinates, nitrates, oxalates, pectinates, persulfates, 3-phenylpropionates, phosphates, picrates, pivalates, propionates, salicylates, succinates, sulfates (such as those formed with sulfuric acid), sulfonates (such as those mentioned herein), tartrates, thiocyanates, toluenesulfonates such as tosylates, undecanoates, and the like.
Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts; alkaline earth metal salts such as calcium and magnesium salts; barium, zinc, and aluminum salts; salts with organic bases (for example, organic amines) such as trialkylamines such as TEA, procaine, dibenzylamine, N-benzyl-~i-phenethylamine, 1-ephenamine, N,N'-dibenzylethylene-diamine, dehydroabietylamine, N-ethylpiperidine, benzylamine, dicyclohexylamine or similar pharmaceutically acceptable amines and salts with amino acids such as arginine, lysine and the like. Basic nitrogen-containing groups can be quaternized with agents such as lower alkyl halides (e.g., methyl, ethyl, propyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g., dimethyl, diethyl, dibutyl, and diamyl sulfates), long chain halides (e.g., decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides), aralkyl halides (e.g., benzyl and phenethyl bromides), and others. Sodium or potassium salts are preferred.
Compounds of the formula (I) and/or compound 6 and salts thereof can exist in their tautomeric form, in which hydrogen atoms are transposed to other parts of the molecules and the chemical bonds between the atoms of the molecules are consepuently rearranged. It should be understood that the all tautomeric forms, insofar as they can exist, are included within the invention. Additionally, inventive compounds can have trans and cis (E and Z) isomers and can contain one or more chiral centers, therefore existing in enantiomeric and diastereomeric forms. The invention includes all such isomers, as well as mixtures of cis and trans isomers, mixtures of diastereomers and racemic mixtures of enantiomers (optical isomers).
When no specific mention is made of the configuration (cis, trans or R or S) of a compound (or of an asymmetric carbon), then any one of the isomers or a mixture of more than one isomer is intended.
Another embodiment of the present invention relates to pharmaceutical or physiological compositions having at least one IKK
inhibitor, or salt thereof, and preferably containing a pharmaceutically or physiologically acceptable vehicle, such as a carrier, diluent, or excipient.
Furthermore, these pharmaceutical or physiological compositions comprise one or more IKK inhibitors, or salt thereof, either alone or in combination with a biologically active agent, such as but not limited to drugs, steroids, or synthetic compounds, particularly for use in the methods according to the present invention. The pharmaceutical compositions can preferably comprise any one of the IKK inhibitors of the present invention, for example, 4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline (compound 6) or any one of the compounds of formula (I). Such a pharmaceutical or physiological composition can be administered to any individual in need of such therapy, including, for example, mammals such as monkeys, dogs, cats, cows, horses, rabbits, and most preferably, humans, for any of the above-described therapeutic or preventative uses and effects.
More particularly, the present invention also provides pharmaceutical compositions capable of treating conditions that are related to the activity of NF-~cB, TNF-a , and/or enzymes modulating NF-oB and/or TNF-a levels such as IKK. Such compositions may contain other therapeutic agents and may be formulated, as described herein.
In the method embodiments of the present invention, IKK inhibitors, or pharmaceutical or physiological compositions thereof, can be administered alone or in combination with at least one other biologically active agent, which can be introduced in any sterile, biologically compatible pharmaceutical or physiologically acceptable carrier, excipient, or diluent, including, but not limited to, saline, buffered saline, dextrose, and water.
The compositions can be administered to a patient alone, or optionally in combination with other biologically active agents, drugs, or hormones.
Additionally, in the methods according to this invention, the IKK
inhibitors, or pharmaceutical or physiological compositions thereof, can be administered by any means suitable for the condition to be treated, which can depend on the need for site-specific treatment or quantity of drug to be delivered, by any number of routes including, but not limited to, oral, nasal, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, and sublingual means. Preferably, IKK inhibitors are administered orally, nasally, topically, or by inhalation.
Administration of IKK inhibitor compositions of the invention can also include local or systemic administration, including injection, oral administration, particle gun, or catheterized administration, and topical administration. Various methods can be used to administer an IKK inhibitor composition directly to a specific site in the body. For example, in instances where topical delivery is preferred, generally for skin-related diseases, transdermal patches and/or permeation enhancers can be used, a variety of which are commonly known in the art. Systematic treatment is preferred for cancerous or pre-cancerous conditions, although other modes of delivery are contemplated.
Both the dose of an IKK inhibitor, or composition thereof, and the means of administration can be determined based on the specific qualities of the IKK inhibitor or therapeutic composition thereof; the condition, age, and weight of the patient; the progression of the disease; and other relevant factors. Preferably, an IKK inhibitor, or therapeutic composition thereof, according to the invention, increases or decreases gene expression of NF-~cB. Methods well known in the art can be used to determine the effectiveness of the mechanism chosen to alter expression of the NF-~cB
gene, such as hybridization of nucleotide probes to mRNA of the NF-KB
gene, quantitative RT-PCR, or detection of an NF-oB protein using specific antibodies (e.g. Santa Cruz Biotechnology; Santa Cruz, CA).
In addition to the active ingredients, the pharmaceutical compositions can contain suitable pharmaceutically acceptable carriers, diluents, or excipients comprising auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration are provided in the latest edition of Remington's Pharmaceutical Sciences (Mack Publishing Co.; Easton, Pa.).
Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.
The compounds of the present invention can be delivered orally, such as in the form of tablets, capsules, granules, powders, or liquid formulations S including syrups; topically, such as in the form of solutions, suspensions, gels, creams, or ointments; nasally such as by inhalation spray; parenterally, such as by subcutaneous, intravenous, intramuscular or intrasternal injection or infusion techniques (e.g., as sterile injectable aqueous or non-aqueous solutions or suspensions); rectally such as in the form of suppositories; sublingually; bucally; or liposomally.
Pharmaceutical preparations for oral use can be obtained by the combination of active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropyl-methylcellulose, or sodium carboxymethylcellulose; gums, including arabic and tragacanth, and proteins such as gelatin and collagen. If desired, disintegrating or solubilizing agents can be added, such as cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a physiologically acceptable salt thereof, such as sodium alginate.
Pharmaceutical preparations, which can be orally administered in the methods according to the present invention, include push-fit capsules made of gelatin, as well as soft, scaled capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds can be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.
Exemplary compositions for oral administration include suspensions which can contain, for example, microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners or flavoring agents such as those known in the art; and immediate release tablets which can contain, for example, microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and/or lactose and/or other excipients, binders, extenders, disintegrants, diluents and lubricants such as those known in the art. The inventive compounds can also be orally delivered by sublingual and/or buccal administration, e.g., with molded, compressed, or freeze-dried tablets. Exemplary compositions can include fast-dissolving diluents such as mannitol, lactose, sucrose, and/or cyclodextrins. Also included in such formulations are high molecular weight excipients such as celluloses (AVICEL~) or polyethylene glycols (PEG); an excipient to aid mucosal adhesion such as hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), sodium carboxymethyl cellulose (SCMC), andlor malefic anhydride copolymer (e.g., GANTREZ~); and agents to control release such as polyacrylic copolymer (e.g., CARBOPOL 934~). Lubricants, glidants, flavors, coloring agents and stabilizers can also be added for ease of fabrication and use.
Exemplary compositions for rectal administration include suppositories which can contain, for example, suitable non-irritating excipients, such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures but liquefy and/or dissolve in the rectal cavity to release the drug.
Dragee cores can be used in conjunction with physiologically suitable coatings, such as concentrated sugar solutions, which can also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/ or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments can be added to the tablets or dragee coatings for product identification, or to characterize the quantity of active compound, i.e., dosage.
Pharmaceutical formulations suitable for parenteral administration in the methods of the present invention can be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions can contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. In addition, suspensions of the active compounds can be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyloleate or triglycerides, or liposomes. Optionally, the suspension can also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. Additional exemplary compositions for parenteral administration include injectable solutions or suspensions which can contain, for example, suitable non-toxic, parenterally acceptable diluents or solvents, such as mannitol, 1,3-butanediol, water, Ringer's solution, an isotonic sodium chloride solution, or other suitable dispersing or wetting and suspending agents, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.
For topical or nasal administration, penetrants or permeation-enhancing agents that are appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art. Exemplary compositions for topical administration include a topical carrier such as PLASTIBASE~ (mineral oil gelled with polyethylene). Exemplary compositions for nasal aerosol or inhalation administration include solutions which can contain, for example, benzyl alcohol or other suitable preservatives, absorption promoters to enhance absorption and/or bioavailability, and/or other solubilizing or dispersing agents such as those known in the art.
The pharmaceutical compositions of the present invention can be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.
Dosage unit formulations containing non-toxic, pharmaceutically acceptable vehicles or diluents can be administered. The compounds can be administered in a form suitable for immediate release or extended release. Immediate release or extended release can be achieved with suitable pharmaceutical compositions or, particularly in the case of extended release, with devices such as subcutaneous implants or osmotic pumps.
The IKK inhibitor, or pharmaceutical composition thereof, can be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, and the like. Salts tend to be more soluble in aqueous solvents, or other protonic solvents, than are the corresponding free base forms. In other cases, the preferred preparation can be a lyophilized powder which can contain any or all of the following: 1-50 mM histidine, 0.1 %-2% sucrose, and 2-7% mannitol, at a pH range of 4.5 to 5.5, combined with a buffer prior to use. After the pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of IKK inhibitors, such labeling would include amount, frequency, and method of administration.
Pharmaceutical compositions comprising one or more IKK inhibitors suitable for use in the present invention include compositions in which the active ingredients are contained in an amount effective to achieve the intended purpose. The determination of an effective dose or amount is well within the capability of those skilled in the art. For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., using neoplastic cells, or in animal models, usually mice, rats, rabbits, dogs, or pigs. The animal model can also be used to determine the appropriate dosage, concentration range and route of administration. Such information can then be used and extrapolated to determine useful doses, concentration ranges, and routes for administration in humans. For guidance, in accordance with the methods of the present invention, an effective amount of IKK inhibitor optimally results in a level of inhibition of IKK activity ranging from about 20-100%, preferably, about 50-100%, more preferably about 80-100%, and most preferably about 90-100%, for the treatment of inflammatory and/ or immune-related diseases.
A therapeutically effective dose refers to that amount of active ingredient or compound, such as an IKK inhibitor, which ameliorates, reduces, or eliminates the symptoms, condition, disease, or disorder.
Therapeutic efficacy and toxicity can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population). The dose ratio of therapeutic to toxic effects is the therapeutic index, which can be expressed as the ratio, ED50/LD50. Pharmaceutical compositions which exhibifi large therapeutic indices are preferred. As understood by the skilled practitioner, data obtained from cell culture assays and animal studies are used in determining a range of dosages for human use. Preferred dosage of a pharmaceutical composition is within a range of circulating concentrations that include the EDSO with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.
It will be understood that the specific dose level and frequency of dosage for any particular subject can be varied and will depend upon a variety of factors; the exact dosage will be determined by the practitioner, who will consider the factors related to the individual requiring treatment.
Dosage and administration are adjusted to provide sufficient levels of the IKK inhibitor active moiety or to maintain the desired effect. Factors which are taken into account include the severity of the individual's disease state, general health of the patient, age, weight, and gender of the patient, diet, and mode, time and frequency of administration, rate of excretion, drug combination(s), reaction sensitivities, and tolerance/response to therapy. As a general guide, long-acting pharmaceutical compositions can be administered every 3 to 4 days, every week, or once every two weeks, depending on half-life and clearance rate of the particular formulation.
Normal dosage amounts can vary from about 0.1 to about 100,000 micrograms (~,g), up to a total dose of about 1 gram (g), depending upon the route of administration. Preferably, dosages range from about 1 to about 100 ~,g. Guidance as to particular dosages and methods of delivery is provided in the literature, via empirical determination, and is generally available to, and routinely able to be determined by practitioners in the art.
Single or multiple doses can be administered on, for example, a daily, every other day, or weekly schedule. In particular, the effective amount of a compound of the present invention can be determined by one of ordinary skill in the art, and includes exemplary dosage amounts for a mammal of from about 0.05 to 100 mg/kg of body weight of active compound per day, which can be administered in a single dose or in the form of individual divided doses, such as from 1 to 4 times per day. Preferred subjects for treatment include animals, most preferably mammalian species such as humans, and domestic animals such as dogs, cats, horses, and the like.
The compounds of the invention, and pharmaceutically acceptable salts thereof, also embrace prodrugs, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents. Prodrugs and solvates of the inventive compounds are also contemplated. As will be appreciated by the skilled practitioner, prodrugs are suitable for use in the methods according to the present invention. Such prodrugs are preferably administered orally since hydrolysis in many instances occurs principally under the influence of the digestive enzymes. Parenteral administration can be used where the ester per se is active, or in those instances where hydrolysis occurs in the blood. Examples of physiologically hydrolyzable esters of compounds of formula (I) include C~_6alkylbenzyl, 4-methoxybenzyl, indanyl, phthalyl, methoxymethyl, C~_6 alkanoyloxy-C~_6alkyl, e.g. acetoxymethyl, pivaloyloxymethyl or propionyloxymethyl, C~_6alkoxycarbonyloxy-C~_6alkyl, e.g. methoxycarbonyl-oxymethyl or ethoxycarbonyloxymethyl, glycy(oxymethyl, pheny(glycyloxymethyl, (5-methyl-2-oxo-1,3-dioxolen-4-yl)-methyl and other well known physiologically hydrolyzable esters used, for example, in the penicillin and cephalosporin arts. Such esters can be prepared by conventional techniques known in the art.
The inventive compounds and compositions can be employed alone or in combination with each other and/or other suitable therapeutic agents useful in treating NF-~cB and TNF-a associated conditions. Exemplary of such other therapeutic agents include corticosteroids, rolipram, calphostin, CSAIDs, 4-substituted imidazo [1,2-A]quinoxalines as disclosed in US Pat.
No. 4,200,750 and Ceccarelli et al., supra; Interleukin-10, glucocorticoids, salicylates, nitric oxide, and other immunosuppressants; nuclear translocation inhibitors, such as deoxyspergualin (DSG); non-steroidal antiinflammatory drugs (NSAIDs) such as ibuprofen, celecoxib and rofecoxib; steroids such as prednisone or dexamethasone; antiviral agents such as abacavir; antiproliferative agents such as methotrexate, leflunomide, FK506 (tacrolimus, Prograf); cytotoxic drugs such as azathiprine and cyclophosphamide; TNF-a inhibitors such as tenidap, anti-TNF antibodies or soluble TNF receptor, and rapamycin (sirolimus or Rapamune) or derivatives thereof; and other cancer drugs and treatments, including radiation treatments and daunorubicin. , The above other therapeutic agents, when employed in combination with the compounds of the present invention, can be used, for example, in those amounts indicated in the Physicians' Desk Reference (PDR) or as otherwise determined by one of ordinary skill in the art.
It should be understood that one skilled in the field is able to make various modifications to the compounds, compositions and schemes described above, applying the ordinary level of skill in the field, without departing from the spirit or scope of the invention. All such modifications are.
intended to be included within the invention as defined in the appended claims.
EXAMPLES
The Examples below are provided to illustrate the subject invention and are not intended to limit the invention.
METHOD OF PREPARATION OF IKK INHIBITOR 4(2' AMINOETHYL)AMINO- 1,8-DIMETHYL-IMIDAZO(1,2-A) QUINOXALINE
(COMPOUND 6) The IKK inhibitory compound 4(2'-aminoethyl)amino- 1,8-dimethylimidazo(1,2-a) quinoxaline, or compound 6 newly described herein, can be prepared by a method as described in the following scheme.
Starting materials are commercially available or can be readily prepared by one of ordinary skill in the art, andl or modifications can be made to the method of the scheme by one skilled in the art, using known methods and practices.
Chemical Scheme for Pre~paringCompound 6 Me COzH Me Me P Me COOEt Me Me / N / N
PhzO, + NHS N ~ ~ ~ \ reflux ~ N
NOz H O 4 H
Me Me PhNEtz _ Me / N s N HzN,~ NH~ Me / N ~, N
POCI3 I ' 60 C ~ ~ ~ NHZ
N CI N
2~ 5 6 Compound 6 or 4(2'-aminoethyl)amino- 1,8-dimethylimidazo(1,2-a) quinoxaline, can be prepared as shown in the above scheme: 3-fluoro-4-nitrotoluene (compound 1) is reacted with ethyl 5-methylimidazole-4-caboxylate (compound 2) according to known procedures to produce, after several steps, the imidazoquinoxalone-2-carboxylic acid (compound 3).
Upon decarboxylation of said acid (compound 3) in a high-boiling solvent, such as diphenyl ether (Ph20), 1,8-dimethylimidazoquinoxalone (compound 4) is produced. Compound 4 is then chlorinated using standard reagents, such as phosphorus oxychloride (POC13) and N,N-diethylaniline (PhNEt2) to give 4-chloro-1,8-dimethylimidazoquinoxaline (compound 5). Compound 5 is then condensed with 1,2-diaminoethane or ethylenediamine to produce the final compound 4(2'-aminoethyl)amino- 1,8-dimethylimidazo(1,2-a) quinoxaline (compound 6).
PREPARATION OF REAGENTS AND STARTING MATERIALS FOR
3-fluoro-4-nitrotoluene (Compound 1) Compound 1 is commercially available from Aldrich Chemical Company (Milwaukee, WI).
Ethyl 5-methylimidazole-4-carboxylate (Compound 2) Compound 2 is commercially available from Aldrich Chemical Company (Milwaukee, WI).
Preparation of imidazoauinoxalone-2-carbox~rlic acid (Compound 3) Compound 1 and compound 2 are reacted to give, after several steps, compound 3, following the procedure of Trieber et al. (German Offen.
4,329,970 (October 6, 1994)).
Preparation of 4,5-Dihydro-1 8-dimethylimidazo(1 2-a)auinoxalin-4-one (Compound 4) A suspension of 4,5-dihydro- 1,8-dimethyfimidazo(1,2-a)quinoxalin-4-one-2-carboxylic acid (compound 3) (32 g, 124 mmol) in diphenyl ether (400 mL) was refluxed at 260°C for 2 hours. After the suspension cooled down to room temperature, hexanes (C6H~4; 500 mL) were added to further precipitate the product. The solid was filtered, giving the title compound 4 as a white solid (29.6 g). ~H nuclear magnetic resonance, NMR (500 MHz, hexadeuterio-dimethylsulfoxide, d6-DMSO) 8 11.7 (s, 1 H), 7.91 (s, 1 H), 7.31 (s, 1 H), 7.29 (d, J=8.1 Hz, 1 H), 7.22 (d, J=8.3 Hz, 1 H), 2.81 (s, 3H), 2.41 (s, 3H); MS (ESI), m/z 214.13 [(M+H)+; calculated for compound 4, C~2H~~N3O:
213.09].
Preparation of 4-chloro- 1 8-dimethylimidazo(1 2-a)auinoxaline (Compound A mixture of 4,5-dihydro-1,8-dimethylimidazo(1,2-a)quinoxalin-4-one (compound 4) (29.6 g, 139 mmol) and N,N-diethylaniline (PhNEt2, 45 mL) was refluxed in phosphorus oxychloride (POC13; 250 mL) for 1 hour. The solvent was evaporated under vacuum; the residue was diluted with chloroform, CHC13 (1000 mL), followed by careful neutralization with cold saturated sodium carbonate, (Na2C03) solution. The aqueous layer was further extracted with CHC13. The combined organic layer was dried over magnesium sulfate (MgS04) filtered and concentrated. Flash chromatography using ethyl acetate and hexanes (EtOAc/ Hexanes, 60/ 40) provided the title compound 5 as a white solid (25 g). ~H NMR (500 MHz, CDC13) 8 8.07 (s, 1 H), 7.93 (d, J=8.3 Hz, 2 H), 7.54 (d, J=0.7 Hz, 1 H), 7.41 (dd, J= 8.4, 1.2 Hz, 1 H), 2.97 (s, 3H), 2.59 (s, 3H); MS (ESI), m/z 232.04 [(M+H)+; calculated for compound 5, C~zH~oCIN3: 231.06].
Preparation of 4(2'-Aminoethyl)amino-1,8-dimethylimidazo(1 2-a) guinoxaline (Compound A solution of 4-chloro-1,8-dimethylimidazo(1,2-a) quinoxaline (compound 5) (4.8 g, 21 mmol) in ethylenediamine (300 mL) was heated at 60°C under nitrogen gas (N2) for 16 hours. The solvent was evaporated under vacuum. The residue was diluted with EtOAc (200 mL), washed with saturated Na2C03 and brine, dried over MgS04, filtered and concentrated.
Flash chromatography using methanol (MeOH) provided a solid, which was then dissolved with CHC13 and filtered to remove any dissolved silica gel.
The filtrate was concentrated under vacuum, providing the title compound 6 as a white solid (4.67 g). ~ H NMR (500 MHz, CDC13) 8 7.88 (s, 1 H), 7.63 (d, J=8.3 Hz, 1 H), 7.26 (s, 1 H), 7.22 (d, J=8.3 Hz, 1 H), 6.31 (s, 1 H), 3.63 (apparent q, J=5.9 Hz, 2 H), 2.96 (t, J=6.0 Hz, 2 H), 2.88 (s, 3 H),1.38 (br, H); MS (ESI), m/z 256.15 [(M+H)+; calculated for compound 6, C~4H~~N~:
255.15].
Preparation of HCI Salt of 4(2'-Aminoethyl)amino-1,8-dimethylimidazo(1,2-a) cLuinoxaline (Compound 6~
Compound 6 or 4(2'-Aminoethyl)amino-1,8-dimethylimidazo(1,2-a) quinoxaline (4.67 g, 18.3 mmol) was dissolved with aqueous hydrochloric acid, HCI (1.0 N, 18.3 mL) and water, H20 (50 mL) at room temperature.
Subsequent removal of water using a lyophilizer provided the hydrochloride salt as a white solid (5.22 g). The hydrochloride salt of compound 6 is preferred in the described methods although other salts, e.g. acetate, sulfate, citrates, as well as the free base of compound 6, are also suitable for use.
In Examples 2-7, a salt form of 4(2'-Aminoethyl)amino-1,8-dimethylimidazo(1,2-a) quinoxaline was used.
ANALYSIS OF INHIBITORY POTENTIAL OF IKK INHIBITORS, USING
4(2'-AMINOETHYL)AMINO- 1,8-DIMETHYLIMIDAZO(1,2-A) QUINOXALINE
(COMPOUND 6) I KK-1 /I KK-2 Enzyme Assay Assays for measuring the inhibitory potential of test compounds, specifically compound 6, (4(2'-aminoethyl)amino- 1,8-dimethylimidazo(1,2-a) quinoxaline), against IKK activity employed 33P-labeled ATP and a recombinant IoB-a as substrates. In this assay, test compound was added to a solution of 0.5 mM hcB-a in 40 mM Tris-HCI, pH 8, containing 4 mM
MgCl2, 1 mM dithiothreitol, and 2 mM 33P-labeled ATP. IKK enzyme (either the multisubunit complex from HeLa cells, recombinantly expressed IKK-1, or recombinantly expressed IKK-2) was then added to initiate the reaction.
The multisubunit complex was isolated according to the procedure of Lee et al. [(1997) Cell 88:213-222] or Mercurio et al. [(1997) 278:860-866]. The recombinant IKK-1 and IKK-2 were expressed using the procedure of Burke et al. [(1999) J. Biol. Chem. 274:36146-36152]. After incubating for 10 minutes at 30°C, the reaction was quenched by the addition of EDTA to a final concentration of 30 mM. In order to separate the phosphorylated IKB-a (Santa Cruz Biotechnology; Santa Cruz, CA) product from unreacted ATP, sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) was performed. Phosphoimager analysis of the amount of 33P incorporation into IKB-a was executed using a Molecular Dynamics 445 Phosphoimager, and the inhibition of IKK activity by the test compound was calculated from control samples containing no inhibitor. The IC5o is defined as the concentration of test compound which produces 50% inhibition of IKK
activity.
The results presented in Table 1 show the inhibition of IKK activity using 33P-labeled ATP and hcB-a as substrates for recombinantly expressed IKK-1 and IKK-2, wherein a test compound concentration of 5 ~M and 0.5 p,M, respectively, was shown to achieve inhibition of (KK activity by 50%.
The IKK inhibitor, compound 6, inhibits IKK-2 at an IC5o which is 10 fold less than that necessary to inhibit IKK-1 by 50%. As presented in Table 1, compound 6 inhibits IKK-2 with greater effectiveness than IKK-1, thus demonstrating a selectivity of this compound for IKK-2 inhibition over IKK-1.
Test Compound IKK-1 ICSO IKK-2 IC5o Compound 6 5 u,M 0.5 u,M
Compound 6 was administered to BALBIc mice either per orally (p.o.) or intravenously (i.v.). Blood was drawn at various times (0.5 to 4 hours) after dosing and the plasma drug levels measured by liquid chromatography-mass spectral analysis. An oral bioavailability of 100% for compound 6 was calculated from the area under the curve (AUC) derived from a plot of plasma levels versus time after the p.o. dose, and then dividing by the AUC from the i.v. dose. An i.v. half-life of 7.9 hours was calculated from the apparent terminal elimination phase after the i.v. dose.
Generally, to be considered, oral bioavailability ranges from about 10% to about 100%, more preferably from about 50% to about 100%, and most preferably from 80% to about 100%.
MEASUREMENT OF MEDIAN SURVIVAL TIME OF TRANSPLANTED
HEARTS IN BALB/C MICE
Murine Neonatal Heart to Ear Transplants Cardiac transplants were performed as described by Fulmer et al.
(Fulmer, R.I. et al. The American Journal of Anatomy 113:273-281, 1963).
Neonatal hearts were obtained from newborn C57BL/6 mice not more than 48 hours after birth. The hearts were transplanted into recipient BALB/c mice, which were prepared under anesthesia by making a small incision at the base of the ear pinna and forming a pocket by gently lifting the skin away from the ear. The incision permitted the insertion of the donor heart subcutaneously into the pocket. Post-operatively, the cardiac tissue typically does not begin to beat until 3 to 5 days after transplantation until vascular connections are established. The pulsations of the heart were measured by contractile activity with an appropriate electrocardiogram (ECG) monitoring device. The contractile activity of the transplanted graft was monitored daily. The time of graft rejection was defined as the day after transplantation on which contractile activity ceased. Without therapeutic intervention, the host mounts an immune response to the transplanted heart (i.e., graft rejection). This immune response causes the transplanted heart to cease beating typically 10-14 days post transplantation.
Test compounds were administered in daily doses either alone or in combination with other therapies, such as Cyclosporine A (15 mg/ kg, orally, "p.o.") or CTLA4-Ig (200 gg in 200 ~,I PBS given intraperitaneally on only days 0, 2, and 4). Table 2 presents fihe effects of test compounds on median survival time of transplanted hearts, either alone or in combination with Cyclosporine A (CsA). Table 3 presents the effects of test compounds on median survival time of transplanted hearts, either alone or in combination with CTLA4-Ig.
Test Compound Median Graft Statistical Significance Survival Time Vehicle water) 12 da s C closporine A, 15 m /k 14 da s , .o.
Com ound 6, 50 m /k , 12 da s .o.
Cyclosporine A, 15 mg/kg, P < 0.01 vs. vehicle, p.o. 29 days P < 0.01 vs. CsA alone Plus Compound 6, 50 m /k , p.o.
Test Compound Median Graft Statistical Significance Survival Time Vehicle water 12 da s CTLA4-I 22 da s P < 0.01 vs. vehicle Com ound 6, 50 m /k , 12 da s I
.o.
Com ound 6, 100 m /k , 18 da s P < 0.01 vs. vehicle p.o.
CTLA4-Ig ' Plus 32 days P < 0.01 vs. vehicle, I
Compound 6, 50 mg/kg, P = 0.02 vs. CTLA4-Ig p.o.
alone CTLA4-Ig Plus >60 days P < 0.01 vs. vehicle, Compound 6, 100 mg/kg, P < 0.01 vs. CTLA4-Ig p.o.
alone The synergistic effects between compound 6 and either cyclosporine A or CTLA4-Ig indicate that an IKK inhibitor is highly efficacious in the in vivo treatment of solid organ transplant rejection particularly when co-administered with other immunosuppressive agents. Because these agents are not completely effective when administered alone, transplant patients typically receive a "cocktail" of immunosuppressive agents.
EFFECT OF IKK INHIBITOR 4(2'-AMINOETHYL)AMINO- 1,8 DIMETHYLIMIDAZO(1,2-A) QUINOXALINE (COMPOUND 6) ON DISEASE
INCIDENCE IN THE MURINE MODEL OF COLLAGEN-INDUCED
ARTHRITIS
Collagen-Induced Arthritis The murine model of collagen-induced arthritis is widely used to study disease mechanisms and potential therapies for rheumatoid arthritis in humans (Staines et al., Br. J. Rheumatol. 33:798-807, 1994; Feldmann et al., Annu. Rev. Immunol. 14:397-440, 1996).
DBA/1 LacJ male mice 6-8 wk (Jackson Laboratories; Bar Harbor, ME) were immunized subcutaneously on day 0 and on day 21 with 100 p,g bovine type II collagen in 0.1 mL RIBI Adjuvant System (RAS) with monophosphoryl lipid A (RIBI ImmunoChem Research; Hamilton, MT). In this model, disease onset occurs within one week after the second collagen injection.
When treated in a preventative mode, test compounds were administered daily beginning on day 0 through day 41. Figure 1 shows a graph of the percentage of mice within each treatment group (6-10 animals per group) which show any sign of disease regardless of severity.
Administration of 4(2'-aminoethyl)amino- 1,8-dimethylimidazo(1,2-a) quinoxaline (compound 6) at a concentration of 100 mg/ kg, resulted in a significant difference in incidence of disease compared with vehicle alone.
In the established (i.e. therapeutic) mode, the administration of test compounds was initiated only after paw inflammation of an animal had achieved a score of 2 (as defined below), at which time, the animal was randomly assigned to a treatment group. Treatment continued daily for all four paws as described below.
Following the Day 21 booster, mice were regularly monitored for the development and severity of paw inflammation. Each paw was visually scored by the following clinical scoring scheme as presented in Table 4:
Score Description 0 Normal 1 One or more 'oints inflamed on di its 2 Plantar surface of paw inflamed and aw thickness increased 3 Ankylosis (significantly reduced hock 'oint motion on flexion/ extension Clinical paw scores for all four paws were summed for each mouse and the mean ~ standard deviation (SD) was calculated for each treatment group. The incidence of disease is defined as the percent of animals within a treatment group which showed any sign of disease regardless of severity.
Histological scoring involved evaluating histologically and grading semi-quantitatively tibiotarsal joints of sacrificed mice, specifically examining the severity of inflammation, synovial hyperplasia, bone resorption, and cartilage erosion. Cumulative arthritis injury scores for each group were compared by the nonparametric Kruskal-Wallis analysis of variance.
Figure 2 shows the average gross clinical score for all mice within each treatment in the collagen-induced arthritis murine model as determined on each study day. The test compound was administered once daily in the preventative dosing mode. Table 5 presents the histological evaluation of the effect of 4(2'-aminoethyl)amino- 1,8-dimethylimidazo(1,2-a) quinoxaline (compound 6) on the cumulative arthritis injury scores ~ standard error mean (sem) upon sacrificing the animals at the end of the study in the murine model of collagen-induced arthritis. Administration of 4(2'-aminoethyl)amino- 1,8-dimethylimidazo(1,2-a) quinoxaline (compound 6) at concentrations of 30 and 100 mg/ kg resulted in histological cumulative arthritis injury scores of 0.4 and 0, which parallels the results depicted in Figure 2.
Preventative Mode Treatment Cumulative arthritis Statistical Significance in'ur score (sem Vehicle (water) 4.4 1.5 Compound 6, 10 mg/kg5.3 1.7 Compound 6, 30 mg/kg0.4 0.4 P = 0.02 Compound 6, 100 mg/kg0.0 P = 0.004 'ws. vehicle-treated group.
Figure 3 shows the effects of 4(2'-aminoethyl)amino- 1,8-dimethylimidazo(1,2-a) quinoxaline (compound 6) administered in the established disease mode (i.e., after disease onset) on the average gross clinical score for all mice within each treatment in the murine model of collagen-induced arthritis as determined on the days following disease onset.
Table 6 presents the histological evaluation of the effect of 4(2'-aminoethyl)amino- 1,8-dimethylimidazo(1,2-a) quinoxaline (compound 6) on the cumulative arthritis injury scores in the established disease mode of murine model of collagen-induced arthritis two weeks after disease onset.
Established Mode Treatment ~ Cumulative ArthritisStatistical In'ur Score (sem) significance*
Vehicle (water) 7.0 0.5 Compound 6, 10 mg/kg 4.2 1.0 P = 0.028 Compound 6, 30 mg/kg 2.1 0.9 P = 0.004 Compound 6, 100 mg/kg 0.9 0.5 P = 0.001 ~'vs. vehicle-treated group.
The murine model of collagen-induced arthritis shares many of the same biochemical and pathological mechanisms as does rheumatoid arthritis in humans, and was used for preventing and treating arthritis upon the administration of 4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a) quinoxaline (compound 6). Figures 1 and 2 and Table 5 show that daily administration of 30 mg/kg (p.o.) of compound 6 inhibited disease onset, and that 100 mg/kg (p.o.) of compound 6 prevented any disease onset when dosed in a preventative mode. When the IKK inhibitor was administered after disease onset (i.e., established mode of therapy), Figure 3 and Table 6 show that treatment with 30 mg/kg (p.o.) of compound 6 significantly inhibited disease progression when compared with vehicle treated animals, while a dose of 100 mg/kg (p.o.) of compound 6 actually led to significant disease resolution. These results support the advantages provided by the present invention in which inflammatory diseases or disorders, such as rheumatoid arthritis, are prevented or ameliorated by inhibiting IKK activity.
EFFECT OF IKK INHIBITOR 4(2'-AMINOETHYL)AMINO- 1,8 DIMETHYLIMIDAZO(1,2-A) QUINOXALINE ON DISEASE INCIDENCE IN
THE MURINE MODEL OF DEXTRAN SULFATE SODIUM-INDUCED
INFLAMMATORY BOWEL DISEASE
Dextran Sulfate Sodium-Induced Murine Model of Inflammatory Bowel Disease Dextran sulfate sodium (DSS)-induced colitis in mice shows several of the same pathological mechanisms of inflammatory bowel disease (IBD) as it presents in humans, and has been used to study various treatments (Okayasu et al., Gastroenterology 98:694-702, 1990; Axelsson et al., Aliment. Pharmacol. Ther. 12:925-934, 1998). The mouse models are used as predictors of IBD in humans and to develop effective treatments for human use.
IS In this model, Swiss-Webster mice (8 weeks old, 5 animals per treatment group) were given 6% DSS in their drinking water for 7 consecutive days to induce intestinal inflammation. Test compounds were administered daily throughout the study. On day 9, animals were sacrificed and the colons were removed for clinical and histological evaluation.
Clinical scoring was determined by the gross clinical evaluation of the injury on a scale from 0 (normal) to 3 (severe) as detailed in Table 7.
Score Description 0 Normal 1 Relatively normal colon length, slight thickenin of tissue.
2 Shortened colon length, thick along entire length of colon with loss of striations. Some areas of redness.
3 Considerably shortened length with very thick tissue containing areas of raised lesions.
For histological scoring, colon sections were graded as to the severity of crypt injury and the degree of inflammation. The crypt injury was scored as detailed in Table 8, wherein the crypt is part of the glandular make-up of the colon.
Score Description 0 Normal; intact c pt 1 Loss of basilar - one- third of the cr pt 2 Loss of basilar - two-thirds of the crypt 3 Loss of the entire crypt with surface epithelium intact 4 Loss of the entire crypt with epithelial erosion Tissue involvement was scored as detailed in Table 9. Any signs of crypt injury or inflammation, regardless of severity, constitute tissue involvement.
Score Description 0 No involvement 1 1-25% involvement 2 26-50% involvement 3 51-75% involvement 4 76-100% involvement The injury histological score is defined as the product of the crypt injury grade and the tissue involvement grade. The scoring of severity of inflammation is detailed in Table 10.
Score Description 0 Normal; non-remarkable 1 Minimal 2 -- -Mild Score Description 3 Moderate 4 Severe The infilammation histological score is the product of the severity of inflammation grade and the extent ofi tissue involvement grade. Crypt injury and inflammatory scoring were performed on each colon section and a mean score and standard error were determined for each section.
Cumulative crypt injury and inflammatory scores for each group were determined. Table 11 presents the clinical scores of colons in mice with DSS-induced colitis. The results of Table 12 present the cumulative injury and inflammation scores of colons in mice with DSS-induced colitis.
Treatment Mean clinical score UNTREATED 2.50 0.45 COMPOUND 6, 30 mg/kg, 1.10 0.49*
p.o.
COMPOUND 6, 100 mg/kg, 1.00 0.35*
p.o.
*Statistical significance vs. untreated group, P<0.05 Treatment Group Mean Injury Group Mean Histological Score Inflammation Histolo ical Score UNTREATED 8.52 0.81 12.33 0.40 COMPOUND 6, 30 4.83 0.55* 7.58 0.81*
m /k , .o.
COMPOUND 6, 100 5.66 0.87* 6.82 0.85*
m /k , .o.
*Statistical significance vs. untreated group, P<0.05 The results show that 4(2'-aminoethyl)amino- 1,8-dimethylimidazo(1,2-a) quinoxaline (compound 6) prevented and treated IBD in the well-established murine model of inflammatory bowel disease (IBD) in humans. Tables 11 and 12 show that daily administration of the IKK
inhibitor (compound 6) resulted in a statistically significant decrease in clinical and histological score when compared with untreated mice. Such results support the advantageous outcome afforded by the present invention in which inhibition of the IKK enzyme prevents and/ or ameliorates inflammatory diseases and disorders such as IBD.
EFFECT OF IKK INHIBITOR 4(2'-AMINOETHYL)AMINO- 1,8 DIMETHYLIMIDAZO(1,2-A) QUINOXALINE ON DISEASE INCIDENCE IN
THE MURINE MODEL OF OVALBUMIN-INDUCED INFLAMMATORY CELL
INFILTRATION IN THE LUNG OF SENSITIZED MICE
Inflammatory Cell Infiltration into the Lung of Ovalbumin-Challenged Mice Pulmonary inflammation with infiltration of eosinophils and other inflammatory cells is a hallmark of asthma and other allergic respiratory disorders. To determine whether an IKK inhibitor was efficacious in the in vivo treatment of respiratory disorders which afflict many patients, test compounds were administered in a murine model of pulmonary inflammation similar to that described by Kung et al. (Kung, T.T. et al., Int. Arch.
Allergy Immunol. 105:83-90, 1994).
In the pulmonary inflammation animal model, BALB/c mice were sensitized by an intraperitoneal injection of 0.1 mL alum-precipitated antigen containing 40 ~,g ovalbumin adsorbed to aluminum hydroxide gel on days 0 and 10. On day 14, animals received intranasal challenge with 100 ~g ovalbumin in 50 p1 saline (PBS). Mice were injected intraperitoneally with antigen to sensitize the animals prior to intranasal challenge to induce lung inflammation. Administration of the test compound was given on days 14 to 17. On day 18, bronchoalveolar lavage fluid (BAL) was collected for measurements of total inflammatory cell infiltration (eosinophils, monocytes, lymphocytes, and neutrophils). Table 13 presents the effect of 4(2'-aminoethyl)amino- 1,8-dimethylimidazo(1,2-a) quinoxaline (compound 6) on ovalbumin-induced inflammatory cell infiltration into the lungs of sensitized mice after daily administration of compound.
Test Compound Total InflammatoryStatistical Cells in BAL Significance vs.
Vehicle Control Vehicle (water) 5.8x10 1.2x10 Compound 6, 30 mg/kg, 2.8x10 1.3x10 P = 0.13 p.o.
Compound 6, 100 mg/kg, 2.2x10 0.3x10 P = 0.02 p.o. ~
'Statistical significance vs. untreated group, P<0.05 Ovalbumin-induced inflammatory cell infiltration in murine lung provides a model system for pulmonary inflammation, specifically asthma and other allergic respiratory disorders in humans. Compound 6, 4(2'-aminoethyl)amino- 1,8-dimethylimidazo(1,2-a) quinoxaline, was administered in a murine model of pulmonary inflammation for the treatment of inflammation and immune-related conditions. The results presented in Table 13 show that administration of compound 6 after ovalbumin challenge to sensitized mice resulted in a statistically significant decrease in total inflammatory cells in the lungs, as determined by measurements from bronchoalveolar lavage fluid when compared with untreated mice. These results support the advantages provided by the present invention in which inflammatory diseases or disorders, such as asthma and chronic obstructive pulmonary disease, are ameliorated by inhibiting IKK activity.
TNFa PRODUCTION ASSAY
THP-1 (human monocytic cell line) obtained from ATCC was cultured in RPMI-1640 supplemented with 10% FBS, sodium pyruvate, HEPES, 2-mercaptoethanol, Penicillin/Streptomycin. To a 96-well plate containing THP-1 cells (1.4x106/mL, 2.5x105 cells/well) in 180 p,L RPMI-1640 was added 20 ~,L of the test compound in 10% DMSO. Typically, test compound concentrations of 0.1-100 ~M were used in the assay. After one hour at 37°C, 20 ~,L of 1000 ng/mL lipopolysaccharide (LPS from Salmonella typhosa, Sigma) was added to each well. After an additional 6 hours at 37°C, the supernatants were collected following a 5 minute centrifugation of the plate to pellet the cells. The amount of TNFa in these supernatants was then measured using a TNFa-specific ELISA (Pharmingen). After subtracting out the amount of TNFa in a control that had not been treated with LPS, the percent inhibition was calculated versus a control that was treated with LPS but with no test compound added. ICSO values were calculated from the percentage inhibition at various doses. In the TNF-a production assay, compound 6 was determined to have an ICSO of 4 ~,M.
Compounds of Examples 12-19 demonstrated IC5o values of below 9 ~,M, with preferred and more preferred compounds having ICSO values of below 2 ~.M and 1 ~,M, respectively, in this assay.
TNFa-STIMULATED DEGRADATION OF hcBa IN THP-1 CELLS
TNFa stimulation of monocytic THP-1 cells leads to the proteolytic degradation of IxBa. Both an IKK-dependent phosphorylation and ubiquitin ligase-dependent ubiquitination of IxBa are essential steps in the TNFa-stimulated pathway targeting IKBa for proteolytic degradation by the proteosome.
THP-1 cells were suspended in RPMI-1640 supplemented with 10%
fetal bovine serum, preincubated for 60 mins with test agent, then stimulated for 15 mins with TNFa (100 ng/mL, R&D Systems). Total cell lysates were fractionated by sodium dodecylsulfate-polyacrylamide electrophoresis followed by Western blot analysis. IxBa was detected using a polyclonal antibody from Santa Cruz (catalog #sc-4094) and ECL reagents (Amersham). Films were scanned using a Kodak ID Image Analysis system t to quantitate the amount of IxBa. Compounds of formula (I) demonstrated up to 100% inhibition of the TNFa-induced degradation of IKBa in THP-1 cells at 10 p,M. In the IxB degradation assay, compound 6 had an ICSO of 5 ~,M upon measuring the TNFa-induced degradation of IKBa in THP-1.
LPS-INDUCED SERUM TNFa IN MICE
As a measure of activity against NF-KB-dependent TNFa production in vivo, test compounds were administered to BALB/c mice subsequently challenged with an intravenous dose of E. coli LPS (1 ~g in 100 p,L
phosphate-buffered saline). One hour after LPS challenge, blood was collected from the mice and the levels of TNFa in the serum measured by EIA (R&D Systems). Inhibition was calculated from control animals which received LPS challenge with no test compound. Compounds of formula (I) demonstrated inhibition of the LPS-induced serum TNFa levels in vivo in the range of about 30 to 65% at 10 mg/kg, p.o; in the range of about 70 to 90%
at 30 mg/kg, p.o.; and in the range of above 90% at 100 mg/kg p.o.
Compound 6 demonstrated inhibition of the LPS-induced serum TNF levels in vivo in the range of about 27-63% at 10 mg/kg, p.o.; in the range of about 53-89% at 30 mg/kg, p.o.; and in the range of about 83-92% at 50 mg/kg, p.o.
Accordingly, compounds of formula (I) have been tested and shown active as inhibitors of TNF-a and the NF-xB pathway.
METHODS OF PREPARATION RELATED TO FORMULA (I) COMPOUNDS
The inventive compounds of formula (I) can be prepared by methods such as those illustrated in the following Schemes I to V in this example.
Starting materials are commercially available or can be readily prepared by one of ordinary skill in the art, and/or modifications can be made to the methods of Schemes I to V by one skilled in the art, using known methods.
For all of the schemes and compounds, the groups R~, R2, R3 and R4 are as described herein for a compound of formula (I), unless otherwise indicated, and appropriate starting materials can be selected by one skilled in the field having the desired groups R~, RZ, R3 and R4. Groups designated R', as well as solvents, temperatures, pressures, and other reaction conditions, can be selected by one of ordinary skill in the art. For example, in these schemes chlorinating agents can include phosphorous oxychloride, catalytic agents can include metals such as Pd, and solvents can be selected from 1,2-dichlorobenzene, methylene chloride, DMF, THF, alcohols, ethers, dioxane, acetonitrile, water, mixtures of ethers and water, and the like.
Abbreviations For ease of reference the following abbreviations are used in the schemes and Examples herein:
Me = methyl Et = ethyl MeOH = methanol EtOH = ethanol i-PrOH = isopropanol Ph = phenyl Bz = benzyl DCM = dichloromethane DMF = dimethyl formamide DMSO = dimethyl sulfoxide NaOH = sodium hydroxide TEA or Et3N = triethylamine TFA = trifluoroacetic acid THF = tetrahydrofuran K2C03 = potassium carbonate Na2S203= sodium thiosulfate min = minutes) L = LITER
mL = milliliter ~,L = microliter G = GRAMS) mg = milligrams) mol = moles mmol = millimole(s) meq = milliequivalent RT = room temperature sat or sat'd = saturated aq. = aqueous TLC = thin layer chromatographyHPLC = high performance liquid chromatography LC/MS = high performance MS = mass spectrometry liquid chromatography/mass spectrometry NMR = nuclear magnetic resonancemp = melting point Definitions Of Terms Used In The Reaction Schemes in Example 11 The following are definitions of terms used herein and in the reaction schemes.
"Acetal, ketal, thioacetal or thioketal formation" are processes known in the art and illustrated in "Protective Groups in Organic Synthesis", Second Ed., T. W. Green and P. G. W. Wuts, John Wiley & Sons, New York, 1991, Chapter 4 and references therein, incorporated herein by reference.
"Acid halide formation" includes methods of converting a carboxylic acid to an acid halide. For example, this reaction can be performed with thionyl chloride, oxalyl chloride or bromide in the presence of DMF in DCM
and phosphorus trichloride or tribromide.
"Alkylation" includes all alkylation procedures such as alkylation of desired alcohol or ketone groups by treatment with organic or inorganic base in an appropriate organic solvent, followed by addition of an alkylating agent such as an alkyl, allyl or benzyl halide, mesylate or tosylate to the generated enolate, phenolate or thiophenolate.
"Aromatic substitution" includes all aromatic substitution methods known in the field including nucleophilic substitutions of aromatic halides by water in presence of sulfuric acid or trifluoroacetic acid, or by alkoxides, aryloxides, thioalkoxides or thioaryloxides in an inert organic solvent.
Copper salts can be used to promote the reaction of aryl halides with alkoxides, and Pd(0) salts can be used to promote the reaction with thioalkoxides.
"Aromatic halogenation" includes the addition of chlorine, bromine or iodine to an aromatic ring optionally with a catalyst, e.g. iron or a Lewis acid.
It also includes the reaction of N-chloro and N-bromoamides catalyzed by the addition of acids. For iodination, iodine can be used with copper salts, silver trifluoromethanesulfonate, thallium(I) acetate, or with an oxidizing agent such as nitric acid, iodic acid, sulfur trioxide or hydrogen peroxide.
Iodine monochloride can also bemused.
"Cross-coupling" includes all cross-coupling methods known by those skilled in the art. Such methods include the reaction of a vinyl or aromatic triflate, bromide or iodide with a tin (Stills-type), zinc, magnesium or boronate (Suzuki-type) derivative catalyzed by a palladium(0), palladium(II), nickel(0) or nickel(II) catalyst. Copper iodide, lithium chloride, zinc chloride or triphenylarsine, tris(2-furyl)phosphine or tris(2,4,6-trimethoxyphenyl)phosphine advantageously can also be added. When a boronic acid derivative is used, the reaction proceeds in the presence of an inorganic base such as potassium phosphate or carbonate or sodium carbonate. The cross-coupling reactions are performed in an inert organic solvent.
"Grignard type reaction" includes the addition of an organometallic compound to a carbonyl-containing compound. This includes addition of Grignard reagents, alkyl or aryllithiums, alkylzinc, alkylaluminum, organotitanium, organozirconium or organocerium compounds in an inert organic solvent such as ethyl ether, THF, DCM, benzene, toluene, or the like. Complexing of the ketone or the Grignard reagent with cerium halides, perchlorate salts or tetraalkylammonium halides can sometimes be advantageous to improve the addition reaction. The term "Grignard type reaction" is also intended to include the addition of a Grignard reagent to an acid chloride that has been first reacted with tributylphosphine to form the corresponding phosphonium salt. The reaction is performed in an inert .
organic solvent.
"Hydrolysis" includes the hydrolysis of esters and carbonyl protecting groups. For example, methyl or ethyl esters can be removed with aqueous ' solutions of sodium or potassium alkoxides in THF or EtOH. The hydrolysis of tent-butyl esters advantageously is carried out under acidic conditions such as 90% trifluoroacetic acid or 6N hydrochloric acid in solvents such as THF or DCM. Allyl esters can be removed with Pd(0) catalyst in an organic solvent. Silyl esters such as trimethylsilylethyl esters can be cleaved with tetrabutylammonium fluoride in THF. The hydrolysis of ketals and acetals can be carried out under acidic conditions such as 1 N hydrochloric acid, 80% acetic acid or p-toluenesulfonic acid in solvents such as THF or acetone.
"Imine formation" procedures are known in the field. For example, a ketone can be reacted with an amine in presence of an acid with or without a drying agent. Various inorganic and organic acids can be used, such as zinc chloride, titanium chloride, hydrochloric acid, sulfuric acid, trifluoroacetic acid, acetic acid, p-toluenesulfonic acid and the like, in solvents such as DCM, EtOH, benzene, toluene, THF, DMF and the like.
Scheme I
Benzo-imidazo-quinoxalines NHZ ~ ~ NH O
/ /
~R4) ~ R3)~NHZ ~R4) ~ ( 3)m NH O
~ N\ CI ~ ~ N\ NH-CHZCH(OR)2 ~ ~ N N
/ / ~ ~/// ~ ~ ~///
(R4) ~ (R3)m N CI (Rq)n (R3)m N CI (Rq)n (R3)m N CI
g 4a 5a N\ CI ~ ~ N\ NH-CHZCH(OR)Z ~ ~ N N
/ / ~ ~/// N~ ~///
NH-R N NH-R~
(R4)n (R3)m N NH-RZ (R4)n (R3)m 2 (R4)n (R3)m ' 4b 5b la Benzo-imidazo-quinoxalines of formula la (wherein Y~ of formula (I) is N, X is CRS and R~ is hydrogen) can be prepared as above. Substituted 2,3-diaminonaphthalenes 1 are reacted with, for example, diethyl oxalate or oxalyl chloride to give annulated quinoxalinediones 2. Diones 2 are reacted with a chlorinating agent to give dichlorides 3. Dichlorides 3 are reacted with amine reagents comprising aminoacetaldehyde acetal and an appropriate primary amine (R2-NH2), and cyclized, wherein the order of reactivity can be adjusted depending upon chlorine atom reactivity.
For example, dichlorides 3 can first be reacted with an aminoacetaldehyde acetal to give amino-chloro derivatives 4a. The amino-chloro derivatives 4a can be cyclized to give the chloro-benzo-imidazoquinoxaline 5~ which can, in turn, be reacted with various primary amines (R2-NH2) to give compounds of formula (la).
Alternatively, where the undesired chlorine atom has greater reactivity (e.g., due to substituents R3 and R4), the order of addition of the amine reagents can be reversed, as shown for structures 4b and 5b.
Dichloride 3 is reacted with primary amines (R2-NH2) to give amino-chloro derivatives 4b, which are then reacted with an aminoacetaldhyde acetal to give diamino compounds 5b, which are then cyclized to give the compound of formula la.
Exemplary aminoacetaldehyde acetals comprise amino-acetaldehyde, dimethyl acetal, or aminoacetaldehyde, diethyl acetal.
Cyclization is typically performed under acidic conditions.
Scheme II
1-Substituted benzo-imidazo-guinoxalines R~
R~
\ \ N~ CI \ \ N\ NH % \ \ N N
/ / ~ ~ ~/// ~ ~///
(R4) ~ / N CI (R4)n (R3)m N CI (R4)n (R3)m N CI
(R3)m 3 6a 7 R~
Rq \ \ Nw CI \ \ N\ NH ~ \ \ N N
/ / ~ ~/ / / N_ \ ~ / /
NH-R ~ _ (R4) ~ ( )m N NH-RZ (R4)n (R3)m Z (R4)n (R3)m N NH R2 4b gb Ib 1-Substituted benzo-imidazo(1,2-a)quinoxalines of formula Ib (wherein Y1 of formula (I) is N, X is CR1 and R1 is substituted lower alkyl) can be prepared as shown in Scheme II. Dichloro compounds 3 are prepared as shown in Scheme I and reacted with substituted propargylamines (R1-C---C-CH2-NH2) to give amino-chloro derivatives 6a, which are cyclized to 1-substituted chloro-benzo-imidazoquinoxalines 7.
Suitable primary amines are reacted with 7 to give compounds of formula Ib.
Alternatively, the order of reactivity can be adjusted, wherein dichloro compounds 3 are first reacted with suitable primary amines to give derivatives 4b, as in Scheme I, and then reacted with propargyl amines to amino derivatives 6b, which can be cyclized as above to give compounds of formula Ib.
Scheme III
Benzo-Pyrazolo-Quinazolines R I ~N
\ \ \ Ns / / 0 ~ \ , N
(R3) ~ (R4)n \ / ~ n N / (R3)m (R4)n C02Me O Ts I \\N I \\N
\ H ~ \ \
~.//~/.~ /~/~ _ _ (R3)m (R4)n C~2H (R3)m (R4)n N C U
11 ~ 11b I \N ' \N ' ~N
\ \ ~ N' \ \ ~ N' \ \ N, (R3)m (R4)n NH O (R3)m (R4)n N CI (R3)m (R4)n N NH-R2 12 13 Ic Benzo-pyrazolo-quinazolines of formula Ic (wherein Y~ of formula (I) is N, X is CHR~ and R~ is as defined above) can be prepared as shown in Scheme III. Reagents 8c and 9c are condensed in the presence of catalyst in a Stille-type reaction to give coupled product 10, which is hydrolyzed to give compound 11. Treatment of 11 with, for example, diphenyl phosphoryl azide followed by heat, produces an intermediate isocyanate 11 b, which will spontaneously cyclize under the reaction conditions to give compound 12.
Treatment of 12 with a chlorinating agent gives chloro compound 13, which can be reacted with suitable primary amines (R2-NH2) to give compounds of formula Ic.
Scheme Illa \ \ NH2 \ \ ~ \ \
~R3) ~~/~R4 n OH R ~~~~ ~ OH ~R3~ ~~~~ ~ O\
31m ~R4O ~ ~ 4~n 8a gb 8 Rq R~ ~ \N R~
~N ~ O; S ~ Sn / \N
H p ~ \ ~ N
/ Ts ga 9b 9 Reagents 8 and 9 for Scheme III above can be prepared as shown in Scheme Illa. Substituted 3-amino-2-naphthoic acids 8a can be converted to substituted 3-iodo-2-naphthoic acids 8b by, for example, diazotization followed by treatment with an iodide salt. Esterification of compound 8b produces 3-iodo-2-napthoic acid esters 8. 4-Substituted pyrazoles 9a can be treated with a p-toluenesulfonating agent, such as p-toluenesulfonyl chloride, to give p-toluenesulfonamide 9b. Deprotonation of compound 9b with a strong base, such as t-butyl lithium, and treatment with a stannylating agent, such as trimethyl chloro stannane, gives reagent 9.
Scheme IV
Benzo-imidazo-quinolines O N
\ \ ~ ~ \ \ B\O ~ \ \ ~N
W ~~~/ Ow ( 3)m (R4)n p~ (Ra)n (~s)m ~R4)n (~3 m O C~ O
8 ~OB~B p~ 14 ~('N\ N 15 \N~ N~ \N~
\ \ ~N ~ \ \ N ~ ~ \ \ N
// ~/ OH R / R// N.Boc // //
(R4)n (Rs)m ~ ( 4)n ( 3)m ~ (R4)n (R3)m NH2 O H
16 1~ 18 N~ \N~ \N~
N
\ \ ~ ~ \ \ ~ N ~ \ \ \ N
/ N O ~// /~/~ ~ CI // ° / ~ R
(R4)n (Rg)m ~ (R4)n ~R3~\N (R4)n ~~R~ ~N~\[vJH' O H
~ N-a N~ 'N 19 2p Id Benzo-imidazo-quinolines of formula Id (wherein X of formula (I) is NR~ and R~ is methyl) can be prepared as shown in Scheme IV. Substituted 3-iodo-2-naphthoic acid esters 8 prepared as in Scheme Illa are converted to boronate derivatives 14 using catalyst and a reagent such as bis(pinacolato)diboron. Condensation of compound 14 with 1-methyl-5-bromoimidazole and catalyst in a Suzuki-type reaction gives coupled ester 15. Ester 15 is hydrolyzed to give acid 16, which is converted via treatment with diphenylphosphoryl azide (through an intermediate isocyanate -- see 11 b) and t-butanol into protected amine 17. Acid treatment converts 17 to free amine 18, which is heated in a high-boiling point inert solvent such as 1,2-dichlorobenzene with carbonyldiimidazole to give cyclized product 19.
Treatment with a chlorinating agent converts compound 19 to the chloro derivative 20, which can be converted by treatment with suitable primary amines (R2-NH2) to give compounds of formula Id.
Scheme V
BENZO(G)THIAZOLO(4,5-C)QUINOLINES
O SAN
\ \ B~O ~ \ \
O
(R4)n~~~~ \ S~ (R4)n( ) /~COOCH3 N
s~ s~ s~
N ~ N ~ N
a R ~~~/~COOH ~ R ~~ ~ /~ NH'Boc R ~/ ~ /~ NHZ
( a) (R3)m ( a) (R3)m ( a) (R3)m S~ S-N N
O R ~/ / NH O R ~/ /~ N CI
_ ( a) (R3)m ( a) (R3)m N~ N 25 26 N
~~~ / \~
(R4)n (R3)m N NH-R
1e Benzo-thiazolo-quinolines can be prepared as shown above in Scheme V. Substituted 3-boronato-2-naphthoic acid ester 14 is condensed with 5-bromothiazole in a Suzuki-type reaction, catalyzed by a metal such as Pd, to give coupled product 21. The ester 21 is hydrolyzed under standard conditions to give acid 22, which is then converted via treatment with diphenylphosphoryl azide (through an intermediate isocyanate similar to 11 b) and t-butanol into the protected amine 23. Acid treatment can convert compound 23 to the free amine 24, which is heated in a high-boiling inert solvent such as 1,2-dichlorobenzene with carbonyldiimidazole to give cyclized product 25. Compound 25 can be converted to the chloro derivative 26 by treatment with a chlorinating agent, and compound 26 is converted by treatment with suitable primary amines (R2-NH2) to give the compound of formula 1e.
The.following preparations illustrate embodiments of the invention and are not intended to limit the scope of the claims. The reagents and starting materials of Preparations 1-19 are useful in synthesizing compounds of formula (I), or salts thereof, such as illustrated in Schemes I-V. In the following preparations, anhydrous reactions were performed under an atmosphere of nitrogen or argon using either commercially available dry solvents or freshly distilled solvents. Melting points were determined in an open capillary tube with a Thomas-Hoover melting point apparatus. Column chromatography was performed using EM Soience silica gel 60 (230-400 mesh) with the designated solvent system as eluant. Thin-layer chromatography was done on E. Merck silica gel 60 F2sa plates (0.5 mm).
HPLC purity determinations were done using either an HP 1090 DR5 with a diode array detector and a Waters Nova-Pak C18 column (3.9 x 150 mm), or a Shimadzu LC-10AS with a SPD-10AV UV-Vis detector and one of the following columns: YMC Combiscreen ODS-A (4.6 x 50 mm); HP Zorbax SB-C18 (4.6 x 750 mm). Infrared spectra and ~HNMR spectra were recorded and chemical shifts are expressed in parts per million (ppm or 8) with the solvent in use as internal standard. Coupling constants are given in Hertz and multiplets are designated as follows; singlet (s), doublet (d), triplet (t), quartet (q), muliplet (m), and broad (br). Low resolution mass spectra were determined on a Finnigan Matt TSQ-7000 triple stage quadrapole spectrometer (positive/negative ESI) operated in the negative ion mode.
Preparation of Reagents and Starting Materials for the Preparation of Compounds of Formula (I) Preparation 1 1,4-Dihydrobenzo[g]guinoxalin-2,3-dione H
N O
/ /
N O
H
A mixture of 2,3-diaminonaphthalene (2.87 g, 18.14 mmol) and diethyl oxalate (30 mL, 223 mmol) was heated to reflux for 14 hours, cooled to RT and filtered. The residue was washed with EtOH and dried in vacuo to give the title compound as a brown solid (3.15 g, 82%); mp > 350 °C;
IR
(KBr, cm -~) 3045, 2942, 2869, 1716, 1642, 1406, 877; ~H NMR (DMSO) s 12.11 (s, 2H), 7.84-7.81 (m, 2H), 7.54 (s, 2H) 7.39 (dd, J = 6.3, 3.0, 2H);
LC/MS 92.5% (220 nm), m/z (M + H+) 213.
Preparation 2 2,3-Dichlorobenzo[g]'auinoxaline NCI
/ /
N CI
One gram (1 g; 4.72 mmol) of 1,4-dihydrobenzo[g]quinoxalin-2,3-dione was stirred in 2 ml of phosphorus oxychloride for 5 hours at reflux.
The mixture was concentrated by evaporation and dried under high vacuum.
A saturated K2C03 solution was carefully added to the residue, and the solid was filtered off and washed with water to afford the title compound as a brown solid (1.00 g, 85%); mp 239-242 °C; IR (KBr, cm ~) 1200, 1109, 998, 886, 748; ~H NMR (DMSO) b 8.78 (s, 2H), 8.31-8.28 (m, 2H), 7.75-7.73 (m, 2H).
Preparation 3 2-Chloro-3-(hroparqylamino benzo[g]Ig~uinoxaline \ \ N\ N
/ /
N~ CI
A mixture of 2,3-dichlorobenzo[g]quinoxaline (0.634 g, 2.55 mmol), propargylamine (0.21 ml, 3.05 mmol) and TEA (0.53 mL, 3.83 mmol) in 15 mL of dioxane was heated to reflux for 4.5 hours. After evaporating the resulting mixture under vacuum, the crude product was chromatographed (CH2C12) to afford the title compound as a yellow solid (0.496 g, 73%); mp 169-172 °C; IR (KBr, cm -~) 3412, 3283, 3235, 1570, 1508, 1335; ~H NMR
(DMSO) 8 8.44 (s, 1 H), 8.26 (s,1 H), 8.16-8.06 (m, 3H), 7.58-7.54 (m, 1 H), 7.51-7.48 (m, 1 H), 4.28 (dd, J = 6.1, 2.5, 2H), 3.12 (t, J = 2.5, 1 H); LC/MS
97.8% (220 nm), m/z (M + H+) 268.
Preparation 4 4-Chloro-1-methylbenzo[aJimidazo[1,2-a]quinoxaline \ \ N rN
N CI
2-Chloro-3-(propargylamino)benzo[g]quinoxaline (0.420 g, 1.57 mmol) was treated with 4 mL of concentrated HZS04 and the mixture was stirred at 80 °C for 1 hour, cooled to RT and poured into ice water.
The mixture was cautiously neutralized with aqueous NaOH, and the resulting precipitate was filtered, washed with water, and dried in vacuo to give the title compound as a beige solid (0.124 g, 30%); mp 221-223° C; IR
(ICBr, cm -~) 1538, 1479, 1456, 1398, 1101, 919;'H NMR (DMSO) 8 8.79 (s, 1H), 8.53 (s, 1 H), 8.23 (d, J = 8.1, 1 H), 8.13 (d, J = 8.5, 1 H), 7.69-7.59 (m, 3H), 3.04 (s, 3H); LC/MS 100% (220 nm), m/z (M + H+) 268.
Preparation 5 3-lodo-2-napthoic acid I
/ / OH
I
O
To a beaker of 3-amino-2-napthoic acid (6.01 g, 80% pure; 25.69 mmol), was added a solution of concentrated HCI (10.0 mL) and water (15.0 mL). After the resulting pink paste was stirred for 17 min, it was cooled to 0°C and treated with a solution of water (10 mL) and NaNO2 (2.54 g, 36.81 mmol) drop-wise (over 8 min). One minute later, the brown reaction mixture was treated with a cooled (0°C) water (10.0 mL) solution of KI (10.0 g, 60.24 mmol) drop-wise (over 12 min). The cooling bath was removed, water (15 mL) was added, and the reaction mixture was stirred for 10 min at RT and heated at 95°C for 65 min. It was then diluted with water (50 mL) and extracted with EtOAc (250 mL). The organic layer was washed with water (50 mL) and brine, dried (MgS04), filtered, and evaporated in vacuo. The resultant crude material was submitted to flash chromatography (sample was loaded as a silica gel mesh; EtOAc) to afford the title compound as an iodine colored fluffy solid weighing 6.50 g. ~H NMR (DMSO, 8 = 2.50):
13.36 (br s, 1 H), 8.63 (s, 1 H), 8.37 (s, 1 H), 8.05 (d, J = 7.9, 1 H), 7.93 (d, J =
8.0, 1 H), 7.67-7.60 (m, 2H).
Preparation 6 Methyl 3-lodo-2-napthoate / / o w To 3-iodo-2-napthoic acid (Preparation 5) (6.50 g), were added MeOH (100 mL) and concentrated H2S04 (2 mL), and the resultant heterogeneous mixture was refluxed for 13 hr. The reaction mixture was allowed to cool to RT, then neutralized with NaHC03 (6.0 g), and the volatile component was removed in vacuo. The residue was partitioned between water (50 mL) and EtOAc (300 mL). The organic layer was washed with Na2S203 solution (4.2 g + 50 mL of water) and brine, dried (MgS04), filtered and evaporated in vacuo. The resulting crude material was submitted to flash chromatography (sample was loaded as a silica gel mesh, 10%
EtOAc/hexanes) to isolate the title compound as a light-yellow solid (5.50g, 2 steps combined yield of 69%). ~H NMR (DMSO, ~ = 2.50): 8.66 (s, 1 H), 8.39 (s, 1 H), 8.06 (d, J = 8.0, 1 H), 7.95 (d, J = 8.0, 1 H), 7.69-7.62 (m, 2H), 3.91 (s, 3H). (DGI) m/z (M+H)+ = 313Ø Anal. calculated for C~2HgIO2: C, 46.18; H, 2.91. Found: C, 46.28; H, 2.85.
Preparation 7 4-Methyl-1-(4-tolunesulfonyl)pyrazole \N
N
~~S
p-TsCI (9.81g,51.46 mmol) was added in batches over a few minutes to a CH2C12 (100 mL) solution of 4-methylpyrazole (4.00 g, 48.72 mmol) and pyridine (6.0 mL, 74.18 mmol). The reaction mixture was stirred for 95 min, then diluted with CH2C12 (250 mL) and washed with NaHC03 solution [a mixture of sat'd NaHC03 solution (20 mL) and H20 (40 mL)], and water (60 mL). The organic layer was dried (MgS04), filtered and evaporated in vacuo.
The resulting crude material was purified by flash chromatography (sample was loaded as a silica gel mesh; CH2C12) to afford the title compound as a white solid (10.88 g, 95%). ~H NMR (CDC13, 8 = 7.26): 7.87 (d, J = 8.4, 2H), 7.84 (s, 1 H), 7.54 (s, 1 H), 7.32 (d, J = 8.40, 2H), 2.41 (s, 3H), 2.06 (s, 3H).
(ESI) m/z (M+H)+ = 236.7. Anal. calculated for C~~H~2N202S: C, 55.91; H, 5.12; N, 11.86. Found: C, 55.81; H, 4.94; N, 11.76.
Preparation 8 4-Methy~4-tolunesulfonyl~5-trimethylstannylp razole ~Sn NON
I
TS
t-BuLi (1.7 M/pentane) was added over 10 min to a cooled (-78 °C) THF (60 mL) semi-suspension of 4-methyl-1-(4-tolunesulfonyl)pyrazole (Preparation 7) (6.01 g, 25.43 mmol). After the mixture.was stirred for 10 min, it was treated drop-wise (over 20 min) with Me3SnCl (28.0 mL of 1.0 M/THF, 28.0 mmol). The resulting mixture was stirred for 4.3 hr while the bath was allowed to thaw to -55 °C, and then for 70 min. at RT. The reaction mixture was diluted with EtOAc (250 mL) and washed with water (50 mL) and brine, dried (MgS04), filtered, and evaporated in vacuo. The crude material was submitted to flash chromatography (sample was loaded as a silica gel mesh; 15-20% EtOAc/hexanes) to afFord the title compound as a dense white solid (4.406 g, 43%). Non-consumed pyrazole of Preparation 7, above, was also retrieved (1.954 g, 33%). ~H NMR of the title compound (DMSO, 8 = 2.50): 7.74 (s, 1 H), 7.70 (d, J = 8.3, 2H), 7.45 (d, J =
8.3, 2H), 2.38 (s, 3H), 2.08 (s, 3H; satellite peaks due to Sn-H with J =
4.5), 0.45 (s, 9H; satellite peaks due to Sn-H with J = 59.8 and 57.3). (ESI) m/z (M+H)+ = 400.9.
Preparation 9 Methyl 3-(4-meth I-1- 4-toluenesulfonyl~pyrazol-5-yl)-2-naphthoate I \N
\ \ N~
TS
C02Me DMF (26.0 mL) was added into a mixture of methyl-3-iodo-2-napthoate (Preparation 6) (2.017 g, 6.463 mmol), 4-methyl-1-(4-tolunesulfonyl)-5-trimethylstannylpyrazole (Preparation 8) (2.895 g, 7.254 mmol), Pd2dba3 (236 mg, 0.258 mmol), Ph3As (317.2 mg, 1.036 mmol), and Cul (130.7 mg, 0.686 mmol). After nitrogen was bubbled through the heterogeneous mixture for a few minutes, it was stirred at RT for 7 min and at 90°C for 12 hr. The volatile component was removed in vacuo, and the resultant viscous residue was submitted to flash chromatography (sample was loaded as a silica gel mesh; 0-10 % EtOAclCH2Cl2) to afford the titled compound as a yellow solid (1.485 g, 55%). ~H NMR (DMSO, 8 = 2.50): 8.73 (s, 1 H), 8.23 (d, J = 7.7, 1 H), 8.05 (d, J = 7.7, 1 H), 7.83 (s, 1 H), 7.81 (s, 1 H), 7.77-7.71 (m, 2H), 7.50 (d, J = 8.2, 2H), 7.38 (d, J = 8.2, 2H), 3.66 (s, 3H), 2.38 (s, 3H), 1.77 (s, 3H). (ESI) m/z (M+H)+ = 421Ø
Preparation 10 3-(4-methypyrazol-5-yl -2-na~hthoic acid THF (12.0 mL), MeOH (8.0 mL) and NaOH solution (7.5 mL of 1.0 N/H20) were added to methyl-3-(4-methyl-1-(4-tolunesulfonyl)pyrazol-5-yl)-2-napthoate (Preparation 9) (1.240 g, 2.949 mmol), and the reaction mixture was heated at 80°C for 4.2 hr. It was then diluted with water (20 mL), acidified to pH ~ 4.5 with 1 N HCI, and extracted with EtOAc (75 ml, 2x). The combined organic layer was washed with brine, dried (MgS04), filtered, and evaporated in vacuo. The resulting crude material was submitted to flash chromatography (sample was loaded as a silica gel mesh; 10%
I \N
Hi / /
MeOH/CH~C12) to isolate the title compound as faint-yellow solid (300 mg, 40%). ~ H NMR (DMSO, 8 = 2.50; one tautomer was observed): 12.70 (br s, 2H), 8.37 (s, 1 H), 8.08 (d, J = 7.9, 1 H), 8.01 (d, J = 8,0, 1 H), 7.93 (s, 1 H), 7.65-7.58 (m, 2H), 7.47 (s, 1 H), 2.01 (s, 3H). (ESI) mlz (M+H)+ = 252.99.
Preparation 11 1-Methylbenzo(g)pyrazolo(1,5-c)quinazolin-5-one \N
\ \ ~ N' N ~O
H
Et3,N (300 p,L, 2.152 mmol) and (Ph0)2PON3 (440 pL, 2.064 mmol) were added to a C6H6 (10.0 mL) suspension of 3-(4-methylpyrazol-5-yl)-2-naphthoic acid (Preparation 10) (257 mg, 1.019 mmol), and the mixture was heated at 50°C for 2 hr. The volatile component was removed in vacuo, and the resulting yellow solid was dissolved in o-dichlorobenzene (8.0 mL) and heated at 150°C for 4 hr. During the latter heating, there was a gradual evolution of gas accompanied by the formation of a suspension. The reaction mixture was allowed to cool to RT, and the precipitate was filtered and washed with copious ether to afford the title compound as a fluffy light-yellow solid (170.8 mg, 67%).'H NMR (DMSO, s = 2.50): 11.86 (s, 1H), 8.57 (s, 1 H), 8.13 (d, J = 8.2, 1 H), 7.99 (s, 1 H), 7.92 (d, J'= 8.3, 1 H), 7.22 (s, 1 H), 7.56 (app t, J = 7.21, 1 H), 7.49 (app t, J = 7.48, 1 H), 2.60 (s, 3H):
(ESI) m/z (M+H)+ = 250.00.
Preparation 12 1-Methyl-5-chlorobenzo(g)pyrazolo 1,5-c)auinazoline \N
\ \ ~ N' N "CI
PhNEt2 (1.50 mL) and POC13 (15.0 mL) were added to 1-methylbenzo(g)pyrazolo(1,5-c)quinazolin-5-one (Preparation 11) (184.7 mg, _78-0.741 mmol), and the resulting heterogeneous mixture was heated at reflux for 46 hr. During heating, the suspension (the starting material), gradually started to dissolve. The dark-green reaction mixture was filtered to remove non-consumed starting material (16.2 mg, 8.8%), and the filtrate was exposed to high vacuum to remove most of the POC13. The residue was partitioned between water (30 mL) and EtOAc (70 mL). The organic layer was washed with brine, dried (MgS04), filtered, and evaporated in vacuo.
The crude material was submitted to flash chromatography (sample was loaded as a silica gel mesh; 20% EtOAc/hexanes) to afford the title chloride as an off-white solid (153 mg, 77%).'H NMR (DMSO, s= 2.50): 8.80 (s, 1H), 8.46 (s, 1 H), 8.29-8.27 (m, 1 H), 8.19 (s, 1 H), 8.17-8.15 (m, 1 H), 7.70-7.65 (m, 2H), 2.70 (s, 3H). (ESI) m/z (M+H)+ = 267.98.
Preparation 13 Methy~4,4,5,5-tetramethyl-1,3.2-dioxaborolan-2-yl)-2-naphthoate o~
To a solution of 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi-1,3,2-dioxaborolane (30.0 g, 0.118 mol) and methyl 3-iodo-2-naphthoate (Preparation 6) (33.5 g, 0.107 mol) in DMSO (600 mL) were added PdCl2(dppf) (2.62 g, 0.21 mmol) and KOAc (31.51 g, 0.321 mol). The mixture was degassed and purged with N2, and then heated at 85°C for 18 hours. The brown reaction mixture was cooled to RT, diluted with water (1.5 L), and extracted with EtOAc (2.5 L, then 2x500 mL). The combined organic layer was washed with brine (9x500 mL), dried over MgS04, filtered and evaporated in vacuo. The resulting crude material was submitted to flash chromatography (2.0% MeOH/CHC13), affording the title compound as a yellow solid (19.5 g, 58%). ~ H NMR (CDC13): 8.50(s, 1 H), 7.99(s, 1 H), 7.90(d, J=8.1, 1 H), 7.86(d, J=8.1,1 H), 7.57(m, 1 H), 7.54(m, 1 H), 3.98(s, 3H), 1.47(s, 12H). (ESI) m/z (M+H)+ = 313.16 Preparation 14 Meth rLl-3-~1-methyl-imidazol-5-~ -2-naphthoate N-l \ .~ ~ N
/ O~
O
To a mixture of methyl-3-(4,4,5,5,-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-naphthoate (Preparation 13) (15.37 g, 49.3 mmol) and 5-bromo-1-methyl-1 H-imidazole (9.06 g, 49.3 mmol) in toluene/EtOH (350 mL/36 mL) were added Pd(PPh3)4 (11.37 g, 9.84 mmol), Na2C03 (20.9 g, 197.2 mmof) and water (106 mL). The mixture was degassed, purged with N2, and heated to reflux for 20 hours. It was then cooled to RT, neutralized with HCI
(1.0 N, 100 mL), and concentrated in vacuo. The residue was partitioned between water (300 mL) and EtOAc (1 L). The organic layer was washed with water (2 L) and brine, dried over MgSO4, filtered and evaporated in vacuo. The resulting crude material was submitted to flash chromatography (1.5% MeOH/CHC13), furnishing the title compound as a light-yellow solid (9.5 g, 72%). ~ H NMR(CDCI3): 8.53(s, 1 H), 7.99(d, J=8.1, 1 H), 7.80(d, J=8.1, 1 H), 7.77(s, 1 H), 7.56(m, 1 H), 7.54(m, 1 H), 7.54(s, 1 H), 6.94(s, 1 H), 3.73(s, 3H), 3.29(s, 3H). (ESI) m/z (M+H)+ = 267.11.
Preparation 15 3-(1-Methyl-imidazol-5-yl -2-naphthoic acid N
\ \ \ N
/ OH
O
A solution of methyl-3-(1-methyl-imidazol-5-yl)-2-naphthoate (Preparation 14) (8.5 g, 32 mmol) in THF/MeOH (3/2, 120 mL) was treated with aqueous NaOH (1.0 N, 48 mL). After 20 hours at RT, it was neutralized with aqueous HCI (1.0 N, 20 mL). The solvent was evaporated in vacuo.
The solid residue was treated with MeOH (5 mL), then evaporated again.
The resulting crude material was purified by flash chromatography (5%
MeOH/EtOAc) affording the title compound as a pale-yellow solid (6.0 g, 74%). ~ H NMR(CDC13): 8.34(s, 1 H), 7.95(d, J=8.1, 1 H), 7.90(d, J=8.1, 1 H), 7.72(s, 1 H), 7.53(s, 1 H), 7.52(m, 1 H), 7.50(m, 1 H), 6.83 (s, 1 H), 3.16(s, 3H).
(ESI) m/z (M+H)+ = 253.10.
Preparation 16 1,1-Dimethylethy~(1-methylimidazol-5-y,-2-naphthyl~carbamate N-\ \ \ N
_ BOC
N
I
H
To a mixture of 3-(1-methyl-imidazol-5-yl)-2-naphthoic acid (Preparation 15) (1.0 g, 3.95 mmol) and Et3N (1.1 mL, 7.91 mmol) in 20m1 t BuOH was added diphenylphosphorylazide (1.63 g, 5.93 mmol). After 40 minutes at 80°C, the mixture was cooled to RT. The slurry was diluted with EtOAc (300 mL), and washed once with water (50 mL) and three times with brine. The organic layer was dried over MgS04, filtered, and evaporated in vacuo. The crude material was submitted to flash chromatography (0.5%
MeOH/EtOAc) afFording the title compound as a pale-yellow solid (0.67 g, 51 %). ~ H NMR(CDC13): 8.34(s, 1 H), 7.95(d, J=8.1, 1 H), 7.90(d, J=8.1, 1 H), 7.72(s, 1 H), 7.53(s, 1 H), 7.52(m, 1 H), 7.50(m, 1 H), 6.83 (s, 1 H), 3.16(s, 3H), 1.43(s, 9H). (ESI) m/z (M+H)+ = 324.15 Preparation 17 5~3-Amino-2-nalahth~rl)-1-methylimidazole N
A solution of 1,1-dimethylethyl-3-((1-methylimidazol-5-yl)-2-naphthyl)carbamate (Preparation 16) (1.0 g, 2.98 mmol) in TFA/CH2C12 (1:10, 50 mL) was stirred at RT for 18 hours. After concentration, the residue was diluted with EtOAc (200 mL), washed with aqueous NaHC03 (100 mL) and brine. The organic layer was then dried over MgS04, filtered and evaporated in vacuo. .The crude material was submitted to flash chromatography (5% MeOH/EtOAc) affording the title compound as a light yellow solid (0.49 g, 70%). ~H NMR(CDC13): 7.65(d, J=8.1, 1H), 7.59(d, J=8.1, 1 H), 7.57(s, 1 H), 56(s, 1 H), 7.36(m, 1 H), 7.22(m, 1 H), 7.13(s, 1 H) 7.03 (s, 1 H), 3.96(b, 2H), 3.46(s, 3H). (ESI) m/z (M+H)+ = 224.08 Preparation 18 1-methyl-4,5-dihydrobenzo~g~imidazo 4,5-c)guinolin-4-one N
N
N O
H
A mixture of 5-(3-amino-2-naphthyl)-1-methylimidazole (Preparation 17) (0.48 g, 2.14 mmoi) and 1,1'-carbonyldiimidazole (0.42 g, 2.57 mmol) in o-dichlorobenzene (22 mL) was heated at 180°C for 5 hours. The suspension was cooled to RT, filtered, and dried under vacuum, affording the title compound as a light yellow solid (0.22 g, 42%). ~ H NMR(DMSO):
11.57(s, 1 H), 8.71 (s, 1 H), 8.15(s, 1 H), 8.10(d, J=8.4, 1 H), 7.89(d, J=8.4, 1 H), 7.84(s, 1 H), 7.53(m, 1 H), 7.46(m, 1 H), 4.30(s, 3H). (ESI) m/z (M+H)+
_ 250.08.
Preparation 19 1-Meth~~l-4-chlorobenzo(g)imidazo 4,5-c)auinoline N-~ \ ~ N
/ N CI
To a mixture of 1-methyl-4,5-dihydrobenzo(g)imidazo(4,5-c)quinolin-4-one (Preparation 18) (200 mg, 0.80 mmol) and PhNEt2 (2.5 mL, 1.6 mmol) was added POC13 (8 mL). The mixture was then heated to reflux for 4 hours.
After cooling, excess POC13 was removed under vacuum. The residue was diluted with EtOAc (150 mL), and treated with NaHC03 (1 g) to neutralize the acid. The organic layer was washed with brine, dried over MgS04, filtered and evaporated in vacuo. The crude material was submitted to flash chromatography (EtOAc) affording the title compound as a light yellow solid (0.18 g, 90°l°). ~ H NMR(CDC13): 8.61 (s, 1 H), 8.57(s, 1 H), 8.01 (d, J=8.8, 1 H), 7.98(d, J=8.8, 1 H), 7.89(s, 1 H), 7.57(m, 1 H), 7.54(m, 1 H), 4.35(s, 3H).
(ESI) m/z (M+H)+ = 268.08.
Examples 12-19 provide compounds as described herein.
1-METHYL-4-METHYLAMINOBENZO[G]IMIDAZO[1,2-A]QUINOXALINE
\ \ N iN
/ ~ i N N
H
To a solution of 4-chloro-1-methylbenzo[g]imidazo[1,2-a]quinoxaline (0.063 g, 0.236 mmol) (Preparation 4 in Example 11) in 4 mL of THF was added MeNH2 (40% in H20, 0.16 mL, 1.88 mmol). The reaction tube was sealed and the mixture stirred at 80°C for 18 hours. The cooled mixture was then taken up in EtOAc, washed with water and brine, dried (Na2S04) and evaporated. The resulting residue was recrystallized using i-PrOH to give Example 12 as beige needles (0.043 g, 69%); mp 201-202 °C, IR
(KBr, cm -~) 3324, 1575, 1557, 1411, 1121; ~H NMR (DMSO) 8 8.62 (s, 1H), 8.10 (s, 1 H), 8.08 (d, J = 8.1, 1 H), 7.94 (d, J = 8.1, 1 H), 7.77 (br d, J = 4.5, 1 H), 7.49-7.45 (m, 2H), 7.35 (s, 1 H), 3.06 (d, J = 4.6, 3H), 2.98 (s, 3H); MS
(~ESI, M + H+) m/z 263; HPLC: 99.5% (230 nm); HRMS calculated for C~6H~4N4:
262.1219; found 262.1226. Inhibition of IKK-1 activity was measured using the assay of Example 2, where the inhibitory potential of the compound of Example 12 resulted in an IC5o of 0.23 p,M.
1-METHYL-4-(2-N-METHYLAMINOETHYLAMI NO)BENZO[G]IM IDAZO[1,2 A]QUINOXALINE HYDROCHLORIDE
\ \ N rN
~NHMe.HCI
N N
H
To a solution of 4-chloro-1-methylbenzo[g]imidazo[1,2-a]quinoxaline (0.075 g, 0.281 mmol) (Preparation 4 in Example 11) in 4 mL of THF was added N-methylethylene diamine (0.20 mL, 2.25 mmol). The reaction tube was sealed and the mixture stirred at 80°C for 18 hours. The resulting cooled mixture was then taken up in EtOAc, washed with water and brine, dried (Na2S04) and evaporated. Purifying the residue by preparative TLC
(CH2C12:MeOH, 8:2) yielded 1-methyl-4-(2-N-methylaminoethylamino)benzo[g]imidazo[1,2-a] quinoxaline. This solid was dissolved in CH2CI2/EtOH and a solution of 1 N HCI in EtOH was added to form the hydrochloride salt, which was filtered, washed with EtOH and dried in vacuo to afford the above titled salt as an off-white solid (0.025 g, 26%);
mp 265-275 °C dec; IR (KBr, cm-~) 3448, 2958, 2780, 1656, 1532, 1420;
~H
NMR (CD30D) 8.72 (s, 1 H), 8.42 (s, 1 H), 8.13-8.11 (m, 1 H), 8.01-7.98 (m, 1 H), 7.63-7.57 (m, 3H), 4.23-4.20 (m, 2H), 3.54-3.51 (m, 2H), 3.07 (s, 3H), 2.86 (s, 3H); MS (+ESI, M + H+) m/z 306; HPLC: 98.3% (230 nm); HRMS
calculated for C~sH~9N5: 306.1719; found 306.1708. Inhibition of IKK-1 activity was measured using the assay of Example 2, where the inhibitory potential.of the~compound of Example 13 resulted in an IC5o of 0.35 p.M.
1-METHYL-4-METHYLAMINOBENZO[G]PYRAZOLO[1,5-C]QU INAZOLI NE
\N
\ \ wN~
N~N~
H
A mixture of 4-methyl-1-(4-tolunesulfonyl)-5-trimethylstannylpyrazole (Preparation 8 in Example 11) (24.0 mg, 0.0896 mmol) and MeNH2 (3.0 mL
of 2.0 M/THF, 6.0 mmol) in a pressure tube was heated at 60°C for 5 hr.
After the reaction mixture was cooled to RT, it was treated with NaHC03 (57 mg) and water (2 pipet-drops) and stirred for 5 min. Silica gel was added and the volatile component was removed in vacuo. The resulting silica gel mesh was submitted to flash chromatography (20% EtOAc/hexanes) to afford the title compound as a light yellow solid (23.0 mg, 98%).'H NMR
(DMSO, b = 2.50): 8.60 (s, 1 H), 8.10 (s, d, J = 8.3, 1 H), 8.03 (s, 1 H), 8.01 (s, 1 H), 7.95 (d, J = 8.01, 1 H), 7.92 (q, J = 4.7, 1 H), 7.50 (t, J = 7.5, 1 H), 7.44 (t, J = 7.4, 1 H), 3.09 (d, J = 4.7, 3H), 2.66 (s, 3H). (ESI) m/z (M+H)+ = 263.02.
Inhibition of IKK-1 activity was measured using the assay of Example 2, where the inhibitory potential of the compound of Example 14 resulted in an ICSO of 0.67 p,M.
1-M ETHYL-4-(2-N-METHYLAMINOETHYLAMINO)BENZO[G]PYRAZOLO[1,5-C]QUINAZOLINE
wN~
I H
/ /
N~N~N\
H
N-methyl-ethylenediamine (250 ~,L, 2.836 mmol) was added rapidly to a THF (2.0 mL) semi-suspension of 4-methyl-1-(4-tolunesulfonyl)-5-trimethylstannylpyrazole (Preparation 8 in Example 11 ) (30.5 mg, 0.114 mmol). The reaction mixture was stirred at RT for 1 hr and at 75°C for 2.3 hr.
After the reaction mixture was cooled to RT, it was treated with NaHCO3 (57 mg) and water (2 pipet-drops) and stirred for a few minutes. The volatile components, including the excess diamine, were removed in vacuo. The crude material was submitted to flash chromatography (sample was loaded as a silica gel mesh; 0-100% MeOH/EtOAc) to afford the title compound as a yellow waxy-solid (43.4 mg; the weight is 8.6 mg more than the theoretical yield). ~ H NMR (DMSO, 8 = 2.50): 8.60 (s, 1 H), 8.10 (d, J = 8.1, 1 H), 8.02 (s, 2H, signal overlap), 7.95 (d, J = 8.1, 1 H), 7.73 (t, J = 5.5, 1 H), 7.51 (ddd, J =
8.2, 6.8, 1.1, 1 H), 7.45 (ddd, J = 8.0, 6.9, 1.0, 1 H), 3.66 (apt q, J = 6.1, 2H), 2.82 (t, J = 6.3, 2H), 2.66 (s, 3H), 2.35 (s, 3H), 1.81 (s, 1 H). (ESI) m/z (M+H)+ = 306.05.
1-METHYL-4-METHYLAMINOBENZO(G)IMIDAZO(4,5-C)QUINOLINE
N N
\ \ \~
/ /
A mixture of 1-methyl-4-chlorobenzo(g)imidazo(4,5-c)quinoline (Preparation 19 in Example 11) (130 mg, 0.49 mmol) and MeNH2 (2.OM/THF, 1.5 mL, 2.92 mmol) was heated in a pressure tube at 80°C for 18 hours. After the reaction mixture was cooled to RT, it was diluted with EtOAc (100 mL), washed with saturated NaC03 (50 mL), and brine. The organic layer was dried over MgS04, filtered and evaporated in vacuo. The crude material was submitted to flash chromatography (5% MeOH/EtOAc) affording the title compound as a pale white solid (5.2 mg, 4%). ~H
NMR(CDCI3): 8.44(s, 1 H), 8.35(s, 1 H), 7.94(d, J=8.3, 1 H), 7.90(d, J=8.3, 1 H), 7.72(s, 1 H), 7.46(m, 1 H), 7.40(m, 1 H), 5.95(b, 1 H), 4.28(s, 3H), 3.31 (s, 3H). (ESI) m/z (M+H)~ = 263.14. Inhibition of IKK-1 activity was measured using the assay of Example 2, where the inhibitory potential of the compound of Example 16 resulted in an IC5° of 0.80 ~,M.
1-METHYL-4-(2-N-METHYLAMINOETHYLAMINO)BENZO(G)IM1DAZ0(4,5-?0 C)QUINOLINE
N
N
\ \
/ /
NH-CHyCH2NH2 A solution of 1-methyl-4-chlorobenzo(g)imidazo(4,5-c)quinoline (Preparation 19 in Example 11) (130 mg, 0.49 mmol) in NH2CH2CH2NH2 (3.2 mL, 49 mmol), was heated at 60°C for 18 hours. The solvent was evaporated in vacuo. The residue was diluted with EtOAc (50 mL) and washed with brine (20 mL). The organic layer was dried over MgS04, filtered, and concentrated. The crude material was submitted to flash chromatography (MeOH) affording the title compound as a pale white solid (6.9 mg, 5%). ~ H NMR(CDC13): 8.52(s, 1 H), 8.33(s, 1 H), 7.96(d, J=8.3, 1 H), 7.94(d, J=8.3, 1 H), 7.77(s, 1 H), 7.46(m, 1 H), 7.42(m, 1 H), 6.22(b, 1 H), 4.36(s, 3H), 3.85(m, 2H), 3.10(m, 2H), 1.60(b, 1 H). (ESI) m/z (M+H)+ _ 292.18. Inhibition of IKK-1 activity was measured using the assay of Example 2, where the inhibitory potential of the compound of Example 17 resulted in an IC5° of 1.0 ~,M.
1-METHYL-4-(2-HYDROXYETHYLAMINO)BENZO[G]IMIDAZO[1,2 A]QUINOXALINE
~N
N i / / ~ OOH
N N
To a solution of 4-chloro-1-methylbenzo[g]imidazo[1,2-a]quinoxaline (0.060 g, 0.225 mmol) (Preparation 4 in Example 11) in 2 mL of THF was added 2-aminoethanol (0.11 mL, 1.80 mmol). The reaction tube was sealed and the mixture stirred at 80°C for 16 hours. The resulting cooled mixture was then taken up in EtOAc, washed with water and brine, dried (Na~S04) and evaporated. The resulting residue was recrystallized using i-PrOH to give Example 18 (0.062 g, 94%); mp 186-188 °C; IR (KBr, cm-') 3370, 3147, 1549, 1485, 1414; ~H NMR (DMSO-d6) 8.64 (s, 1H), 8.10-8.09 (m, 2H), 7.96 (d, J = 7.5, 1 H), 7.51-7.46 (m, 3H), 7.37 (s, 1 H), 4.91 (t, J = 5.2, 1 H), 3.70-3.66 (m, 4H), 3.00 (s, 3H); MS (+ESI, M + H+) m/z 293; HPLC: 98.8% (230 nm). Inhibition of IKK-1 activity was measured using the assay of Example _$$_ 2, where the inhibitory potential of the compound of Example 18 resulted in an ICSO of 0.87 M.
1-METHYL-4-(2-PIPERIDIN-1-YL-ETHYLAMINO)BENZO[G]IMIDAZO[1,2-A]QUINOXALINE
/N
I / /
N N~
H
To a solution of 4-chloro-1-methylbenzo[g]imidazo[1,2-a]quinoxaline (0.055 g, 0.206 mmol) (Preparation 4 in Example 11) in 5 mL.of THF was added 1-(2-aminoethyl)piperidine (0.24 mL, 1.65 mmol). The reaction tube was sealed and the mixture stirred at 80°C for 17 hours. The resulting cooled mixture was then taken up in EtOAc, washed with water and brine, dried (Na2S04) and evaporated. The resulting residue was recrystallized using i-PrOH to give Example 19 (0.063 g, 84%); mp 170-172 °C; IR (KBr, crri ~) 3300, 2932, 1557, 1483, 1408; ~H NMR (DMSO-d6) 8.61 (s, 1H), 8.07-8.06 (m, 2H), 7.94 (d, J = 7.6, 1 H), 7.49-7.34 (m, 4H), 3.66 (br q, J = 6.5, 2H), 2.97 (s, 3H), 2.59 (br t, J = 6.5, 2H), 2.44 (br s, 4H), 1.54-1.39 (m, 6H);
MS (+ESI, M + H+) m/z 360; HPLC: 97.6% (230 nm). Inhibition of IKK-1 activity was measured using the assay of Example 2, where the inhibitory potential of the compound of Example 19 resulted in an IC5o of 1.7 ~,M.
The contents of all patents, patent applications, published PCT
applications and articles, books, references, reference manuals and abstracts cited herein are hereby incorporated by reference in their entirety to more fully describe the state of the art to which the invention pertains.
As various changes can be made in the above-described subject matter without departing from the scope and spirit of the present invention, it _89_ is intended that all subject matter contained in the above description, or defined in the appended claims, be interpreted as descriptive and illustrative of the present invention. Many modifications and variations of the present invention are possible in light of the above teachings.
Claims (50)
1. A method of treating an inflammatory or immune-related disease or disorder comprising administering to a mammal in need thereof, an IKK
inhibitor in an amount effective to treat the inflammatory or immune-related disease or disorder.
inhibitor in an amount effective to treat the inflammatory or immune-related disease or disorder.
2. The method according to claim 1, wherein the IKK inhibitor is administered in combination with at least one biologically active agent, and further wherein the biologically active agent is selected from: i) drugs; ii) hormones; or iii) synthetic compounds.
3. The method according to claim 1, wherein the IKK inhibitor inhibits IKK activity at a level of about 20% to 100%.
4. The method according to claim 1, wherein the IKK inhibitor has an IC50 against IKK activity ranging from about 0.01 µM to about 50 µM.
5. The method according to claim 1, wherein the IKK inhibitor has an IC50 against IKK activity ranging from about 0.01 µM to about 1 µM.
6. The method according to claim 1, wherein the IKK inhibitor selectively inhibits IKK-2.
7. The method according to claim 6, wherein the IKK inhibitor has at least about a 5-fold or greater selectivity for IKK-2 over IKK-1.
8. The method according to claim 1, wherein the IKK inhibitor has an IC50 against IKK-2 activity ranging from about 0.01 µM to about 5 µM.
9. The method according to claim 1, wherein the IKK inhibitor has an IC50 against IKK-2 activity ranging from about 0.01 µM to about 1 µM.
10. The method according to claim 1, wherein the IKK inhibitor has a bioavailability ranging from about 10% to about 100%.
11. The method according to claim 1, wherein the IKK inhibitor is 4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a) quinoxaline.
12. The method according to claim 1, wherein the disease or disorder is an inflammatory disease or disorder.
13. The method according to claim 1, wherein the disease or disorder is an immune-related disease or disorder.
14. The method according to claim 1, wherein the inflammatory or immune-related disease or disorder is selected from the group consisting of:
arthritis, psoriasis, rhinitis, inflammatory bowel disease, pulmonary disease, Alzheimer's disease, brain ischemia, traumatic brain injury, Parkinson's disease, multiple sclerosis, atherosclerosis, amyotrophic lateral sclerosis, subarachnoid hemorrhage, asthma, acute respiratory distress syndrome, chronic obstructive pulmonary disorder, systemic lupus erythematosus, and tissue/organ transplant rejection.
arthritis, psoriasis, rhinitis, inflammatory bowel disease, pulmonary disease, Alzheimer's disease, brain ischemia, traumatic brain injury, Parkinson's disease, multiple sclerosis, atherosclerosis, amyotrophic lateral sclerosis, subarachnoid hemorrhage, asthma, acute respiratory distress syndrome, chronic obstructive pulmonary disorder, systemic lupus erythematosus, and tissue/organ transplant rejection.
15. The method of treating an inflammatory or immune-related disease or disorder according to claim 1, comprising inhibiting IKK catalytic activity by administering to a mammal in need thereof, an IKK inhibitor in an amount effective to inhibit IKK catalytic activity.
16. The method according to claim 15, wherein the IKK inhibitor is administered in combination with at least one biologically active agent, and further wherein the biologically active agent is selected from: i) drugs; ii) hormones; or iii) synthetic compounds.
17. The method according to claim 15, wherein the IKK inhibitor inhibits IKK activity by about 20% to 100%.
18. The method according to claim 15, wherein the IKK inhibitor has an IC50 against IKK activity ranging from about 0.01 µM to about 50 µM.
19. The method according to claim 15, wherein the IKK inhibitor has an IC50 against IKK activity ranging from about 0.01 µM to about 1 µM.
20. The method according to claim 15, wherein the IKK inhibitor selectively inhibits IKK-2.
21. The method according to claim 20, wherein the IKK inhibitor has at least about a 5-fold or greater selectivity for IKK-2 over IKK-1.
22. The method according to claim 15, wherein the IKK inhibitor has an IC50 against IKK-2 activity ranging from about 0.01 µM to about 5 µM.
23. The method according to claim 15, wherein the IKK inhibitor has an IC50 against IKK-2 activity ranging from about 0.01 µM to about 1 µM.
24. The method according to claim 15, wherein the IKK inhibitor has a bioavailability ranging from about 10% to about 100%.
25. The method according to claim 15, wherein the IKK inhibitor is 4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a) quinoxaline.
26. The method according to claim 15, wherein the inflammatory or immune-related disease or disorder is selected from the group consisting of:
arthritis, psoriasis, rhinitis, inflammatory bowel disease, pulmonary disease, Alzheimer's disease, brain ischemia, traumatic brain injury, Parkinson's disease, multiple sclerosis, atherosclerosis, amyotrophic lateral sclerosis, subarachnoid hemorrhage, asthma, acute respiratory distress syndrome, chronic obstructive pulmonary disorder, systemic lupus erythematosus, and tissue/organ transplant rejection.
arthritis, psoriasis, rhinitis, inflammatory bowel disease, pulmonary disease, Alzheimer's disease, brain ischemia, traumatic brain injury, Parkinson's disease, multiple sclerosis, atherosclerosis, amyotrophic lateral sclerosis, subarachnoid hemorrhage, asthma, acute respiratory distress syndrome, chronic obstructive pulmonary disorder, systemic lupus erythematosus, and tissue/organ transplant rejection.
27. A method of treating an inflammatory or immune-related disease or disorder comprising inhibiting phosphorylation of I.kappa.B by administering to a mammal in need thereof, an IKK inhibitor in an amount effective to inhibit phosphorylation of I.kappa.B.
28. A method of inhibiting activation of NF-.kappa.B-dependent gene expression associated with the inhibition of IKK catalytic activity and/ or I.kappa.B
phosphorylation, comprising administering to a mammal in need thereof an amount of the IKK inhibitor effective to inhibit IKK catalytic activity and/
or I.kappa.B phosphorylation, thereby inhibiting activation of NF B-dependent gene expression.
phosphorylation, comprising administering to a mammal in need thereof an amount of the IKK inhibitor effective to inhibit IKK catalytic activity and/
or I.kappa.B phosphorylation, thereby inhibiting activation of NF B-dependent gene expression.
29. A method of treating an inflammatory or immune-related disease or disorder comprising administering to a mammal in need thereof, an IKK
inhibitor in an amount effective to inhibit I.kappa.B kinase (IKK), wherein IKK
inhibition results in one or more of the following:
i) inhibition of IKK catalytic activity;
ii) inhibition of phosphorylation of I.kappa.B; or iii) inhibition of NF-.kappa.B-dependent gene expression.
inhibitor in an amount effective to inhibit I.kappa.B kinase (IKK), wherein IKK
inhibition results in one or more of the following:
i) inhibition of IKK catalytic activity;
ii) inhibition of phosphorylation of I.kappa.B; or iii) inhibition of NF-.kappa.B-dependent gene expression.
30. The method of treating an inflammatory or immune-related disease or disorder according to claim 1 comprising administering to a mammal in need thereof, an IKK inhibitor in an amount effective to treat the inflammatory disease or disorder, where said IKK inhibitor has the following characteristics: i) inhibits IKK activity at a level of about 20% to 100%; ii) selectively inhibits IKK-2; iii) has an IC50 against IKK activity ranging from about 0.01 µM to about 50 µM; and iv) has a bioavailability ranging from about 10% to about 100%.
31. The method of treating an inflammatory or immune-related disease or disorder according to claim 15 comprising inhibiting IKK catalytic activity by administering to a mammal in need thereof, an IKK inhibitor in an amount effective to inhibit IKK catalytic activity, wherein the IKK inhibitor has the following characteristics: i) inhibits IKK activity at a level of about 20% to 100%; ii) selectively inhibits IKK-2; iii) has an IC50 against IKK activity ranging from about 0.01µM to about 50 µM; and iv) has a bioavailability ranging from about 10% to about 100%.
32. The method of treating an inflammatory or immune-related disease or disorder according to claim 27 comprising inhibiting phosphorylation of I.kappa.B
by administering to a mammal in need thereof, an IKK inhibitor in an amount effective to inhibit phosphorylation of I.kappa.B, wherein the IKK inhibitor has the following characteristics: i) inhibits IKK activity at a level of about 20% to 100%; ii) selectively inhibits IKK-2; iii) has an IC50 against IKK activity ranging from about 0.01 µM to about 50µM; and iv) has a bioavailability ranging from about 10% to about 100%.
by administering to a mammal in need thereof, an IKK inhibitor in an amount effective to inhibit phosphorylation of I.kappa.B, wherein the IKK inhibitor has the following characteristics: i) inhibits IKK activity at a level of about 20% to 100%; ii) selectively inhibits IKK-2; iii) has an IC50 against IKK activity ranging from about 0.01 µM to about 50µM; and iv) has a bioavailability ranging from about 10% to about 100%.
33. The method of inhibiting activation of NF-.kappa.B-dependent gene expression associated with the inhibition of IKK catalytic activity and/ or I.kappa.B
phosphorylation according to claim 28, comprising administering to a mammal in need thereof, an IKK inhibitor in an amount effective to inhibit IKK catalytic activity and/ or I.kappa.B phosphorylation thereby inhibiting activation of NF- .kappa.B-dependent gene expression, wherein said IKK inhibitor has the following characteristics: i) inhibits IKK activity at a level of about 20% to 100%; ii) selectively inhibits IKK-2; iii) has an IC50 against IKK activity ranging from about 0.01µM to about 50µM; and iv) has a bioavailability ranging from about 10% to about 100%.
phosphorylation according to claim 28, comprising administering to a mammal in need thereof, an IKK inhibitor in an amount effective to inhibit IKK catalytic activity and/ or I.kappa.B phosphorylation thereby inhibiting activation of NF- .kappa.B-dependent gene expression, wherein said IKK inhibitor has the following characteristics: i) inhibits IKK activity at a level of about 20% to 100%; ii) selectively inhibits IKK-2; iii) has an IC50 against IKK activity ranging from about 0.01µM to about 50µM; and iv) has a bioavailability ranging from about 10% to about 100%.
34. ~A 4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a) quinoxaline compound:
or a pharmaceutically-acceptable salt thereof.
or a pharmaceutically-acceptable salt thereof.
35. ~A pharmaceutical composition comprising the compound according to claim 34, and a pharmaceutically acceptable carrier, excipient, or diluent.
36. ~A kit comprising:
i) an IKK inhibitor or a pharmaceutically-acceptable salt thereof;
ii) diluent for the IKK inhibitor; and, optionally, iii) at least one biologically active agent; and iv) instructions for use.
i) an IKK inhibitor or a pharmaceutically-acceptable salt thereof;
ii) diluent for the IKK inhibitor; and, optionally, iii) at least one biologically active agent; and iv) instructions for use.
37. The kit according to claim 36, wherein the IKK inhibitor is 4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a) quinoxaline.
38. The kit according to claim 36, wherein the at least one biologically active agent is selected from: i) drugs; ii) hormones; or iii) synthetic compounds.
39. A method of preventing an inflammatory or immune-related disease or disorder, comprising administering to a mammal in need thereof an amount of an IKK inhibitor effective to prevent an inflammatory or immune-related disease or disorder.
40. The method according to claim 39, wherein the IKK inhibitor is administered in combination with at least one biologically active agent, and further wherein the biologically active agent is selected from: i) drugs; ii) hormones; or iii) synthetic compounds.
41. The method according to claim 39, wherein the IKK inhibitor inhibits IKK activity by about 20% to 100%.
42. The method according to claim 39, wherein the IKK inhibitor has an IC50 against IKK activity ranging from about 0.01 µM to about 50 µM.
43. The method according to claim 39, wherein the IKK inhibitor has an IC50 against IKK activity ranging from about 0.01 µM to about 1 µM.
44. The method according to claim 39, wherein the IKK inhibitor selectively inhibits IKK-2.
45. The method according to claim 44, wherein the IKK inhibitor has at least about a 5-fold or greater selectivity for IKK-2 over IKK-1.
46. The method according to claim 39, wherein the IKK inhibitior has an IC50 against IKK-2 activity ranging from about 0.01 µM to about 5 µM.
47. The method according to claim 39, wherein the IKK inhibitor has an IC50 against IKK-2 activity ranging from about 0.01 µM to about 1 µM.
48. The method according to claim 39, wherein the IKK inhibitor has a bioavailability ranging from about 10% to about 100%.
49. The method according to claim 39, wherein the IKK inhibitor is 4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a) quinoxaline.
50. The method according to claim 39, wherein the inflammatory or immune-related disease or disorder is selected from the group consisting of:
arthritis, psoriasis, rhinitis, inflammatory bowel disease, pulmonary disease, Alzheimer's disease, brain ischemia, traumatic brain injury, Parkinson's disease, multiple sclerosis, atherosclerosis, amyotrophic lateral sclerosis, subarachnoid hemorrhage, asthma, acute respiratory distress .syndrome, chronic obstructive pulmonary disorder, systemic lupus erythematosus, and tissue/organ transplant rejection.
arthritis, psoriasis, rhinitis, inflammatory bowel disease, pulmonary disease, Alzheimer's disease, brain ischemia, traumatic brain injury, Parkinson's disease, multiple sclerosis, atherosclerosis, amyotrophic lateral sclerosis, subarachnoid hemorrhage, asthma, acute respiratory distress .syndrome, chronic obstructive pulmonary disorder, systemic lupus erythematosus, and tissue/organ transplant rejection.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26585301P | 2001-02-01 | 2001-02-01 | |
US60/265,853 | 2001-02-01 | ||
US09/965,977 US6960585B2 (en) | 2000-10-03 | 2001-09-27 | Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same |
US09/965,977 | 2001-09-27 | ||
PCT/US2002/003060 WO2002060386A2 (en) | 2001-02-01 | 2002-02-01 | METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF IλB KINASE (IKK) |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2436770A1 true CA2436770A1 (en) | 2002-08-08 |
Family
ID=26951465
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002436770A Abandoned CA2436770A1 (en) | 2001-02-01 | 2002-02-01 | Methods of treating inflammatory and immune diseases using inhibitors of ikb kinase (ikk) |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1363993A4 (en) |
JP (1) | JP2004529088A (en) |
AU (1) | AU2002247059B2 (en) |
CA (1) | CA2436770A1 (en) |
CZ (1) | CZ20032287A3 (en) |
HU (1) | HUP0304045A3 (en) |
MX (1) | MXPA03006817A (en) |
NO (1) | NO20033429L (en) |
PL (1) | PL364111A1 (en) |
WO (1) | WO2002060386A2 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2260300T3 (en) * | 2000-10-03 | 2006-11-01 | Bristol-Myers Squibb Company | TETRACICLIC COMPOUNDS REPLACED WITH AMINO USEFUL AS ANTI-INFLAMMATORY AGENTS AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE SAME. |
EP1333834B1 (en) | 2000-10-26 | 2008-04-23 | Amgen Inc. | Antiinflammation agents |
AU2002365611A1 (en) | 2001-12-05 | 2003-06-17 | F. Hoffmann - La Roche Ag | Inflammation modulators |
DE10237722A1 (en) | 2002-08-17 | 2004-08-19 | Aventis Pharma Deutschland Gmbh | Indole or benzimidazole derivatives for the modulation of IKappaB kinase |
US7199119B2 (en) | 2002-10-31 | 2007-04-03 | Amgen Inc. | Antiinflammation agents |
TW200616967A (en) | 2004-06-24 | 2006-06-01 | Smithkline Beecham Corp | Novel indazole carboxamides and their use |
TW200626142A (en) | 2004-09-21 | 2006-08-01 | Glaxo Group Ltd | Chemical compounds |
WO2007005534A2 (en) | 2005-06-30 | 2007-01-11 | Smithkline Beecham Corporation | Chemical compounds |
US8063071B2 (en) | 2007-10-31 | 2011-11-22 | GlaxoSmithKline, LLC | Chemical compounds |
KR20080052650A (en) * | 2005-09-07 | 2008-06-11 | 라보라토리스 세로노 에스.에이. | Ikk inhibitors for the treatment of endometriosis |
US20090175852A1 (en) | 2006-06-06 | 2009-07-09 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
WO2008072779A1 (en) * | 2006-12-13 | 2008-06-19 | Aska Pharmaceutical Co., Ltd. | Quinoxaline derivative |
AR065804A1 (en) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | COMPOSITE OF INDOL CARBOXAMIDE, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT AND USE OF THIS COMPOUND TO PREPARE A MEDICINAL PRODUCT |
AU2009239429B2 (en) | 2008-04-21 | 2013-08-29 | Otonomy, Inc. | Auris formulations for treating otic diseases and conditions |
WO2010000903A2 (en) * | 2008-06-30 | 2010-01-07 | Centro De Investigaciones Energéticas, Medioambientales Y Tecnológicas (Ciemat) | Composition capable of modulating ikkalpha activity for the treatment of diseases associated with acantholysis |
JP5312466B2 (en) | 2008-10-02 | 2013-10-09 | 旭化成ファーマ株式会社 | 8-substituted isoquinoline derivatives and uses thereof |
US8354539B2 (en) | 2009-03-10 | 2013-01-15 | Glaxo Group Limited | Indole derivatives as IKK2 inhibitors |
US10821185B2 (en) | 2016-06-29 | 2020-11-03 | Otonomy Inc. | Triglyceride otic formulations and uses thereof |
EP3494994A1 (en) * | 2017-12-07 | 2019-06-12 | Universität zu Köln | Combinations of ripk1- and ikk-inhibitors for the prevention or treatment of immune diseases |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4160097A (en) * | 1977-01-07 | 1979-07-03 | Westwind Pharmaceuticals, Inc. | 1-(2-Phenylureylene)imidazoles |
US5851812A (en) * | 1997-07-01 | 1998-12-22 | Tularik Inc. | IKK-β proteins, nucleic acids and methods |
US6235740B1 (en) * | 1997-08-25 | 2001-05-22 | Bristol-Myers Squibb Co. | Imidazoquinoxaline protein tyrosine kinase inhibitors |
US6030834A (en) * | 1997-12-30 | 2000-02-29 | Chiron Corporation | Human IKK-beta DNA constructs and cells |
GB0003154D0 (en) * | 2000-02-12 | 2000-04-05 | Astrazeneca Uk Ltd | Novel compounds |
BR0109161A (en) * | 2000-03-15 | 2002-11-26 | Aventis Pharma Gmbh | Beta-carbolines replaced with ikb-kinase inhibiting activity |
ES2260300T3 (en) * | 2000-10-03 | 2006-11-01 | Bristol-Myers Squibb Company | TETRACICLIC COMPOUNDS REPLACED WITH AMINO USEFUL AS ANTI-INFLAMMATORY AGENTS AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE SAME. |
-
2002
- 2002-02-01 WO PCT/US2002/003060 patent/WO2002060386A2/en active Application Filing
- 2002-02-01 AU AU2002247059A patent/AU2002247059B2/en not_active Ceased
- 2002-02-01 HU HU0304045A patent/HUP0304045A3/en unknown
- 2002-02-01 CZ CZ20032287A patent/CZ20032287A3/en unknown
- 2002-02-01 MX MXPA03006817A patent/MXPA03006817A/en active IP Right Grant
- 2002-02-01 JP JP2002560582A patent/JP2004529088A/en active Pending
- 2002-02-01 PL PL02364111A patent/PL364111A1/en not_active Application Discontinuation
- 2002-02-01 CA CA002436770A patent/CA2436770A1/en not_active Abandoned
- 2002-02-01 EP EP02714815A patent/EP1363993A4/en not_active Withdrawn
-
2003
- 2003-07-31 NO NO20033429A patent/NO20033429L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO20033429D0 (en) | 2003-07-31 |
HUP0304045A3 (en) | 2005-05-30 |
NO20033429L (en) | 2003-09-24 |
AU2002247059B2 (en) | 2006-11-16 |
PL364111A1 (en) | 2004-12-13 |
EP1363993A2 (en) | 2003-11-26 |
MXPA03006817A (en) | 2003-11-13 |
WO2002060386A2 (en) | 2002-08-08 |
EP1363993A4 (en) | 2008-11-12 |
WO2002060386A3 (en) | 2002-10-10 |
HUP0304045A2 (en) | 2004-04-28 |
JP2004529088A (en) | 2004-09-24 |
CZ20032287A3 (en) | 2004-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6869956B2 (en) | Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK) | |
AU2002247059B2 (en) | Method of treating inflammatory and immune diseases using inhibitors of IkappaB kinase (IKK) | |
US9890153B2 (en) | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors | |
AU2002247059A1 (en) | Method of treating inflammatory and immune diseases using inhibitors of IkappaB kinase (IKK) | |
JP6181862B2 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of diseases | |
EP1325009B1 (en) | Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same | |
KR20170103838A (en) | Heterocyclic itk inhibitors for treating inflammation and cancer | |
JP6376707B2 (en) | Substituted crosslinked urea analogs as sirtuin modulators | |
CA2666360C (en) | An alzheimer's disease progression inhibitor containing heterocyclic compound having specific structure | |
AU2002211827A1 (en) | Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same | |
EA013434B1 (en) | Imidazoquinolines as lipid kinase inhibitors | |
MXPA04008680A (en) | Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents. | |
TW200946521A (en) | Compounds useful as inhibitors of ROCK kinases | |
CN106232583B (en) | Compounds and methods for inhibiting fascin | |
KR20160104729A (en) | Substituted pyroolopyridines and pyrrolopyrazines for treating cancer or inflammatory diseases | |
US10316038B2 (en) | Pyrrolopyrimidine ITK inhibitors for treating inflammation and cancer | |
JP2008521855A (en) | Novel pyridothienopyrimidine derivatives | |
CN104736202A (en) | Methods for inhibiting fascin | |
WO2018236971A1 (en) | Single molecule compounds providing multi-target inhibition of parp and other proteins and methods of use thereof | |
TW200825083A (en) | Novel fluorene derivatives, compositions containing them and use thereof | |
Asif et al. | Anticonvulsant and Antitubercular Activities of 6-Phenyl/Biphenyl-4-yl-2-[2-(pyridin-2-ylamino)-ethyl]-and 6-(Biphenyl-4yl)-2-(2N-subtituted amin-1-yl)-ethyl derivatives of 4, 5-dihydropyridazin-3 (2H)-one | |
AU2007200555A1 (en) | Methods of treating inflammatory and immune diseases using inhibitors of IKappaB kinase (IKK) | |
JP2023545452A (en) | Compounds and compositions for the treatment of cryptosporidiosis | |
WO2022228509A1 (en) | Pyrrolopyrimidine derivative, preparation method therefor and use thereof | |
JPS61118386A (en) | Triazoloquinoline derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |